TWI281400B - Herbal composition for angina pectoris, method to prepare same and uses thereof - Google Patents

Herbal composition for angina pectoris, method to prepare same and uses thereof Download PDF

Info

Publication number
TWI281400B
TWI281400B TW90132075A TW90132075A TWI281400B TW I281400 B TWI281400 B TW I281400B TW 90132075 A TW90132075 A TW 90132075A TW 90132075 A TW90132075 A TW 90132075A TW I281400 B TWI281400 B TW I281400B
Authority
TW
Taiwan
Prior art keywords
soil
compound danshen
extract
danshen
treatment
Prior art date
Application number
TW90132075A
Other languages
Chinese (zh)
Inventor
Xi-Jun Yan
Nai-Feng Wu
Zhi-Xin Guo
Zheng-Liang Ye
Yan Liu
Original Assignee
Tianjin Tasly Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Tasly Pharmaceutical filed Critical Tianjin Tasly Pharmaceutical
Priority to TW90132075A priority Critical patent/TWI281400B/en
Priority to US10/210,548 priority patent/US8486464B2/en
Application granted granted Critical
Publication of TWI281400B publication Critical patent/TWI281400B/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

This invention provides compositions comprising extracts of Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneol. Said compositions comprise notoginsenoside R1 and ginsenoside Rg1 which are active components for therapeutic applications. This invention also provides a method of preparation of the said compositions and a method of identification and determination of the amount of individual effective components of said compositions. Finally, this invention provides various uses of the compositions.

Description

1281400 A7 B7 五、發明説明(/ ) … (請先閲讀背面之注意事項再填寫本頁) 本專利申請的各種參考文獻放置在說明書的結尾,權 利要求書之前。將本發明公開的內容與參考文獻合爲一 體’其目的是爲了更好地描述截至目前爲止的、技術人員 所能夠瞭解的最新技術發展。 慢性穩定型心絞痛是由於心肌缺血造成的。阿斯匹 林、有機硝酸鹽類藥物、/3受體阻斷劑和鈣拮抗劑等它們 常常單獨或聯合使用,來治療心絞痛。 作爲抗血栓藥的阿斯匹林只能對慢性穩定型心絞痛進 行對症治療。 有機硝酸鹽類藥物用於心絞痛的發作,對於可以預知 症狀的患者,它可以進行預防。對於敏感患者,硝酸鹽類 藥物引起的頭痛會妨礙他們繼續服用。 儘管〆腎上腺素能受體阻滯劑在治療心絞痛方面有著 不可替代的地位,但其禁忌證衆多,特異性的包括氣管阻 滯疾病和嚴重的心室功能紊亂,非特異性的包括糖尿病、 外周血管疾病和心動過緩或心臟阻滯。 經濟部中央標準局員工消費合作社印製 鈣離子拮抗劑在治療心絞痛方面有很好的療效,它是 通過舒張冠心.病患者血管平滑肌、影響外周迴圈、增加心 肌供氧,減少心肌做功來實現的。 儘管許多患者開始聯合使用有機硝酸鹽類藥物、鈣離 子拮抗劑和/3腎上腺素能受體阻滯劑等藥物來治療心絞 痛,並取得了一些進展,但還是需要可以長期服用、低毒 高效的、治療慢性穩定性心絞痛的藥物。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7 _ 五、發明説明(2 ) … (請先閲讀背面之注意事項再填寫本頁) 鑒於上述藥品的這些問題,必須努力尋找使用中草藥 來治療慢性穩定性心絞痛的新途徑。傳統的中藥在這方面 可以發揮其獨到的作用。 美國專利(No. 5288485和 5433957)提到使用小連翹 (Λ少治療和預防血循環素亂引起 的疾病,如心絞痛。 美國專利(No. 5 776463 )提到口服含有琉璃苣花瓣或其 提取物的組合物,可以用來預防和治療由包括心絞痛在內 的心臟迴圏疾病引起的應激緊張。除了小連翹州 ereciw/w 和琉璃苣花瓣,許多其他的草藥也用來治療 心絞痛。其中之一就是闊葉纈草 /α^>//·α)。楊桂雲等( 1 994)報道,82例心絞痛患者(其中 心電圖ST-T段呈缺血表現的患者爲50例)使用闊篥纈草 治療。單純心絞痛(S Τ - Τ段無缺血發現)總有效率爲 8 7.80% ;伴有 ST-T段缺血表現的心絞痛爲有效率爲 8 8.0 0%。另外,還發現闊葉纈草可以降低血漿脂質水平。 對肝、腎和造血組織無毒性。 經濟部中央標準局員工消費合作社印製 吳曄良· ( 1 990)等報道,267例心絞痛患者使用“心痛 康”膠囊進行治療,有效率爲9 3 · 3 %。 另一種草藥製劑“參芍通冠片”用於心絞痛的治療。 » 〆 1 990年,胡錦心等報道,“參芍通冠片”主要是由從人參 和白芍的莖葉提取的皂苷組成,治療心絞痛的總有效率爲 9 4.7 1%。心電福改善率爲63.3 8%。另外,實驗室實驗表明, ___ 2 ____ 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 1281400 at B7 五、發明説明(3) … “參芍通冠片”具有.提高左心室輸出量的功能’降低血液 粘度,抑制血小板聚集等功能。急性毒性試驗、長期毒性 實驗證明“參芍通冠片”無毒副作用。 “擴冠顆粒”爲另一種治療心絞痛的草藥製劑。李應 東等(1 990 )報道,在3 1例冠心病心絞痛患者服用“擴 冠顆粒”之前和服藥一個月之後,採用原子吸收光譜和 D TNB法測定患者血漿中鋅、銅、紅細胞、谷胱甘 和過 氧化酶的含量。結果顯示:服藥前治療組患者血漿鋅、紅 細胞、谷胱甘 和過氧化酶水平比對照組高,銅的水平比 對照組低(P <〇.〇1),服藥後治療組患者血漿鋅、紅細胞、 谷胱甘 和過氧化酶水平比對照組明顯降低,銅的水平比 對照組明顯升高(P <〇.〇1)。這些情況表明:“闊冠顆粒”治 療冠心病心絞痛的機理可能與其對機體的微量元素的調 節有關。 刺蒺藜皂苷是另外一種治療心絞痛的草藥。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 覆方万#片是治療因冠脈缺血導致的慢性穩定性心絞 痛的丹參製劑中的常用處方,自1 977年被中國藥典收載 以來,臨床應用已有幾十年。 複方丹參片爲中藥丹參{Radix Salviae Miltiorrhizae) 和三七以wwwg)等的提取物,含有多種有效成 分。丹參、三七首次記載於西元2 〇 〇年的《神農本草經》。 另外,费方办參片還含有合成冰片。天然冰片最早記載於 西元659年的《唐本草》。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X2973公釐) 1281400 at B7 經濟部中央樣準局員工消費合作社印製 五、發明説明(羊) … 李承珠等[ 1 979午,上海第一醫學院學報]報道,實驗 硏究表明,丹參具有抗血栓的作用。體外觀察家兔的血小 板聚集功能,表明其具有纖維蛋白溶解的作用。注射丹參 後,發現有三點在體外血栓形成方面起到重要作用:(1) 抑制血小板的功能;(2)抑制血小板的聚集;(3)提高纖維 蛋白的溶解。其中的前兩項作用更爲重要。結果證實了丹 參在治療血栓特別是動脈血栓疾病方面的作用。 江文德等[1 9 8 2年,上海第一醫學院學報]報道了丹參 素和其他丹參中的水溶性成分對狗缺血心肌及離體豬冠 脈的影響。3種新的水溶性成分,如丹參素(DS-182, D( + )_3,4-二羥基苯基乳酸),原兒茶醛(pcAD)和從丹參 中分離的雙 酸粗品(DS-187),與雙嘧達莫進行比較。 結果表明:(1)在小鼠試驗中,DS-182具有明顯的抗.缺氧 作用,而PC AD作用不明顯;(2 )DS-1 82對垂體後葉素引 起的心電圖缺血性ST-T上升有明顯的改善作用,對心率 無任何影響。DS_ 187,PC AD和雙嘧達莫只表現了不完全 的保護作用;(3 )對狗冠脈左前降支進行結紮,製成急性 梗塞模型,靜脈注射DS-182。結果表明:在對左心室功能、 左心室最大收縮壓(LVPSP )和左心室末端舒張壓(LVEDP ) 作用方面,DS-182優於DS-187和 PCAD。相反,PCAD * 一 對左心室蕞大收縮壓(LVPSP )和左心室末端舒張壓 (LVEDP )有著相反的作用。雙嘧達莫靜脈給藥,雖然不 能改變LVEDP,但顯著降低LVPSP而呈現明顯的降壓作 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 ______B7 __ 五、發明説明(f ) … °丹*參的所有成分和雙嘧達莫均可以減少心肌梗塞的範 圍(N-Bt評價);Ds_182最爲有效,雙嘧達莫次之,而 PCAD最差;(4)在豬離體冠狀動脈模型中,DS-182可以明 顯降低冠脈血管阻力,而D S -1 8 7、P C AD或另一種丹參的 成分一一丹參酮II-A磺酸鹽卻可以增加這種阻力。在離體 ^ M f莫型中,嗎啡和普萘洛爾的抑制效應可以被預先服用 的DS-182所拮抗。所有這些表明:丹參素可能是丹參治 療缺血性心臟病的主要成分,與嗎啡或普萘洛爾合用是有 益的。 李承珠等[1 9 8 3年,中西醫結合雜誌]報道了丹參抗血 凝的作用。丹參素爲丹參中提取的水溶性單體,也是市售 丹參注射液的主要成分。現代硏究表明:丹參素具有抑制 體外的血栓形成,抑制ADP誘導的血小板聚集和體內體外 凝集系統,減少血小板數量,加速纖維蛋白或纖維蛋白原 降解的作用。家兔注射丹參注射液2 0 m g / k g後,3 0分鐘作 用達到最強,持續1小時,逐漸恢復。 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 程彰華等[ 1 987年,上海第一醫學院學報]報道丹參素 對實驗微循環和血漿乳酸濃度的影響。天然丹參素爲從丹 參中提取的水溶性單體。在家兔體內注射大分子的右旋糖 苷誘導産生微循環障礙的模型中,丹參素(劑量4_ 6 mg/kg) , 〆 可以顯著增> 加球結膜微循環的毛細血管數’同時顯著降低 血漿乳酸水平。在小鼠滴注去甲腎上腺素(4g )造成腸系 膜微循環障礙的模型中,丹參素具有擴張動脈’加速血流 --------5---- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 1281400 A7 B7 五、發明説明(6 ) … (請先閱讀背面之注意事項再填寫本頁) 速度的作用,因此可以排除微循環的血液瘀積。實驗中可 發現合成的丹參素亦具有類似的作用。這表明天然丹參素 與合成丹參素在緩解微循環障礙方面無顯著差異。 1991年,孫錫銘等報道了丹參提取物具有一種新的藥 理作用。論文報道,通過細胞培養的方法,發現含有丹參 素鈉(D( + )-3,4-二羥基苯基乳酸鈉)的丹參提取物具有抑 制細胞內膽固醇生物合成和抗脂質過氧化的藥理作用。與 對照組比較,其電泳遷移率明顯降低,MD A和細胞毒性明 顯降低。結果表明丹參素鈉具有有效預防和治療動脈硬化 的功能。 鄭若玄等[1 992年,中西醫結合雜誌]報道,丹參對小 鼠冠脈結紮造成的心肌缺血有保護作用。腹膜內注射丹參 水溶性提取物(5g生藥/kg),與對照組比較,其對因冠脈 結紮造成的急性心肌缺血具有明顯的保護作用,治療組因 心肌缺血導致的心電圖S-T段升高有明顯降低,左心室缺 血面積減小,生存率明顯增加。 吳堯忠等報道(南京中醫藥大學學報,1 9 9 5,11(6): 經濟部中央標準局員工消費合作社印製 3 5 -3 6 )丹參活血化瘀作用及機理探討。作者認爲丹參的 藥理硏究較爲普遍,但丹參的血液流變學硏究,如由血小 板産生的前列環素12,ET,血栓素A2的硏究則較少見。 , 〆 他們對兔好血栓形成、血小板聚集及PT、KPTT、 FG、 ESR、HCT等的變化進行了硏究,結果顯示丹參能抑制 TXA2的合成,減少血小板聚集和血栓形成。 ' ---—~—-6-------— 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 Λ7 B7 經濟部中央標準局員工消費合作社印裝 五、發明説明(f) … 石琳報道(中國窣理學報,1 9 9 0,( 1 ) : 2 9 - 3 2 )三七總 皂f有升高頸動脈前列環素12及降低血小板血栓素A2的 作用。給兔喂飼100 mg三七總皂f /(kg· day),連續8周 後觀察,與對照組比較,主動脈粥樣硬化斑塊的形成的受 到明顯抑制。用放射免疫測定法來測定三七總皂芬對頸動 脈前列環素12和血小板血栓素A2含量的影響。給兔喂飼 25、50、100 mg三七總皂爷/(kg· day),連續10天後測定, 與對照組比較,頸動脈前列環素12含量增加和血小板血 栓素A2含量減少。這些結果顯示了三七總皂f通過糾正 前列環素12和血栓素A2的失調而達到抗動脈粥樣硬化的 作用。 李杏報道(中國藥理學報,1990,(1): 26-29 )三七皂 著對大鼠實驗性心肌缺血再灌注損傷的保護作用。作者硏 究了三七總皂苷及從三七總皂薈中提純的人參皂f Rb 1和 人參皂爷Rg 1對體內和體外大鼠心臟實驗性心肌缺血再灌 注損傷的作用。用戊巴比妥對大鼠實施麻醉,結紮冠狀動 脈左降支40分鐘,然後再灌注1 20分鐘後測定,與對照 組比較,三七總皂f處理組(100 mg/kg和 200 mg/kg)可 明顯減少心肌梗塞的範圍。對大鼠離體心臟實施球狀缺血 4 0分鐘,再灌注1 5分鐘後測定,與對照組比較,三七總 皂f 12.5 mg/L組、三七總皂f 25 mg/L組,人參皂f Rbl 10mg/L組和人參皂爷Rgl10 mg/L組可明顯抑制心肌肌酸 磷酸激酶的釋放,降低心肌鈣離子和丙二醛水平,而提高 ------Ψ----- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) 1281400 A7 B7 五、發明説明(《) … 超氧化物歧化酶的活性。結果顯示了三七總皂f、人參巷 f Rb 1和人參皂等Rg 1有防止心肌缺血的作用,該作用可 能與抑制脂質過氧化有關。 黃聰報道(中國藥理學通報,1 9 9 1,( 3 )·· 1 9 0 · 1 9 3 )三 七總皂f對淸醒兔心肌缺血再灌注損傷的保護作用。作者 硏究了三七總皂f對淸醒兔心肌缺血再灌注損傷後心電 圖變化、肌酸磷酸激酶和乳酸脫氫酶、心肌缺血面積大小 的影響。三七總巷薈5 0 m g / k g和1 0 0 m g / k g劑量組可使 心肌缺血面積顯著減少。結果顯示三七總皂f對心肌缺血 再灌注損傷有保護作用。 莫啓忠報道(中成藥硏究,1 982,(8) : 5-7 ) 3 H-冰片 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 動力學的硏究。作者爲探討冰片芳香開竅機理,用靜脈注 射或口服的方法對氚標記冰片進行了動力學硏究。SH-冰 片單獨靜脈注射的半衰期爲2 · 8分鐘,提示了藥物很快就 分佈到有關的器官和組織,能快速起效。在體內濃度分佈 較高的器官和組織有血液、心、肺、肝、腎、腦等,這爲 臨床應用提供了一定的理論基礎。冰片口服後的半衰期爲 5.3小時,提示口服冰片不會引起積蓄,但生物利用度差。 並指出進一步的硏究應該是探討劑量與劑型的關係。 陳鐵鐸報道(中國藥理學報,199〇,(1): 42_44)合成 冰片促進西甲基吡嗪的吸收。給SD大鼠預先肌注冰片 (5mg/kg )(以不注射作爲對照組),再肌注磷酸四甲基吡 嗪(5mg/kg ),用氣相色譜法分析血漿四甲基吡嗪濃度, 本紙張尺度適用中國國家標準(CNS ) A4規格(210X29^^7" ' 1281400 經濟部中央標準局員工消費合作社印製 A7 B7_五、發明説明(^ ) … 並用NONLIN程式對資料進行處理。兩組Cmax分別爲 931 和 562(p<〇.〇l),AUC 分別爲 68849 和 3 7 1 74(P<0.05), 提示冰片可促進四甲基吡嗪的吸收’而不是加速它的消 除。· 徐偉等報道(中藥藥理與臨床,199 5,11(6): 31-33) 薄荷醇及冰片對磺胺嘧啶和伊文思藍在腦中分佈的影 響。薄荷醇(1.5g/kg,ig)和冰片(1.5g/kg,ig)可明顯延長 磺胺嘧啶在大鼠體內分佈相半衰期,上述劑量口服同樣可 增加磺胺嘧啶在大鼠腦內的濃度。薄荷醇(〇.5g/kg,ig, 三天)和冰片(〇.5g/kg,ig,三天)可增加伊文思藍在小鼠腦 內的濃度,但顯著低於缺血再灌注損傷小鼠腦內的濃度。 以上結果提示,薄荷醇、冰片可能具有促進磺胺嘧啶透過 血腦屏障的作用,而對血腦屏障結構沒有損傷。 在美國,冠狀動脈粥樣硬化心臟病是導致心血管功能失 調和死亡的最普遍的原因。動脈粥樣硬化是以大、中動脈 內壁上沈積有膽固醇、脂質、細胞殘片的黃色斑塊爲特徵 的動脈功能失調。開始時出現脂紋,逐漸成爲纖維斑塊或 動脈粥樣化損害,血管壁變厚、纖維化、鈣化,血管腔變 窄。 很多動脈粥樣化斑塊保持穩定或者逐漸發展,另一些可 丨 〆 能會破裂而‘導致出血,血小板啓動,血管內血栓形成。冠 狀動脈血栓形成可導致部分或完全的血管阻塞,血流不 暢,引發不穩定性心絞痛或心肌梗死。破裂的斑塊可能會 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 1281400 Λ7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(/〇) … 穩定下來,常常又貪導致更嚴重的狹窄。 運動和精神壓力會引起心肌需氧增加。在正常的生理情 況下,通過小動脈擴張增加血流足以滿足心肌需氧增加的 需要。在動脈粥樣硬化的情況下,小動脈已經擴張到極限 來滿足基本的供氧,不能再滿足增加的需氧量。當需氧超 過供氧時,就會發生心肌缺血。嚴重血管阻塞,血流阻滯, 也會導致心肌缺血。短暫心肌缺血的臨床表現就是心絞 痛,表現爲突發性胸部疼痛,常常放射到臂部特別是左 臂,或者伴有窒息欲死之感。 心絞痛又細分爲兩型:穩定性和不穩定性。在大多數情 況下,穩定性心絞痛是由需氧量增加引發,需氧增加的因 素有運動、精神壓力等,發作的頻率和持續的時間常可預 知。相反i不穩定心絞痛發作則難以找到引發因素,常常 因心肌供氧減少引起。粥樣斑塊的破裂、血小板瘀塞、冠 狀動脈血栓均可減少心肌的供氧。 治療心絞痛的方法有藥物治療、手術、冠狀動脈旁路移 植、氣囊血管成形術、支架放置等。治療穩定性心絞痛首 先要減少心肌的需氧,這也是一種預防措施。治療急性不 穩定性心絞痛則首先考慮抑制血小板活性和溶栓。 目前治療慢性穩定性心絞痛的藥物有硝酸甘油、其他硝 酸鹽類、舞通道阻滞劑、/3 -腎上腺素能受體阻滯劑。單 獨服用這些藥物或聯合用藥能起到緩解和預防心絞痛的 作用,而不是治療心絞痛。 '"本紙張尺度適用中國國家標準(CNS ) A4規格(210X29Y公釐) (請先閱讀背面之注意事項再填寫本頁) 1281400 A7 B7 經濟部中央標準局員工消費合作社印裂 五、發明説明(// ) … 心絞痛發作時,舌下含服硝酸甘油可緩解症狀,同樣也 可用來預防因勞累和緊張引起的心絞痛發作。硝酸鹽類亦 可預防心絞痛發作。硝酸甘油和硝酸鹽類通過舒張血管平 滑機、減少心肌的活動,使得心肌的需氧減少,其副作用 有悸動性頭痛、眩暈、無力、直立性低血壓、心悸亢進等。 /3 -腎上腺素能受體阻滯劑如心得安則在勞累和緊張時 通過減少心肌的需氧而防治心絞痛。主要的禁忌症有支氣 管痙攣疾病、慢脈型心律失常、明顯的心力衰竭等。給有 哮喘和其他氣道阻塞疾患的病人應用Θ -腎上腺素能受體 阻滯劑可能會使病情惡化。 鈣拮抗劑通過減少心肌需氧而防治心絞痛。心肌依靠鈣 的流入而發揮正常功能,鈣拮抗劑通過抑制鈣的流入起到 舒張血管平滑肌、減少心肌的活動、減少心肌需氧的作 用,從而防治心絞痛。鈣拮抗劑的不良反應有面色潮紅、 浮腫、眩暈、噁心等。過量抑制鈣流入心肌可導致嚴重的 副作用,如心臟停博、心博徐緩、充血性心力衰竭等。與 /3 -腎上腺素能受體阻滯劑聯合用藥時,常會加重鈣拮抗 劑的副反應。 自西元200年以來,三七和丹參在中國一直被用來治療 心血管疾病。三七用於治療心絞痛,丹參則活血散瘀。許 * 〆 多臨床前硏究和臨床硏究都證明了三七和丹參的有效性 和安全性。 傳統中藥一般是幾種中草藥混合後的水煎物。治療冠心 ________π___ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) 1281400 A7 _____B7_ 五、發明説明(/JZ ) - (請先閱讀背面之注意事項再填寫本頁) 病的中藥中,複方丹參片的劑型有所改進,它是一種較大 的油質片,直徑長達lcm。複方丹參片是由丹參的提取物、 三七藥材粉末和合成冰片組成,1 977年被收入到中華人民 共和國藥典,用它治療心血管疾病已經長達幾十年。 本發明所公開的複方丹參滴九(又名護心丹)是治療冠 心病的新一代中藥。中藥不僅隨所組成的藥味的不同而不 同’而且隨各藥味之間的比例和配方量大小的不同而不 同。爲控制質量,複方丹參滴九的生産採用標準化配方, 其治療成分含10〜3〇% (常爲20%左右)的丹參水溶性提 取物、2〜6%的三七水溶性提取物和1〜3 %的冰片。此外, 爲快速起效,複方丹參滴九被製成可在舌下迅速溶解吸收 的小九,它能快速入血,直達心肌,迅速緩解心絞痛。 複方丹參滴九的臨床前硏究和臨床硏究證實其治療由 冠狀動脈缺血引起的心血管疾病安全而有效,不僅如此, 不論臨床前硏究還是臨床硏究也均證實複方丹參滴九治 療心血管疾病的作用優於複方丹參片。 經濟部中央標準局員工消費合作社印製 複方丹參滴九199S年被收入中華人民共和國藥典增補 版,2000年進入中華人民共和國藥典。複方丹參滴九自 1 993年中華人民共和國衛生部批准以來,使用人數已達五 百多萬。 本專利公開的複方丹參滴九(D SP )爲新一代用於治療 冠心病的中藥,它是根據標準化的處方進行生産。 複方丹參滴九包括三七、丹參提取物和冰片。其中的 _______12 ____ 本紙張尺度適用中國國家標準(CNS)A4規格(21〇'乂297公釐) 1281400 at B7 五、發明説明(/J ) 三七用於緩解和預防心絞痛的發作;丹參抑制血小板聚 集,預防冠脈血栓的形成,由此改善血液迴圈;冰片則是 心肌治療的主要成分。 複方丹參滴九爲圓形小九’每九重量約爲25m§ ’舌下 含化溶解,因此可以使其療效更迅速。複方丹參滴九預防 和緩解心絞痛的療效已經在臨床即和_臨床硏究中得到證 實。 本發明公開了一種滴丸機,它可以生産複方丹參滴丸 或其他小的九劑。 本發明還公開了此種藥物的質量控制方法’它包括應 用薄層色譜及高效液相色譜法等分析技術,對藥物的有效 成分進行鑒別和定量的控制。 1 圖式簡單說明 圖1·指紋圖譜(批號:1 9990806) 經濟部中夬標準局員工消費合作社印製 r清电閱漬背面之注意事項再填寫本頁) 指紋圖譜峰的位置:I組包括1 #、2#峰(保留時間從7 到15分鐘);Π組包括3#、4#峰(保留時間從15到2〇分鐘); 瓜組包括5#、6#、7#和8#峰(保留時間從20到40分鐘)。 從整體看,I組各峰的豐度最大,因此1#與2#峰的峰 高幾乎一樣高。Π組各峰並肩站立,峰高幾乎一樣高,豐 度非常低。m組包括4個峰,它們的峰高階梯式遞增。這 二組峰包含了複方丹參滴九的特徵峰。 _;___ 13_____ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 經濟部中央標準局員工消費合作社印製 1281400 五、發明説明(/4 ) … 圖 2 ·指紋圖譜(批號:1 9 9 9 0 8 1 5 ) 圖 3·指紋圖譜(批號:1 9 9 90 82 3 ) 本發明公開的藥物複方丹參滴丸,組成如下: (a)丹參[水溶性]提取物,三七[水溶性]提取 物,和冰片; (b) 丹參、三七、冰片和輔料劑; (c) 丹參、三七、冰片和藥用輔料劑; 上述藥物所使用的丹參和三七,在中國自西元200年就 已經應用於冠心病的治療。其中的三七用於治療心絞痛, 丹參用於提高血液迴圈,冰片則有促進有效成分儘快達到 革巴器官的功效。天然冰片自西元6 0 0年就已經開始使用, 由於其過渡開採,現在複方丹參滴九中採用的是合成冰 片。 本發明公開了複方丹參滴九的如下功效: (a) 治療冠心病; (b) 與其他藥物聯合使用治療冠心病; (〇首選用於預防冠心病; (d) 首選與其他藥物聯合使用預防冠心病; (e) 間接用於預防冠心病; 14 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X297公釐) (请先閲讀背面之注意事項再填寫本頁) -I# 訂 1281400 A7 B7 五、發明説明(/jf ) , (f) 間接與其彳也藥物聯合使用預防冠心病; (g) 減少患者有機硝酸鹽類藥物的使用; (h) 降低血淸膽固醇水平。 複方丹參滴九的適應症爲冠狀動脈粥樣硬化疾病(不 僅限於此),如緩解心絞痛,預防由於勞累及緊張引起的 心絞痛,及通過抑制血小板聚集促進血液迴圈而預防冠脈 血栓的形成。應用複方丹參滴九可以減少經常具有緩解和 預防心絞痛作用的硝酸甘油的服用量。應用複方丹參滴九 可以降低血漿中膽固醇的水平,因此可以預防冠狀動脈粥 樣硬化引起損傷。動脈粥樣應硬化往往是由於膽固醇在血 管壁沈積造成的。 本發明公開了此種藥物的質量控制方法,通過應用分 析鑒別等技術,對有效成分進行分析,使得藥物中的有效 成分的組成及含量更加標準化。步驟如下: (a) * 使用分析方法分析本藥物; 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) (b) 通過與相應的純化的標準品進行比較,對治療成 分進行鑒別和含量測定。 上述分析技術主要有薄層色譜法、高效液相色/譜法 等。本藥物中純化的有效成分被認爲是活性成分。例如, 在複方丹參滴九中純化的治療成分包括(不僅限於此): 皂苷類、酚酸類如丹參素及龍腦等。將複方丹參滴九中成 ______15 ___ 本紙張尺度適用中國國家標準(CNS ) A4規格(210、/297公釐) " 1281400 A7 B7 五、發明説明(/6 ) ,. (請先閲讀背面之注意事項再填寫本頁) 分在咼效液相中的保留時間,或薄層色譜中的顔色和位置 等性質與純化標準品進行比較,對其進行鑒別。有效成分 的定量是通過複方丹參滴九的治療部分與已知量的標準 物質進行比較得出來的。例如,複方丹參滴九中皂苷的含 量是通過與已知量純品皂苷的標準曲線比較獲得的。 複方丹參滴九包含5-40%的丹參的水溶性酚酸成分、 1- 10%的三七的水溶性的皂苷類成分和1-5%的冰片。 複方丹參滴九包含10-30%的丹參的水溶性酚酸成分、 2- 6%的三七的水溶性的皂苷類成分和i—3%的冰片。 本發明公開了生産小型九劑的滴九機,這種小型九劑 可以迅速溶化達到靶器官。此滴九機包括以下部分: (a) 滴罐的溫度範圍60- 1 00°C (優選溫度爲:89-93 V ); (b) .冷凝液液體石蠛的溫度低於8°C ; (c) 滴頭,其內徑爲1.8mm,外徑爲 2.35mm (c)滴頭與冷凝液面距離約爲15cm; 經濟部中央標準局員工消費合作社印製 使用上述滴九機生産的小型的九劑,服用後迅速溶解。 九劑的特徵如下: (a) 直徑爲 〇.3 3 -0.3 4cm; (b) 九·重爲 2 1.2 5 -2 8.75mg ; (c) 密度爲 1.13-1.40mg/mm3。 _______16 ____ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 經濟部中央標準局員工消費合作社印製 A7 B7___ 五、發明説明(,7) … 細節描沭 複方丹參滴九的生産 .複方丹參滴九爲小的九劑,每丸重約25mg,其有效成 分包括丹參、三七的水溶性提取物及合成冰片。 複方丹參滴九按以下方法生産,三七、丹參分別用沸 水中回流提取,過濾,濾液減壓濃縮、過濾、沈澱。濃縮 液用樹脂精製後減壓濃縮,精製後的水溶性提取物與合成 .冰片和藥用輔料混合,使用特製的滴九機制成小的九劑, 複方丹參滴九的質量是通過控制其主要治療成分的比例 來控制的,包括皂苷、酚酸如丹參素和冰片。複方丹參滴 九的鑒別及含量測定使用的方法包括薄層色譜、液相色 譜、指紋圖譜和其他分析方法。 複方丹參滴九的生産 1·三七水溶性成分的提取: (a) 藥材加5-7倍量的水; (b) 將三七放入提取罐,保持氣壓在〇 〇4_〇 〇6mPa, 煎煮2小時,提取其水溶性成分; (Ο 再次提取1 .5小時; (d) 提取液過100目篩; 〆 (e) 用大孔吸附樹脂精製濾液,用乙醇洗脫; (g) 洗脫液減壓濃縮至密度爲Km35,其中輸 _____17______ 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇X:297公羡1 ~" (請先閱讀背面之注意事項再填寫本頁)1281400 A7 B7 V. INSTRUCTIONS (/ ) ... (Please read the notes on the back and then fill out this page.) Various references to this patent application are placed at the end of the specification, prior to the claims. The disclosure of the present invention is incorporated herein by reference in its entirety for the purpose of the present disclosure. Chronic stable angina is caused by myocardial ischemia. Aspirin, organic nitrates, /3 receptor blockers, and calcium antagonists are often used alone or in combination to treat angina pectoris. Aspirin as an antithrombotic drug can only be symptomatic for chronic stable angina. Organic nitrates are used in the onset of angina and can be prevented in patients with predictable symptoms. For sensitive patients, headaches caused by nitrates can prevent them from taking them. Although sputum adrenergic receptor blockers have an irreplaceable role in the treatment of angina pectoris, their contraindications are numerous, including tracheal block disease and severe ventricular dysfunction, including non-specific diabetes, peripheral blood vessels. Disease and bradycardia or heart block. The Central Standards Bureau of the Ministry of Economic Affairs, the employee consumption cooperative, printed calcium antagonists has a good effect in the treatment of angina pectoris. It is through the relaxation of coronary heart disease patients with vascular smooth muscle, affecting peripheral circulation, increasing myocardial oxygen supply, reducing myocardial work. Realized. Although many patients have begun to use a combination of organic nitrates, calcium antagonists and /3 adrenergic blockers to treat angina, and have made some progress, but still need to be long-term, low toxicity and high efficiency , a drug for the treatment of chronic stable angina. This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1281400 A7 B7 _ V. Invention description (2 ) ... (Please read the note on the back and fill out this page) In view of these problems of the above drugs, it is necessary Strive to find new ways to use Chinese herbal medicine to treat chronic stable angina. Traditional Chinese medicine can play its unique role in this respect. U.S. Patents (Nos. 5,288,485 and 5,433,957) teach the use of small forsythia (a reduction in the treatment and prevention of diseases caused by circulatory disorders such as angina. US Patent No. 5 776463 mentions oral administration of borage petals or extracts thereof. The composition can be used to prevent and treat stress tension caused by heart rash disease including angina pectoris. In addition to small forsythia ereciw/w and borage petals, many other herbs are also used to treat angina. It is broadleaf sedge /α^>//·α). Yang Guiyun et al (1 994) reported that 82 patients with angina pectoris (50 patients with ischemic manifestations in the ST-T segment of the electrocardiogram) were treated with broad-leaved grass. The total effective rate of angina pectoris (S Τ - 无 无 no ischemia) was 8.80%; the effective rate of angina pectoris with ST-T segment is 8.0 0%. In addition, it has also been found that valerian can reduce plasma lipid levels. Non-toxic to liver, kidney and hematopoietic tissue. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs Wu Yiliang· (1 990) reported that 267 patients with angina pectoris were treated with “Xintongkang” capsules with an effective rate of 93.3%. Another herbal preparation, Shenqi Tongguan Tablet, is used for the treatment of angina pectoris. » 〆 In 990, Hu Jinxin et al reported that “Shenzhen Tongguan Tablet” consisted mainly of saponins extracted from the stems and leaves of ginseng and white peony. The total effective rate of treating angina was 9 4.7 1%. The ECG improvement rate was 63.3 8%. In addition, laboratory experiments show that ___ 2 ____ this paper scale applies to China National Standard (CNS) Α 4 specifications (210X297 mm) 1281400 at B7 V. Invention Description (3) ... "Shenzhen Tongguan Tablet" has. Improve left ventricle The function of the output 'reduces blood viscosity and inhibits platelet aggregation and other functions. Acute toxicity test and long-term toxicity test prove that “Shenzhen Tongguan Tablet” has no toxic side effects. "Expanding Crown Granules" is another herbal preparation for the treatment of angina pectoris. Li Yingdong et al (1 990) reported that in patients with coronary heart disease angina pectoris before taking "expanding crown particles" and one month after taking the drug, the plasma zinc, copper, red blood cells, glutathione were determined by atomic absorption spectrometry and D TNB method. And the content of peroxidase. The results showed that the levels of zinc, red blood cells, glutathione and peroxidase in the treatment group were higher than those in the control group, and the level of copper was lower than that in the control group (P < 〇.〇1). The plasma zinc was treated in the treatment group after taking the drug. The levels of red blood cells, glutathione and peroxidase were significantly lower than those of the control group, and the level of copper was significantly higher than that of the control group (P < 〇.〇1). These conditions indicate that the mechanism of “wide crown granules” for treating angina pectoris may be related to the regulation of trace elements in the body. Hedgehog is another herb that treats angina. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page). Fufang Wan# is a commonly used prescription for the treatment of chronic stable angina due to coronary ischemia. Since its publication in the Chinese Pharmacopoeia in 1977, it has been used clinically for decades. Compound Danshen Tablets is an extract of Chinese herbal medicine Radix Salviae Miltiorrhizae and Sanqi (www.g), and contains various effective ingredients. Danshen and Sanqi were first recorded in the "Shen Nong's Herbal Classic" in the 2nd year of the second year. In addition, Feifang's ginseng tablets also contain synthetic borneol. Natural borneol was first recorded in the "Tang Bencao" in 659 AD. This paper scale applies to China National Standard (CNS) A4 specification (210X2973 mm) 1281400 at B7 Ministry of Economic Affairs Central Sample Bureau employee consumption cooperative printing 5, invention description (sheep) ... Li Chengzhu et al [1 979 noon, Shanghai First Medicine Journal of the hospital] reported that experimental studies have shown that Salvia miltiorrhiza has antithrombotic effects. The blood plate aggregation function of rabbits was observed in vitro, indicating that it has a fibrinolysis effect. After injection of Salvia miltiorrhiza, three points were found to play an important role in in vitro thrombosis: (1) inhibition of platelet function; (2) inhibition of platelet aggregation; and (3) increased fibrin dissolution. The first two of these roles are more important. The results confirmed the role of Danshen in the treatment of thrombosis, especially arterial thrombosis. Jiang Wende et al [1 1982, Journal of Shanghai First Medical College] reported the effects of water-soluble components of Danshen and other Salvia miltiorrhiza on canine ischemic myocardium and isolated porcine coronary arteries. 3 new water-soluble ingredients such as Danshensu (DS-182, D(+)_3,4-dihydroxyphenyllactate), protocatechuic aldehyde (pcAD) and crude dibasic acid isolated from Salvia miltiorrhiza (DS- 187), compared with dipyridamole. The results showed that: (1) DS-182 had obvious anti-hypoxia effect in PC test, but PC AD had no obvious effect; (2) DS-1 82 on electrocardiogram ischemic ST-induced pituitary vasopressin The rise in T has a significant improvement and has no effect on heart rate. DS_ 187, PC AD and dipyridamole showed only incomplete protection; (3) Ligation of the left anterior descending artery of the dog coronary artery, an acute infarction model, and intravenous injection of DS-182. The results showed that DS-182 was superior to DS-187 and PCAD in terms of left ventricular function, left ventricular maximum systolic pressure (LVPSP), and left ventricular end diastolic pressure (LVEDP). In contrast, PCAD* has an opposite effect on left ventricular systolic pressure (LVPSP) and left ventricular end diastolic pressure (LVEDP). Dipyridamole intravenous administration, although it can not change LVEDP, but significantly reduced LVPSP and showed significant antihypertensive effect (please read the back note first and then fill out this page) This paper scale applies Chinese National Standard (CNS) A4 specification ( 210X297 mm) 1281400 A7 ______B7 __ V. Description of invention (f ) ... All components of Dan * ginseng and dipyridamole can reduce the range of myocardial infarction (N-Bt evaluation); Ds_182 is the most effective, dipyridamole Mo, and PCAD is the worst; (4) DS-182 can significantly reduce coronary vascular resistance in the isolated rat coronary artery model, while DS -1 8 7 , PC AD or another Salvia miltiorrhiza component - tanshinone II-A sulfonate can increase this resistance. In the ex vivo ^ M f Mo, the inhibitory effects of morphine and propranolol can be antagonized by pre-administered DS-182. All of this suggests that Danshensu may be the main component of Danshen's treatment of ischemic heart disease and may be beneficial in combination with morphine or propranolol. Li Chengzhu et al [1 1983, Journal of Integrative Medicine] reported the anti-coagulation effect of Salvia miltiorrhiza. Danshensu is a water-soluble monomer extracted from Salvia miltiorrhiza Bunge. It is also the main component of the commercially available Salvia miltiorrhiza injection. Modern studies have shown that Danshensu inhibits thrombosis in vitro, inhibits ADP-induced platelet aggregation and in vitro and in vivo agglutination, reduces platelet count, and accelerates fibrin or fibrinogen degradation. After the injection of Salvia miltiorrhiza injection at 20 m g / k g, the rabbit reached the strongest effect for 30 minutes and continued to recover for 1 hour. Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) Cheng Zhanghua et al [1 987, Journal of Shanghai First Medical College] reported the effect of Danshensu on experimental microcirculation and plasma lactate concentration . Natural Danshensu is a water-soluble monomer extracted from Danshen. In a model of microcirculation disorder induced by injection of macromolecular dextran in rabbits, Danshensu (dose 4-6 mg/kg), sputum can be significantly increased> and the number of capillaries in the microcirculation of the bulbar conjunctiva is significantly reduced. Plasma lactate levels. In a model of mesenteric microcirculatory disorder caused by instillation of norepinephrine (4g) in mice, Danshensu has a dilated artery that accelerates blood flow--------5---- This paper scale applies to Chinese national standards (CNS) A4 size (210X 297 mm) 1281400 A7 B7 V. Invention description (6) ... (Please read the note on the back and fill out this page) The effect of speed, therefore, can eliminate the blood circulation of the microcirculation. Synthetic Danshensu can also be found to have a similar effect in the experiment. This indicates that there is no significant difference between natural Danshensu and synthetic Danshensu in alleviating microcirculatory disorders. In 1991, Sun Ximing et al reported that the extract of Salvia miltiorrhiza has a new pharmacological effect. The paper reported that the Salvia miltiorrhiza extract containing sodium danshensu (D(+)-3,4-dihydroxyphenyl lactate) has a pharmacological effect of inhibiting intracellular cholesterol biosynthesis and anti-lipid peroxidation by cell culture. Compared with the control group, the electrophoretic mobility was significantly reduced, and MD A and cytotoxicity were significantly reduced. The results indicate that Danshensu sodium has an effective function in preventing and treating arteriosclerosis. Zheng Ruoxuan et al [1, 992, Journal of Integrative Medicine] reported that salvia miltiorrhiza has protective effects on myocardial ischemia caused by coronary artery ligation in mice. Intraperitoneal injection of water-soluble extract of Salvia miltiorrhiza (5g crude drug / kg), compared with the control group, it has a significant protective effect on acute myocardial ischemia caused by coronary artery ligation, the ST segment of the electrocardiogram caused by myocardial ischemia in the treatment group The height was significantly reduced, the left ventricular ischemic area was reduced, and the survival rate was significantly increased. Wu Yizhong and other reports (Journal of Nanjing University of Traditional Chinese Medicine, 1 9 9 5, 11 (6): Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs 3 5 -3 6 ) The role and mechanism of Danshen's blood circulation and phlegm. The authors believe that the pharmacological studies of Salvia miltiorrhiza are more common, but the blood rheology of Salvia miltiorrhiza, such as prostacyclin 12, ET, and thromboxane A2 produced by blood platelets are rare. 〆 They studied the thrombosis, platelet aggregation and changes of PT, KPTT, FG, ESR and HCT in rabbits. The results showed that Salvia miltiorrhiza can inhibit the synthesis of TXA2 and reduce platelet aggregation and thrombosis. ' ----~--6-------- This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1281400 Λ7 B7 Ministry of Economic Affairs Central Bureau of Standards Staff Consumer Cooperatives Printing 5, Invention Explanation (f) ... Shi Lin reports (Chinese Journal of Pelican, 1 9 9 0, (1): 2 9 - 3 2 ) Panax notoginseng f has elevated carotid prostacyclin 12 and decreased platelet thromboxane A2 effect. The rabbits were fed with 100 mg of Panax notoginseng total f/(kg·day) for 8 consecutive weeks, and the formation of aortic atherosclerotic plaques was significantly inhibited compared with the control group. Radioimmunoassay was used to determine the effect of Panax notoginseng saponins on the content of cervical prostacyclin 12 and thromboxane A2. The rabbits were fed with 25, 50, 100 mg of Panax notoginseng/(kg·day), and after 10 consecutive days, the carotid prostacyclin 12 content and thrombopoietin A2 content were decreased compared with the control group. These results show that Panax notoginseng total soap f achieves anti-atherosclerosis by correcting the imbalance of prostacyclin 12 and thromboxane A2. Li Xing reports (Chinese Journal of Pharmacology, 1990, (1): 26-29) The protective effect of Panax notoginseng on experimental myocardial ischemia-reperfusion injury in rats. The authors investigated the effects of Panax notoginseng saponins and ginseng soap f Rb 1 purified from Panax notoginseng saponins and ginsenoside Rg 1 on experimental myocardial ischemia reperfusion injury in vivo and in vitro. The rats were anesthetized with pentobarbital, the left descending coronary artery was ligated for 40 minutes, and then reperfused for 1 20 minutes. Compared with the control group, the Panax notoginseng total f treatment group (100 mg/kg and 200 mg/ Kg) can significantly reduce the extent of myocardial infarction. The isolated heart of the rat was subjected to spheroid ischemia for 40 minutes, and after reperfusion for 15 minutes, compared with the control group, the total saponin f 12.5 mg/L group and the panax notoginseng f 25 mg/L group were compared. The ginseng soap f Rbl 10mg/L group and the ginseng saponin Rgl10 mg/L group can significantly inhibit the release of cardiac creatine phosphokinase, reduce the myocardial calcium ion and malondialdehyde levels, and improve ------Ψ--- -- This paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm) (please read the note on the back and fill out this page) 1281400 A7 B7 V. Inventive Note (") ... Superoxide dismutase activity . The results showed that Panax notoginseng total soap f, ginseng lane f Rb 1 and ginseng soap and other Rg 1 have the effect of preventing myocardial ischemia, which may be related to inhibition of lipid peroxidation. Huang Cong reports (Chinese Pharmacological Bulletin, 1 9 9 1, (3)·· 1 9 0 · 1 9 3 ) Sanqi total soap f protective effect on myocardial ischemia-reperfusion injury in rabbits. The authors investigated the effects of Panax notoginseng saponins f on electrocardiographic changes, creatine phosphokinase and lactate dehydrogenase, and myocardial ischemic area after myocardial ischemia-reperfusion injury in rabbits. The myocardial ischemic area was significantly reduced in the dose group of 5 0 m g / k g and 100 m g / k g. The results showed that Panax notoginseng saponins f had protective effects on myocardial ischemia-reperfusion injury. Mo Qizhong reports (Chinese patent medicine research, 1 982, (8): 5-7) 3 H-Ice Film Economics Department Central Standards Bureau employee consumption cooperative printing (please read the back of the note and fill in this page) Dynamics The study. In order to explore the mechanism of borneol aroma, the authors used venous injection or oral methods to study the dynamics of sputum-labeled borneol. The half-life of SH-ice tablets alone for 2 · 8 minutes suggests that the drug is quickly distributed to the relevant organs and tissues and can work quickly. Organs and tissues with high concentration in the body have blood, heart, lung, liver, kidney, brain, etc., which provide a theoretical basis for clinical application. The half-life of borneol after oral administration was 5.3 hours, suggesting that oral borneol does not cause accumulation, but the bioavailability is poor. And pointed out that further research should be to explore the relationship between dosage and dosage form. Chen Tiezhen reports (Chinese Journal of Pharmacology, 199 〇, (1): 42_44) Synthetic borneol promotes the absorption of cypropyrazine. Intramuscular injection of borneol (5mg/kg) in SD rats (with no injection as a control group), intramuscular injection of tetramethylpyrazine phosphate (5mg/kg), analysis of plasma tetramethylpyrazine concentration by gas chromatography This paper scale applies to China National Standard (CNS) A4 specification (210X29^^7" ' 1281400 Ministry of Economic Affairs Central Bureau of Standards Bureau employee consumption cooperatives print A7 B7_5, invention description (^) ... and use NONLIN program to process the data. The Cmax of the two groups were 931 and 562, respectively (p<〇.〇l), and the AUC were 68849 and 3 7 1 74 (P<0.05), respectively, suggesting that borneol can promote the absorption of tetramethylpyrazine instead of accelerating its elimination. Xu Wei et al. (Pharmacology and Clinical Medicine of Chinese Medicine, 199 5,11(6): 31-33) Effects of menthol and borneol on the distribution of sulfadiazine and Evans blue in the brain. Menthol (1.5g/kg, Ig) and borneol (1.5g/kg, ig) can significantly prolong the distribution phase half-life of sulfadiazine in rats. The above dose can also increase the concentration of sulfadiazine in rat brain. Menthol (〇.5g/kg, Ig, three days) and borneol (〇.5g/kg, ig, three days) can increase Evans blue in mice The concentration within the brain was significantly lower than that in the brain of mice with ischemia-reperfusion injury. The above results suggest that menthol and borneol may have the effect of promoting the passage of sulfadiazine through the blood-brain barrier without damage to the blood-brain barrier structure. In the United States, coronary atherosclerotic heart disease is the most common cause of cardiovascular dysfunction and death. Atherosclerosis is a yellow plaque with cholesterol, lipids, and cell debris deposited on the inner wall of the large and middle arteries. Characteristic arterial dysfunction. At the beginning, fatty streaks appear, gradually becoming fibrous plaque or atheromatous lesions, thickening of blood vessels, fibrosis, calcification, narrowing of the lumen of the blood vessels. Many atheromatous plaques remain stable or gradually Development, others can rupture and cause bleeding, platelet activation, and intravascular thrombosis. Coronary thrombosis can lead to partial or complete vascular occlusion, poor blood flow, and instability of angina or myocardial infarction. Broken plaque may be (please read the notes on the back and fill out this page). This paper scale applies to the Chinese national standard. (CNS) A4 specification (210X 297 mm) 1281400 Λ7 B7 Ministry of Economic Affairs Central Bureau of Standards Bureau employee consumption cooperative printing 5, invention description (/〇) ... Stabilized, often greedy leads to more serious stenosis. Sports and mental stress Causes an increase in myocardial aerobics. Under normal physiological conditions, increased blood flow through small arteriolar expansion is sufficient to meet the need for increased myocardial aerobics. In the case of atherosclerosis, the small arteries have expanded to the limit to meet basic oxygen supply. The increased oxygen demand can no longer be met. When aerobic excess exceeds oxygen supply, myocardial ischemia occurs. Severe vascular occlusion, blockage of blood flow, can also lead to myocardial ischemia. The clinical manifestation of transient myocardial ischemia is angina, manifested as sudden chest pain, often radiating to the arm, especially the left arm, or with a sense of suffocation. Angina is subdivided into two types: stability and instability. In most cases, stable angina is caused by an increase in oxygen demand. The factors that increase aerobics are exercise, mental stress, etc. The frequency and duration of seizures are often predictable. On the contrary, it is difficult to find the triggering factor for the unstable angina pectoris, which is often caused by the decrease of myocardial oxygen supply. The rupture of atheromatous plaque, platelet congestion, and coronary thrombosis can reduce myocardial oxygen supply. Methods for treating angina include medication, surgery, coronary artery bypass grafting, balloon angioplasty, and stent placement. Therapeutic stability of angina is the first to reduce myocardial aerobics, which is also a preventive measure. Treatment of acute unstable angina is first considered to inhibit platelet activity and thrombolysis. Current drugs for the treatment of chronic stable angina include nitroglycerin, other nitrates, dance channel blockers, and /3 - adrenergic receptor blockers. Taking these drugs or combination alone can relieve and prevent angina, rather than treating angina. '"This paper scale applies to China National Standard (CNS) A4 specification (210X29Y mm) (please read the note on the back and fill out this page) 1281400 A7 B7 Ministry of Economic Affairs Central Bureau of Standards Staff Cooperatives Printed 5, Invention Description (/ / ) ... When angina pectoris occurs, sublingual nitroglycerin can relieve symptoms, as well as prevent angina pectoris caused by fatigue and tension. Nitrate can also prevent angina attacks. Nitroglycerin and nitrates reduce the myocardial aerobics by relaxing the vascular smoothing machine and reducing myocardial activity. The side effects include inflammatory headache, dizziness, weakness, orthostatic hypotension, and palpitations. /3 - Adrenergic blockers such as propranolol prevent angina by reducing myocardial aerobics during exertion and stress. The main contraindications are bronchial stenosis, slow pulse arrhythmia, and obvious heart failure. Applying a sputum-adrenergic receptor blocker to patients with asthma and other airway obstructive disorders may worsen the condition. Calcium antagonists prevent angina by reducing myocardial aerobics. The myocardium plays a normal function by relying on the influx of calcium. Calcium antagonists prevent angina by inhibiting the influx of calcium to relax vascular smooth muscle, reduce myocardial activity, and reduce myocardial oxygenation. Adverse reactions of calcium antagonists include flushing, edema, dizziness, and nausea. Excessive inhibition of calcium influx into the myocardium can lead to serious side effects such as cardiac arrest, bradycardia, and congestive heart failure. When used in combination with /3 - adrenergic receptor blockers, side effects of calcium antagonists are often aggravated. Since the 200th year of the AD, Sanqi and Salvia have been used in China to treat cardiovascular diseases. Sanqi is used to treat angina pectoris, and salvia miltiorrhiza is used to promote blood stasis. Xu * 〆 Many preclinical studies and clinical studies have demonstrated the efficacy and safety of Panax notoginseng and Salvia miltiorrhiza. Traditional Chinese medicine is generally a mixture of several Chinese herbal medicines. Treatment of coronary heart ________π___ This paper scale applies to Chinese National Standard (CNS) A4 specification (210X297 mm) (Please read the note on the back and fill out this page) 1281400 A7 _____B7_ V. Invention Description (/JZ) - (Please first Read the precautions on the back and fill out this page. In the traditional Chinese medicine, the dosage of Fufang Danshen Tablet has been improved. It is a large oily tablet with a diameter of up to 1cm. Compound Danshen Tablets is composed of Salvia miltiorrhiza extract, Panax notoginseng powder and synthetic borneol. It was included in the Pharmacopoeia of the People's Republic of China in 1977 and has been used to treat cardiovascular diseases for decades. The compound Danshen Drip Nine (also known as Huxin Dan) disclosed in the present invention is a new generation of traditional Chinese medicine for treating coronary heart disease. Traditional Chinese medicines are not only different depending on the medicinal taste of the composition, but also vary with the ratio between the medicinal tastes and the amount of the formulation. In order to control the quality, the compound Danshen Dijiu is produced in a standardized formula, and its therapeutic ingredients contain 10~3〇% (usually about 20%) of water-soluble extract of Salvia miltiorrhiza, 2~6% of water-soluble extract of Panax notoginseng and 1 ~ 3% of borneol. In addition, in order to achieve rapid onset, the compound Danshen Drop Nine is made into a small nine that can be quickly dissolved and absorbed under the tongue. It can quickly enter the bloodstream, reach the heart muscle, and quickly relieve angina. The preclinical study and clinical study of compound Danshen Dianjiu confirmed that the treatment of cardiovascular disease caused by coronary ischemia is safe and effective. Moreover, both preclinical studies and clinical studies have confirmed the compound Danshen drip therapy. Cardiovascular disease is superior to compound Danshen tablets. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. Compound Danshen Dianjiu 199S was included in the Supplementary Edition of the Pharmacopoeia of the People's Republic of China. Since the approval of the Ministry of Health of the People's Republic of China in 993, the compound Danshen Distillation has reached more than 5 million. The compound Danshen Drip Nine (D SP ) disclosed in this patent is a new generation of traditional Chinese medicine for treating coronary heart disease, which is produced according to a standardized prescription. Compound Danshen Drop 9 includes Panax notoginseng, Salvia miltiorrhiza extract and borneol. The _______12 ____ paper scale applies to the Chinese National Standard (CNS) A4 specification (21〇'乂297 mm) 1281400 at B7 V. Invention Description (/J) Sanqi is used to relieve and prevent the onset of angina pectoris; Platelet aggregation prevents the formation of coronary thrombosis, thereby improving blood circulation; borneol is the main component of myocardial therapy. Compound Danshen Drop Nine is a round small nine 'every nine weights of about 25m § ‘ sublingual dissolution, so it can make it more effective. The efficacy of Compound Danshen Dropping Nine in preventing and relieving angina pectoris has been confirmed in clinical and _ clinical studies. The invention discloses a dropping machine which can produce compound Danshen dropping pills or other small nine agents. The present invention also discloses a method for quality control of such a drug, which comprises the use of analytical techniques such as thin layer chromatography and high performance liquid chromatography to identify and quantify the effective components of the drug. 1 Schematic description of the figure Figure 1 · Fingerprint (batch number: 1 9990806) Ministry of Economic Affairs, China Bureau of Standards and Staff, Consumer Cooperatives, printing, r, clearing the back of the stains, please fill out this page) Location of the fingerprint peak: Group I includes 1 #, 2# peak (retention time from 7 to 15 minutes); Π group includes 3#, 4# peak (retention time from 15 to 2 minutes); melon group including 5#, 6#, 7# and 8# Peak (retention time from 20 to 40 minutes). Overall, the peaks of the I groups are the most abundant, so the peak heights of the 1# and 2# peaks are almost the same. The peaks of the Π group stand side by side, the peak height is almost the same, and the abundance is very low. The m group consists of 4 peaks whose peak height is stepped up. These two sets of peaks contain the characteristic peaks of the compound Danshen Drip. _;___ 13_____ This paper scale applies to China National Standard (CNS) A4 specification (210X 297 mm) Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs 1281400 V. Invention Description (/4 ) ... Figure 2 · Fingerprint (batch number: 1 9 9 9 0 8 1 5 ) Figure 3·Fingerprint (batch number: 1 9 9 90 82 3 ) The compound compound Danshen Dripping Pill disclosed in the present invention has the following composition: (a) Salvia miltiorrhiza [water-soluble] extract, Sanqi [Water-soluble] extracts, and borneol; (b) Salvia, Panax notoginseng, borneol and adjuvants; (c) Salvia, Panax notoginseng, borneol and medicinal adjuvants; Danshen and Sanqi used in the above drugs, in China It has been used in the treatment of coronary heart disease since 200 AD. Among them, Sanqi is used to treat angina pectoris, Salvia miltiorrhiza is used to improve blood circulation, and borneol is used to promote the effective ingredients to reach the organs of Geba as soon as possible. Natural borneol has been used since the year 2000. Due to its transitional mining, synthetic borneol is now used in the compound Danshen Drop 9. The invention discloses the following effects of the compound Danshen Dianjiu: (a) treatment of coronary heart disease; (b) treatment of coronary heart disease in combination with other drugs; (〇 is preferred for prevention of coronary heart disease; (d) preferred combination with other drugs for prevention Coronary heart disease; (e) Indirect use for prevention of coronary heart disease; 14 This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) (please read the note on the back and fill out this page) -I# order 1281400 A7 B7 V. Inventive Note (/jf), (f) Indirect use of a combination of drugs to prevent coronary heart disease; (g) Reduce the use of organic nitrates in patients; (h) Reduce blood cholesterol levels. Compound Danshen drops The indications for Nine are coronary atherosclerotic diseases (not limited to this), such as relieving angina pectoris, preventing angina caused by fatigue and tension, and preventing the formation of coronary thrombosis by inhibiting platelet aggregation and promoting blood circulation. Drip Nine can reduce the amount of nitroglycerin that often has the effect of relieving and preventing angina. The application of Compound Danshen Drop 9 can lower the level of cholesterol in plasma. Therefore, coronary atherosclerosis can be prevented from causing damage. Atherosclerosis should be caused by deposition of cholesterol in the blood vessel wall. The present invention discloses a quality control method for such a drug, and the active ingredient is applied by applying techniques such as analysis and identification. Analysis makes the composition and content of the active ingredients in the drug more standardized. The steps are as follows: (a) * Analyze the drug using analytical methods; Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill in the form) (b) Identification and determination of therapeutic components by comparison with corresponding purified standards. The above analysis techniques mainly include thin layer chromatography, high performance liquid chromatography/spectroscopy, etc. The purification of the drug is effective. The ingredients are considered to be active ingredients. For example, the therapeutic ingredients purified in the compound Danshen Drop No. 9 include (not limited to this): saponins, phenolic acids such as Danshensu and borneol, etc. Compound Danshen drops in the middle of ______15 ___ This paper scale applies to the Chinese National Standard (CNS) A4 specification (210, / 297 mm) " 1281400 A7 B7 DESCRIPTION OF THE INVENTION (/6) ,. (Please read the notes on the back and then fill out this page.) The retention time in the effect liquid phase, or the color and position in the thin layer chromatography are compared with the purified standard. It is identified. The quantitative determination of the active ingredient is obtained by comparing the therapeutic part of the compound Danshen Dropping Nine with a known amount of the reference substance. For example, the content of the saponin in the compound Danshen Drop No. 9 is obtained by using a known amount of pure saponin. The compound standard curve is obtained by comparison. The compound Danshen Drop 9 contains 5-40% of the water-soluble phenolic acid component of Salvia miltiorrhiza, 1-10% of the water-soluble saponin of Panax notoginseng and 1-5% of borneol. Nine contains 10-30% of the water-soluble phenolic acid component of Salvia miltiorrhiza, 2-6% of the water-soluble saponin component of Panax notoginseng and i-3% borneol. The present invention discloses a drip nine machine for producing a small nine-agent, which can rapidly dissolve to reach a target organ. The drip machine includes the following parts: (a) The drip tank temperature range is 60-100 ° C (preferably temperature: 89-93 V); (b) The condensate liquid dendrite temperature is lower than 8 ° C; (c) The dripper has an inner diameter of 1.8 mm and an outer diameter of 2.35 mm. (c) The distance between the dripper and the condensate surface is approximately 15 cm. The Central Bureau of Standards and Staff of the Ministry of Economic Affairs prints a small size produced by the above-mentioned drip machine. Nine doses, quickly dissolved after taking. The characteristics of the nine doses are as follows: (a) The diameter is 〇.3 3 -0.3 4 cm; (b) The weight of IX is 2 1.2 5 -2 8.75 mg; (c) The density is 1.13-1.40 mg/mm3. _______16 ____ This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1281400 Ministry of Economic Affairs Central Bureau of Standards Staff Consumer Cooperatives Print A7 B7___ V. Invention Description (, 7) ... Details of the production of compound Danshen Dianjiu The compound Danshen Drop Nine is a small nine doses, each weighing about 25mg, and its active ingredients include water-soluble extracts of Salvia miltiorrhiza and Panax notoginseng and synthetic borneol. Compound Danshen Dropping Nine is produced according to the following method: Sanqi and Salvia miltiorrhiza are separately extracted with boiling water, filtered, and the filtrate is concentrated under reduced pressure, filtered and precipitated. The concentrate is refined with a resin and concentrated under reduced pressure. The purified water-soluble extract is mixed with synthetic borneol and medicinal excipients, and a special nine-dose machine is used to make a small nine-dosage. The quality of the compound Danshen drip is controlled by controlling the main The proportion of therapeutic ingredients is controlled, including saponins, phenolic acids such as Danshensu and borneol. The methods used for the identification and determination of compound Danshen Drop Nine include thin layer chromatography, liquid chromatography, fingerprinting and other analytical methods. Production of Compound Danshen Drip Nine 1. Extraction of water-soluble components of Panax notoginseng: (a) Add 5-7 times the amount of water to the medicinal material; (b) Put the notoginseng into the extraction tank and keep the air pressure at 〇〇4_〇〇6mPa , boiling for 2 hours, extracting its water-soluble ingredients; (Ο re-extracting for 1.5 hours; (d) extract through a 100 mesh sieve; 〆 (e) purifying the filtrate with macroporous adsorption resin, eluting with ethanol; The eluent is concentrated under reduced pressure to a density of Km35, of which the _____17______ paper size applies to the Chinese National Standard (CNS) A4 specification (21〇X: 297 羡1 ~" (please read the notes on the back and fill in the form) This page)

1281400 A7 B7____ 五、發明説明(A?) … 入空氣壓力爲 0 04-0 06 mPa ’真空度爲-0.076〜-0·088 mP a ° (請先閲讀背面之注意事項再填寫本頁) 2 . ·丹參水溶性成分的提取 (a) 藥材加5-7倍量的水; (b) 將丹參放入提取罐,保持氣壓爲0.04-0.06mPa, 煎煮2小時,提取其水溶性成分; (c) 再次提取1.5小時; (d) 濾提取液過100目篩; (e) 真空濃縮濾液,至生藥量1 : 1 ( W/V); (f) 濃縮液加乙醇沈澱; (g) 醇沈液用100目篩濾過; (h) 真空濃縮濾液,進氣壓力爲0.04-0.06 mPa,真空 度爲 0.076-0.088 mPa; (i) .使用葡聚糖凝膠色譜精製,用乙醇洗脫; (j) 洗脫液濃縮至密度爲1.33_ 1.35。 經濟部中央標準局員工消費合作社印製 3.複方丹參滴九成品的生産 (a) 按4·〇:20.6:1.9:79·5稱取丹參提取物、三七提取 物、合成冰片和聚乙二醇- 6000,混合; (b) .混合物加熱熔融; … (Ο用滴九機將混合物製成複方丹參滴九,滴九機技 術參數如下:滴灌溫度保持89_ 93 ,冷凝液液體石蠘溫 18 1281400 A7 B7 五、發明説明(ΛΠ 度低於8°c,滴頭內徑爲1.8mm,滴頭外徑爲2 4mm,滴 頭距離液體石鱲表面距離爲15cm 6 (d)離心,轉速SOO-llOOrpm,;^分鐘,除去石蠘。 複方丹參滴九質量控制 複方丹參滴九包括了已知的治療成分,如原兒茶醛和 皂苷以及許多其他成分。藥物中含有的成分的變化很大。 爲了確保複方丹參滴九的有效成分的含量,因此對其進行 了質量控制,其方法涉及鑒別和含量測定。具體過程如下: (a) 取30粒滴九溶於3 ml甲醇中,超聲處理1〇分鐘; (b) 離心5分鐘; (c) 取上淸液,作爲薄層色譜和液相色譜供試品溶 液; (請先閲讀背面之注意事項再填寫本頁) 醛方 茶複 兒對 原來 、 色 鈉顔 素和 參小 丹大璧 如、行 品置進 照位分 對的成 與中效 品譜有 試色的 供在中 較等九 比苷滴 過皂參 通和丹 別 經濟部中央標準局員工消費合作社印製 品方 試複 供對; 較來量 比色定 過顔和 .通和別 位 的 中 譜 色 在 品 照 對 與 成 效 有 的 中 九 滴 參 丹 小鑒 大行 、 進 置分 相九 的滴 峰/.參 中丹 譜方 圖複 紋別 指鑒 準來 標積 九面 滴峰 參對 丹相。 方和分 複間成 較時效 比留。有 過保的 通If中 f /(\ 適 度 一尺 I張 一紙 本 I釐 公 A7 1281400 B7 _ 五、發明説明U〇 ) … 複方丹參滴九薄層色譜法鑒別 (請先閱讀背面之注意事項再填寫本頁) 一種能夠治療慢性穩定性心絞痛的中藥組合物,用薄層層 析鑒別·其所含丹參素納和原兒茶醛的方法由以下步驟組 成: a) 檢測有如下步驟: .取所述組合物3 0粒,加曱醇3 m 1,超聲1 〇分鐘 使之溶解; .離心5分鐘,取上淸液; .吸取上述溶液1 〇 // 1點於含0.5 %羧甲基纖維素 納的矽膠G板上; •以氯仿-丙酮-甲酸(10: 4: 1.6)爲展開劑,展開; .晾乾,用氨氣熏,放置1 5分鐘後檢查; •在紫外光燈下檢視,供試品色譜中在與對照品色 譜相.應的位置上,顯相同顔色的斑點。 b) 以丹參素納和原兒茶醛爲對照品。 經濟部中央標準局員工消費合作社印製 2 · —種能夠治療慢性穩定性心絞痛的中藥組合物,用薄 層層析鑒別其所含皂ί的方法由以下步驟組成: a)檢測有如下步驟: .取所述組合物3 〇粒,加氨水5 ml,超聲便之溶 解; ‘ .過大孔樹脂柱,洗脫速度爲〇.5/分鐘; ____ 20 ______ 本紙張又度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7 五、發明説明) … .先用1〇ml萃餾水沖洗,再用2ml甲醇洗脫; .收集洗脫液; (請先閲讀背面之注意事項再填寫本頁) •吸取上述溶液1 0 // 1點於含〇 . 5 %羧甲基纖維素 納的矽膠G板上; •以氯仿-丙酮-水(6: 2: 1)在l〇°C放置2小時後的 下層溶液爲展開劑,展開; •晾乾,噴以10%的硫酸乙醇溶液,在l〇5°C烘烤 數分鐘; ♦在可見光下檢視’供試品色譜中在與對照品色譜 相應的位置上,顯相同顔色的斑.點。 b )以總皂苷、三七皂:f R 1和人參皂:f r g 1爲對照品。 複方丹參滴九指紋圖譜 1 .指紋圖譜製備 (1 ) 色譜系統和系統適用性條件 經濟部中央標準局員工消費合作社印製 以十八烷基矽烷鍵合矽膠作爲固定相塡充劑;以混合溶 劑A和B作爲流動相進行梯度洗脫,a爲甲醇,b爲水_ Ν,Ν-二甲 胺-冰醋酸(1〇〇: 45: 4),梯度條件爲0-> 25min,A : 5%— 30% ;檢測波長爲281nm.理論塔板數以 丹參素峰社算應不少於2000。 1 儀器和試劑 2 惠普1100高效液相色譜儀 1281400 A7 B7 五、發明説明(22 ) ’ 惠普VWD-stile紫外檢測器1281400 A7 B7____ V. INSTRUCTIONS (A?) ... The air pressure is 0 04-0 06 mPa 'The vacuum is -0.076~-0·088 mP a ° (Please read the back note first and then fill in this page) 2 · Extraction of water-soluble components of Salvia miltiorrhiza (a) Add 5-7 times of water to the medicinal material; (b) Put the salvia miltiorrhiza into the extraction tank, keep the air pressure at 0.04-0.06 mPa, and decoct for 2 hours to extract the water-soluble components; (c) Extract for another 1.5 hours; (d) Filter the extract through a 100 mesh sieve; (e) Concentrate the filtrate in vacuo to a crude dose of 1: 1 (W/V); (f) Concentrate with ethanol to precipitate; (g) The alcohol precipitation liquid was filtered through a 100 mesh sieve; (h) The filtrate was concentrated under vacuum, the inlet pressure was 0.04-0.06 mPa, and the vacuum was 0.076-0.088 mPa; (i). Purified by dextran gel chromatography and eluted with ethanol. (j) The eluent is concentrated to a density of 1.33 to 1.35. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 3. Production of Compound Danshen Dianjiu (a) Weighed Salvia miltiorrhiza extract, Sanqi extract, synthetic borneol and polyethyl b. by 4·〇:20.6:1.9:79·5 Glycol-6000, mixed; (b). The mixture is heated and melted; ... (The mixture is made into a compound Danshen drop nine with a drip machine, and the technical parameters of the drip nine machine are as follows: drip irrigation temperature is maintained at 89_93, condensate liquid stone temperature 18 1281400 A7 B7 V. INSTRUCTIONS (The temperature is less than 8 ° C, the inner diameter of the dripper is 1.8 mm, the outer diameter of the dripper is 24 mm, and the distance of the dripper from the surface of the liquid stone is 15 cm 6 (d) Centrifugal, rotation speed SOO-llOOrpm,; ^ minutes, remove sarcophagus. Compound Danshen Drop Nine Quality Control Compound Danshen Drop 9 includes known therapeutic ingredients such as protocatechuic aldehyde and saponin and many other ingredients. The composition of the drug varies very much. In order to ensure the content of the active ingredients of the compound Danshen Drop No. 9, the quality control is carried out, and the method involves identification and content determination. The specific process is as follows: (a) Take 30 drops of 9 dissolved in 3 ml of methanol, ultrasound Treatment for 1 minute; (b) centrifugation 5 (c) Take the sputum and use it as a sample solution for thin-layer chromatography and liquid chromatography; (please read the precautions on the back and fill out this page.) Aldehyde tea complexes on the original, serotonin and ginseng Xiaodan Daxu, such as the line of products into the position of the pair of points and the intermediate effect of the product has a trial color in the comparison of the nine-glycosides drip soap and the Danish Ministry of Economic Affairs Central Bureau of Standards staff consumption cooperatives The product side is tested and re-supplied; the color is more than the color of the color and the color of the pass and the other is in the middle of the product and the effect is in the nine drops of the Shen Dan Xiao Jian Da Xing, the placement of the phase of the nine drops Peak /. Participate in the Chinese map of the spectrum of the complex map of the complex map of the standard to the standard of the nine sides of the peak of the peak of the pair of Dan. The square and the division of the complex time ratio than stay. Have a guarantee of the pass If / f / (\ moderate one尺 I张一纸一 I PCT A7 1281400 B7 _ 5, invention description U〇) ... Compound Danshen Drop nine thin layer chromatography identification (please read the back of the note before filling this page) One can treat chronic stable angina Traditional Chinese medicine composition, identified by thin layer chromatography, containing Danshensu The method of protocatechuic aldehyde consists of the following steps: a) The following steps are carried out: 1. Take 30 parts of the composition, add 3 m of sterol, dissolve it by ultrasonic for 1 ; minutes; centrifuge for 5 minutes, take The above solution was taken up 1 〇 / / 1 point on a gelatin G plate containing 0.5% carboxymethylcellulose nano; • chloroform-acetone-formic acid (10: 4: 1.6) as a developing agent; Dry, smear with ammonia, and check for 15 minutes. • Check under ultraviolet light. The chromatogram of the test sample will show the same color spot at the position corresponding to the chromatogram of the reference. b) Take Danshensu sodium and protocatechuic aldehyde as reference. The Central Bureau of Standards of the Ministry of Economic Affairs, the Consumers' Cooperatives, printed 2 kinds of traditional Chinese medicine compositions capable of treating chronic stable angina. The method for identifying the soaps contained by thin layer chromatography consists of the following steps: a) The test has the following steps: Take the composition 3 granules, add 5 ml of ammonia water, dissolve in the ultrasonic; '. Over-porous resin column, elution rate is 〇.5 / min; ____ 20 ______ This paper is again applicable to Chinese national standards (CNS A4 size (210X297 mm) 1281400 A7 B7 V. Invention description) .... First rinse with 1 ml of distilled water and then with 2 ml of methanol; collect the eluent; (please read the precautions on the back) Fill in this page) • Draw the above solution 1 0 // 1 point on a silicone G plate containing 5. 5 % carboxymethylcellulose; • chloroform-acetone-water (6: 2: 1) at l〇° The lower layer solution after 2 hours of C is used as a developing solvent, and unrolled; • air-dried, sprayed with 10% sulfuric acid ethanol solution, and baked at l〇5 °C for several minutes; ♦ under visible light, 'in the chromatogram of the test sample Spots of the same color are displayed at positions corresponding to the chromatogram of the reference substance. b) Total saponin, notoginsenoside: f R 1 and ginseng soap: f r g 1 as reference substance. Compound Danshen Drop Nine Fingerprints 1. Preparation of Fingerprints (1) Chromatographic System and System Suitability Conditions The Ministry of Economic Affairs, Central Bureau of Standards, Staff Consumer Cooperatives, printed octadecyl decane bonded tantalum as a stationary phase sputum; A and B were gradient eluted as mobile phase, a was methanol, b was water _ Ν, Ν-dimethylamine-glacial acetic acid (1 〇〇: 45: 4), gradient condition was 0-> 25 min, A: 5% - 30%; detection wavelength is 281nm. The number of theoretical plates should be no less than 2000 by Danshen Sufeng. 1 Instruments and reagents 2 HP 1100 High Performance Liquid Chromatograph 1281400 A7 B7 V. Inventions (22 ) ’ HP VWD-stile UV Detector

Alltech 公司 ODS 柱(5u,250x4.6mm) (請先閱讀背面之注意事項再填寫本頁)Alltech ODS column (5u, 250x4.6mm) (please read the notes on the back and fill out this page)

Alltech 公司 Alltima C 18 預柱(5u )Alltech Corporation Alltima C 18 Precolumn (5u)

柱溫:3 0 °C (3) 對照品溶液製備 取丹酚酸B、丹參素和原兒茶醛對照品,用曱醇分別配 製成每lml含50 // g、40 // g和10 // g的溶液,作爲對照 品溶液。 (4) 供試品溶液的配製 取滴九10粒,放於25ml容量瓶內,加20ml甲醇,超 聲2 0 m i η使其溶解,放冷,加甲醇稀釋至刻度,離心,取 上淸液爲供試品。 (5) 測定 經濟部中央標準局員工消費合作社印製 精密吸取供試品溶液和對照品溶液各1 〇 # 1,分別注入 色譜儀,記錄色譜圖,計算,即得。 2.複方丹參滴九不同批號指紋圖譜 按上述方法對20批的複方丹參滴九進行了測定,其結 果見表1 4、1 5和16。測定的資料顯示,複方丹參滴九具 有自己獨特的指紋圖譜,有8個峰共同存在于複方丹參滴 九不同的批號中。以原兒茶醛峰爲參考峰(相對保留時間 ____22_____ 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐)^ ’ 1281400 at B7 五、發明説明Us) … 爲1 ),測得這8個峰的相對保留時間分別爲〇.6 72,1 ·00 ^ 1.417,1.512,2.016,2.2 35,2.407,2.757,其相對保留時間 和峰面積的値在不同批號中相當穩定。在8個峰中,1號 峰爲丹參素,2號峰爲原兒茶醛,7號峰爲丹酚酸B,它們 的相對峰面積的比率分別爲 0.476-0.668: 1: 0.3 9 1 · 0.6 4 1。三批樣品的指紋圖譜見圖1、圖2和圖3。 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 23 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7B7 五、發明説明U4) M NJ K) N) K) K) -JOCN〇^0^.〇^.〇U)〇l〇〇 lOOOO — OlOOOOlsJ C\〇aN〇w〇NJ〇〇N〇〇j〇〇s〇c\〇^v〇 〇〇〇〇〇〇〇 〇 — * O v〇 ,Column temperature: 30 °C (3) Preparation of reference solution to take salvianolic acid B, Danshensu and protocatechuic aldehyde reference substance, prepared with sterol to form 50 // g, 40 // g per lml and 10 / g solution, as a reference solution. (4) Preparation of the test solution: Take 10 pieces of 10 drops, put in a 25ml volumetric flask, add 20ml of methanol, dissolve it by ultrasonic 20 μm, let cool, add methanol to dilute to the mark, centrifuge, and take the sputum For the test. (5) Measurement Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs. The precision sample solution and the reference solution are each 1 〇 # 1, respectively injected into the chromatograph, and the chromatogram is recorded and calculated. 2. Compound Danshen Dropping Nine Different Batch Fingerprints Twenty batches of compound Danshen Drips were measured according to the above method. The results are shown in Tables 1, 4, 15 and 16. The measured data showed that the compound Danshen Drop Nine has its own unique fingerprint map, and 8 peaks coexist in the different batch numbers of the compound Danshen Drop. The reference value of the original tea aldehyde peak (relative retention time ____22_____) This paper scale applies Chinese National Standard (CNS) Α4 specification (210Χ297 mm)^ '1281400 at B7 V. Invention description Us) ... is 1), measured The relative retention times of the eight peaks were 〇.6 72,1 ·00 ^ 1.417, 1.512, 2.016, 2.2 35, 2.407, 2.757, and their relative retention times and peak areas were quite stable in different batches. Among the 8 peaks, the 1st peak is Danshensu, the 2nd peak is protocatechuic aldehyde, and the 7th peak is salvianolic acid B, and their relative peak area ratios are 0.476-0.668: 1: 0.3 9 1 · 0.6 4 1. The fingerprints of the three batches of samples are shown in Figures 1, 2 and 3. (Please read the notes on the back and fill out this page.) Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs 23 Paper scale applicable to China National Standard (CNS) A4 specification (210X297 mm) 1281400 A7B7 V. Invention description U4) M N) K) N) K) K) -JOCN〇^0^.〇^.〇U)〇l〇〇lOOOO — OlOOOOlsJ C\〇aN〇w〇NJ〇〇N〇〇j〇〇s〇c\〇 ^v〇〇〇〇〇〇〇〇〇— * O v〇 ,

t〇VC〇V〇〇'〇〇V〇'〇VCS〇S〇〇〇V〇〇〇VC〇〇VC O ·— Ο Ο Ο Ο Ό ,〒·美 CfrOO — v〇t〇Oi〇v〇i〇v〇i"-v〇〇\D v〇 Ό v〇 CNV〇^.v〇OOO^—v〇U)v〇Utv〇C\v〇 — — 〇〇〇〇〇t〇VC〇V〇〇'〇〇V〇'〇VCS〇S〇〇〇V〇〇〇VC〇〇VC O ·—Ο Ο Ο Ο Ό ,〒·美 CfrOO — v〇t〇Oi〇v〇 I〇v〇i"-v〇〇\D v〇Ό v〇CNV〇^.v〇OOO^—v〇U)v〇Utv〇C\v〇— —

一薄黑 (/¾ g S 00.3為7 0.6 7 6 00. 3 1 3 0.6 7 6 00.28 50.672 00.302 0.672 8.299 0.672 00. 2 9 0 0.6 7 2 8.295 0.672 1 8.2860.672 1 00. 2 9 1 0.6 7 2 .00. 2 9 1 0.6 7 2 8.2007 0.672 00. 2 9 么 0.6 7 1 8.256 0.670 8.272 0.670 00.2 7公 0.670 00.276 0.670 8.273 0.670 OO.28 30.670 ;U» —办·— ς/» —公 CN i〇 --J K) Ο N) 00 一么一 一 LAi 一 一么一办一 t〇 一 W 一·一 一 L/i 一 W 一 Ο 一么一 t〇\〇K>v〇K)S>K)〇〇t〇〇t〇i— lOvoto^jto^tOiotootoooto^K),— to 2雞標 ^—3, 1.000 1 · 000 0 0 0 0 0 0 0 0 0 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 000 1.000 17.6 6 2 17.6 3 1 1 7 .厶 900 17.5 5 3 17.5 為9 1 7 λ 9 6 17.5 13 1 7Μ 77 17.5 02 17.5 0 0 17.5 0 3 17.5 3 6 1 7.厶 0 2 1 7 .厶 200 1 7丄 2 5 1 7 .办 3 9 1 7.厶 2 1 1 7.厶 13 ο 一 一 一 t—^ to 一 一 一 一 to VO hJ 一 〇 Ό 00 00 00 〇 S〇 ►—* VO * 00 00 '-J 00 Ν-» I—» I— 00 u\ as O ►—1 K> ^ O ^ 00 ►—k 〇s »—* 〇S »—» ^ V00000000\00--J00-U00v£)00〇00t000U)00^J00A thin black (/3⁄4 g S 00.3 is 7 0.6 7 6 00. 3 1 3 0.6 7 6 00.28 50.672 00.302 0.672 8.299 0.672 00. 2 9 0 0.6 7 2 8.295 0.672 1 8.2860.672 1 00. 2 9 1 0.6 7 2 .00. 2 9 1 0.6 7 2 8.2007 0.672 00. 2 9 0.67 1 8.256 0.670 8.272 0.670 00.2 7 public 0.670 00.276 0.670 8.273 0.670 OO.28 30.670 ;U»—办·— ς/» — public CN i 〇--JK) Ο N) 00 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一〇一〇一〇一〇一〇K>v〇K)S> K)〇〇t〇〇t〇i— lOvoto^jto^tOiotootoooto^K), — to 2 chicken standard^—3, 1.000 1 · 000 0 0 0 0 0 0 0 0 0 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 000 1.000 17.6 6 2 17.6 3 1 1 7 .厶900 17.5 5 3 17.5 is 9 1 7 λ 9 6 17.5 13 1 7Μ 77 17.5 02 17.5 0 0 17.5 0 3 17.5 3 6 1 7.厶0 2 1 7 .厶200 1 7丄2 5 1 7 .3 3 1 7.厶2 1 1 7.厶13 ο 一一一t —^ to 一一一to to VO hJ 一〇Ό 00 00 00 〇S〇►—* VO * 00 00 '-J 00 Ν-» I—» I— 00 u\ as O ►—1 K> ^ O ^ 00 ►—k 〇s »—* S »-» ^ V00000000 \ 00 - J00-U00v £) 00〇00t000U) 00 ^ J00

KJKJ

U to 一 u> u> ·— 00 u> _ -J Os 0\U to a u>u> ·— 00 u> _ -J Os 0\

t〇 »—* W η-* ^ 〇s i—* 〇 -•JOOVOOOWOOVOOONJOO o o On t-Ao o 1-Λo 00 o Ό N—*u»T〇 »—* W η-* ^ 〇s i—* 〇 -•JOOVOOOWOOVOOONJOO o o On t-Ao o 1-Λo 00 o Ό N—*u»

Ui — K)Ui — K)

OiOi

Ui H-» u> K) to -t^ J^NJ^K>v〇t〇v〇b〇^t〇CNt〇OOK>a\l〇〇Nt〇0〇NJ^K>0〇b〇Ot〇^t〇OMU)t〇-gN>Ot〇 公么 CaA — J^vc 办 CO 各 公 to^tktoj^toj^vo 公 U)«^00«fc^U»iyi 公 3 涵®a S 56 涵晒 Φ 5ία 搽 0 3 3 0 3 8 02 9 02 5 02 1 0 17 0 17 0 16 0 16 0 15 0 15 0 15 0 17 0 12 0000 0 0 7 005 003 ^.tOUitO^JtONOKiUitO^tOvOKJ^iOCNiOvOiO'JNJOroOMONtO'—tO^KiVOtOOtOra^ 經濟部中央標準局員工消費合作社印製 2.253 2 5 9 2厶9 2為办 2 3 9 2 3 6 2 3 7 2 3 6 2 3 6 2 3厶 2 3 5 2 3办 2 3 5 2 3 0 2 2 7 2 2 5 22 3 22 1 —Ν) N) K) Ul to K) 一 to to U) lO K> to o N) U) S) K) ΙΟ K) l〇 o -J Κ) Ό Κ) U) ν〇 u v〇 Ui v〇 K) v〇 U) v〇 v〇 O v〇 Ό 00 v〇 -0 K> VO VO U) VO Ln ν〇 ν〇 Cs ο ο Ui KJ\ U\ LA Cs a\ -J 00 00 00 ο ο 涵Ε§ K) K) to to s> s> to s> S) to K) K> NJ κ> to C-wT U> U) u> (-〇 UJ 办 办 么 搽 00 v〇 v〇 v〇 o O o o ι- — N—» — 一 Κ) U) VO 一 u> 00 VO '-J Ο 一 o U> Ό U> s> K)U)|— 1 U) CnU>〇NU)S>U)〇UJK>U)i--*U)·— Ό VC o cT O 〇 O o ο o o O 一 一 ο 〇〇 S) to Si K) to to to ί〇 to NJ K) ΪΟ to Κ) K) c-Cjr 7 6 7 7 7 1 77 1 766 7 5 8 Ί 5 6 7 5 7 7 5 9 7 5 7 756 7 5 8 7 5 8 7 6 3 7 5払 7 5 1 7-4 9 *M 7 74 6 24 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 霉 c-wP 攝 S Βΰ 驻 1¾¾¾ 架軺 E. iUi H-» u> K) to -t^ J^NJ^K>v〇t〇v〇b〇^t〇CNt〇OOK>a\l〇〇Nt〇0〇NJ^K>0〇b〇 Ot〇^t〇OMU)t〇-gN>Ot〇公么CaA — J^vc Office CO Each to^tktoj^toj^vo Public U)«^00«fc^U»iyi 公3 涵®a S 56 涵晒Φ 5ία 搽0 3 3 0 3 8 02 9 02 5 02 1 0 17 0 17 0 16 0 16 0 15 0 15 0 15 0 17 0 12 0000 0 0 7 005 003 ^.tOUitO^JtONOKiUitO^tOvOKJ^ iOCNiOvOiO'JNJOroOMONtO'-tO^KiVOtOOtOra^ Ministry of Economic Affairs Central Bureau of Standards Staff Consumer Cooperatives Printed 2.253 2 5 9 2厶9 2 for Office 2 3 9 2 3 6 2 3 7 2 3 6 2 3 6 2 3厶2 3 5 2 3 Office 2 3 5 2 3 0 2 2 7 2 2 5 22 3 22 1 —Ν) N) K) Ul to K) One to to U) lO K> to o N) U) S) K) ΙΟ K L〇o -J Κ) Ό Κ) U) ν〇uv〇Ui v〇K) v〇U) v〇v〇O v〇Ό 00 v〇-0 K> VO VO U) VO Ln ν〇ν 〇Cs ο ο Ui KJ\ U\ LA Cs a\ -J 00 00 00 ο ο 涵Ε§ K) K) to to s>s> to s> S) to K) K> NJ κ> to C-wT U> U) u> (-〇UJ?搽00 v〇v〇v〇o O oo ι- — N—» — one U) U) VO a u> 00 VO '-J Ο a u U> Ό U>s> K)U)|— 1 U CnU>〇NU)S>U)〇UJK>U)i--*U)·— Ό VC o cT O 〇O o ο oo O 一 ο 〇〇S) to Si K) to to 〇 To NJ K) ΪΟ to Κ) K) c-Cjr 7 6 7 7 7 1 77 1 766 7 5 8 Ί 5 6 7 5 7 7 5 9 7 5 7 756 7 5 8 7 5 8 7 6 3 7 5払7 5 1 7-4 9 *M 7 74 6 24 This paper size applies to Chinese National Standard (CNS) Α4 size (210Χ297 mm). Mold c-wP SS Βΰ Station 13⁄43⁄43⁄4 轺E. i

(請先閱讀背面之注意事項再填寫本頁) -裝· 訂 1281400 A7 B7 五、發明説明(2i) 2 0 0 0 0 7 2 8 2 0 0 0 0 8 CM zps β USD%(Please read the notes on the back and fill out this page) -Installation · Order 1281400 A7 B7 V. Inventions (2i) 2 0 0 0 0 7 2 8 2 0 0 0 0 8 CM zps β USD%

8.287 00. 2 7厶 8.289 0.225 0.670 0.670 0.672 0 · 2 6 68.287 00. 2 7厶 8.289 0.225 0.670 0.670 0.672 0 · 2 6 6

U) s> N— to 〇〇 KJ 1.000 1.000 1.000 0.000 〇 \〇 I— 00 I • U) Ui v〇 ^ 么公私 <U 、J N) 上 I 〇 〇S V〇 ►—* KJ\ h—» 00 00 U> 00 OJ · — On < σ\ toU) s> N—to 〇〇KJ 1.000 1.000 1.000 0.000 〇\〇I— 00 I • U) Ui v〇^ Public-private <U, JN) On I 〇〇SV〇►—* KJ\ h—» 00 00 U> 00 OJ · — On < σ\ to

Ui o σ\ o 00 2 7.5 2.00 6 0 0 2.ΪΟ23 2 7 M 2.00-u厶一 2.222 27· 5 2.016 86 2.235 0.39 0·為 76 9 0.^63 3涵 菊晒 眾 fLgm fnlllgf 蔽ffi UE-Ui o σ\ o 00 2 7.5 2.00 6 0 0 2.ΪΟ23 2 7 M 2.00-u厶2.222 27· 5 2.016 86 2.235 0.39 0· is 76 9 0.^63 3 涵菊晒众fLgm fnlllgf cover ffi UE -

SSIaa您 箱 E^iai0 31¾¾^ ^ ^ ffi8¾ sKK眾涵S2SS 晒 0 βSSIaa you box E^iai0 313⁄43⁄4^ ^ ^ ffi83⁄4 sKK Zhonghan S2SS Sun 0 β

BfB (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製BfB (please read the notes on the back and fill out this page) Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs

W oo — K> —ts^^jro ^ V〇 v〇 U> VO 〇 ί〇 Κ) κ> 〇\ u> u> 〇 〇 VO as ο 一 v〇〇UiW J^U>OU> 〇 各—OJ — «fck S) — O VD O Ο Κ) N) Κ) -J Lh u> oc v〇W oo — K> —ts^^jro ^ V〇v〇U> VO 〇ί〇Κ) κ> 〇\ u>u> 〇〇VO as ο a v〇〇UiW J^U>OU> OJ — «fck S) — O VD O Ο Κ) N) Κ) -J Lh u> oc v〇

lrs=I 00雜# zr 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400Lrs=I 00杂# zr This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1281400

AA

7 B 五 1 9 9 9 0000 61 9 9 9 0OC151 9 9 9 0002 . 3 1999092 1 1999092 00 1999101 么1999102 6 19991109 19991127 19991205 2000010 6 . 2000021 6 2000032) 3 彡2 0 0 0 0為0 26 ^ 0 0 0 0厶2 2印 2 0 0 0 0 5 1説 W ^>2000060 6發2000072 0 3 1 0 5 3 .〇〇0 00 5 1 0 8 9.6 0 0 0 ^ 二 3 0 〇〇0 0 0 1 1 1 Μ . 9 0 0 000 1 0 8 0.0 0 0 0 9 1 1 3 2 · 6 0 0 0 3 1 1 2 為· 4 0 0 000 1 0 800. 2 0 0 0 ^ 1033.20 0 0 5 9005.2 50 0 9 10^-4.8 0 0 003 厶.3 0 0 1 0 3 6.1 0 0 9OC0.8厶 0 1 0 6 8.0 0 0 9 Ξ . 6 6 0 9700. 10 0 9 7厶 32 6 6 1 5 6 3 0 0 5 7 一么办00 0 0 5 7 1OO00 0 0 5 6 1 72 6 0 0 5厶 1 9為3 0 0 5 8 1 6 7 0 0 0 5 5 1 7 500 0 0 6 0 16 17 0 0 5 6 1 8 6 5 0 0 5 6 1 9 3 1 0 0 5 7 1 9 7 9 00 5 厶IO0U)為 0 0 5 9 1000 1 0 0 500JVO為u> 0 0 5 0 22 1 2 0 0 56 1928 0 0 57 1796 0 0 5 6 1 7 3 0 0 07 B 5 1 9 9 9 0000 61 9 9 9 0OC151 9 9 9 0002 . 3 1999092 1 1999092 00 1999101 19991998 6 19991109 19991127 19991205 2000010 6 . 2000021 6 2000032) 3 彡2 0 0 0 0 is 0 26 ^ 0 0 0 0厶2 2印2 0 0 0 0 5 1 said W ^>2000060 6 issued 2000072 0 3 1 0 5 3 .〇〇0 00 5 1 0 8 9.6 0 0 0 ^ 2 3 0 〇〇0 0 0 1 1 1 Μ . 9 0 0 000 1 0 8 0.0 0 0 0 9 1 1 3 2 · 6 0 0 0 3 1 1 2 for · 4 0 0 000 1 0 800. 2 0 0 0 ^ 1033.20 0 0 5 9005.2 50 0 9 10^-4.8 0 0 003 厶.3 0 0 1 0 3 6.1 0 0 9OC0.8厶0 1 0 6 8.0 0 0 9 Ξ . 6 6 0 9700. 10 0 9 7厶32 6 6 1 5 6 3 0 0 5 7 One 00 0 0 5 7 1OO00 0 0 5 6 1 72 6 0 0 5厶1 9 is 3 0 0 5 8 1 6 7 0 0 0 5 5 1 7 500 0 0 6 0 16 17 0 0 5 6 1 8 6 5 0 0 5 6 1 9 3 1 0 0 5 7 1 9 7 9 00 5 厶IO0U) is 0 0 5 9 1000 1 0 0 500JVO is u> 0 0 5 0 22 1 2 0 0 56 1928 0 0 57 1796 0 0 5 6 1 7 3 0 0 0

K)〇Jtou)t〇v〇〇\〇〇K>u> N--vc^j〇o〇u>vcoo 〇 O O O O CD O O O O ^ O 0 0 2 6 9 0 0 0 3 5 9 0 0 0 么0 9 0 0 0 3 7 9 0 0 0 3 9 7 0 0 0 3 5 3 0 0 0 3 為 8 0 0 0 3 3 4 0 0 0 厶 1 3 0 0 0 3 9 1 0 0 0 厶 0 8 0 0 0 厶 1 9 0 0 0 3 2 3 0 00^31 0 0 0 3 7 8 0 0 0 3 9 0 0 00 厶08 0 0 0 3002 0 U\ • o .K)〇Jtou)t〇v〇〇\〇〇K>u>N--vc^j〇o〇u>vcoo 〇OOOO CD OOOO ^ O 0 0 2 6 9 0 0 0 3 5 9 0 0 0 0 9 0 0 0 3 7 9 0 0 0 3 9 7 0 0 0 3 5 3 0 0 0 3 is 8 0 0 0 3 3 4 0 0 0 厶1 3 0 0 0 3 9 1 0 0 0 厶0 8 0 0 0 厶1 9 0 0 0 3 2 3 0 00^31 0 0 0 3 7 8 0 0 0 3 9 0 0 00 厶08 0 0 0 3002 0 U\ • o .

to hJ O Ln O to Ο I o 00 00 o v〇 VO C\ K) K> to u> o Lrt o σ\ OK)〇^OOCN〇〇s〇U>〇lsJ〇To hJ O Ln O to Ο I o 00 00 o v〇 VO C\ K) K> to u> o Lrt o σ\ OK)〇^OOCN〇〇s〇U>〇lsJ〇

〇〇〇〇*— O-C^OOO 17 2^0 0 2办 3厶7 ο 2 2 3 3 厶 ο 2 2 3 1 7 ο 2 0 3 2 9 ο 2 1 2 9 7 ο 19 2002 ο 2 0 2 7 5 ο 2 2 3 2 7 0 2 0 3 3 公 0 2 0 3 公 7 0 20 為 26 0 1 7 2 9厶 0 2 2 3*Μ 0 1 7 3 5 6 0 2 0 3 3 1 0 2 2 3 3 3 0 2 2 3 2 2 0〇〇〇〇*— OC^OOO 17 2^0 0 2 Office 3厶7 ο 2 2 3 3 厶ο 2 2 3 1 7 ο 2 0 3 2 9 ο 2 1 2 9 7 ο 19 2002 ο 2 0 2 7 5 ο 2 2 3 2 7 0 2 0 3 3 Male 0 2 0 3 Male 7 0 20 is 26 0 1 7 2 9厶0 2 2 3*Μ 0 1 7 3 5 6 0 2 0 3 3 1 0 2 2 3 3 3 0 2 2 3 2 2 0

K>r〇M〇\〇o^j〇oot〇C\ 〇L^〇s 么 \〇 — II— N-*v〇^〇\〇j\〇^ ^ Ut U\ bJ 〇\ 00 ^ 〇N〇^Ot〇0^-0〇J〇J^〇v〇〇C\〇U>〇C\〇00*— OOOOvOO-^OOnOOOJ^O 1 5 2 6 6 0 2 办 3^0 0 18 為 8 6 0 18^98 0 1 6 5 1 4 0 1 7 5CM 0 16^51 0 1 7 4 7 7 0 17^99 0 1 7 各600 0 1 7 5 1 2 0 2 0 5 70 0 1 6 5 6 2 0 1 9 6 0 9 0 1 6 5 *M 0* 1 7丄 6 6 0 100厶ooLn 0 1 8 5 0 2 0K>r〇M〇\〇o^j〇oot〇C\ 〇L^〇s 么\〇—II—N-*v〇^〇\〇j\〇^ ^ Ut U\ bJ 〇\ 00 ^ 〇 N〇^Ot〇0^-0〇J〇J^〇v〇〇C\〇U>〇C\〇00*— OOOOvOO-^OOnOOOJ^O 1 5 2 6 6 0 2 Do 3^0 0 18 8 6 0 18^98 0 1 6 5 1 4 0 1 7 5CM 0 16^51 0 1 7 4 7 7 0 17^99 0 1 7 Each 600 0 1 7 5 1 2 0 2 0 5 70 0 1 6 5 6 2 0 1 9 6 0 9 0 1 6 5 *M 0* 1 7丄6 6 0 100厶ooLn 0 1 8 5 0 2 0

UiiOOON·— L^'vJOtO'vJUJUiOOtO ^^UiO <-^OLA Ul00K>iO4^·— U>V〇〇〇^O^sJU»v〇Jik OOOOlOOOOOJOKJON-OsooSiOooo^O'^JOtOOLAO^OOOO^OOO K>K)t〇K)UJU)K)K)NJ K> S>K> Uit〇K>t〇K>^ 5 8 3 0 3公8 0 為9 5 0 為7 9 0 5 9 5 0 5 04 0 為一 6 0 厶9 1 0 52 1 0 52 1 0 5 19 0 52 1 0 602 0 65 5 0 6 9 2 0 5 100 0 為9 2 0 為8 3 0 OVOMVOOO^-·— 00〇\V〇CNUlC>^.00 〇NK)〇>JU>a\〇ly»0^ I— ο ο 1-Λ OJ 〇 VO U) vOOJu.OvOOWO'vJOJi.OONOlOOOOvOO^O^JOlOO^OOOOUtO^-OU» 經濟部中央標準局員工消費合作社印製 371001.8 0 0 2 厶 6 0 0.2 1 0 2 7 8 2 3 M3 0 27 875.厶公 0 30 1092.7 0 0 3 0007 9.4 2 0 -230000.66 0 30836.83 0 -27 1 S7.2 00 2 7009 0.000 0 2 6 8 9 1 .009 0 25 1232.2 00 3 3 10厶1 . 6 00 3 3 1 1 6 6.6 0 0 3 1 1 1009.7 00 26 886.30 0 -2 7 8 2 1.5 2 0 .2700000.2 1 0 5 0 0.6厶 么一 公5 5 0 5 6 5 2 公5 5 1 5 6 1 0.^6 1 厶5 6 0 5 *7 6 0 5 3 為6 厶5 1 5 6 8.0 0 0 9 9 4.7厶 0 16 3 2 0 0 1 5 100 0 0 182 8 0 0 13 7 8 0 0 13 0 3 0 0 13 02 00 16-4 3 00 1 6 5 9 0 0 17^7 0 0 1767 0 0 1 5厶厶 〇〇 , 1 6為2 0 0 17 5 8 0 0 1750 0 0 1 6 1 3 0 0 15 2 3 0 0 2 2 0 8 0 7 8 〇 00 〇 00 〇 Ui ο Ο、 JO v〇 O ί〇 O VO o — -o ON o — o Lh 〇 o o o o、 JO' JO u> 一 00 00 00 0〇 00 00 00 00 00 oc 00 VC a\ o 00 VO ο VO Ln On 00 KJ\ 00 o 00 o 00 o 2ί 0〇n〇v〇〇v〇〇〇〇〇〇n〇C\〇0〇0 00 Cn I O 00 O U) oUiiOOON·—L^'vJOtO'vJUJUiOOtO ^^UiO <-^OLA Ul00K>iO4^·— U>V〇〇〇^O^sJU»v〇Jik OOOOlOOOOOJOKJON-OsooSiOooo^O'^JOtOOLAO^OOOO^OOO K&gt ;K)t〇K)UJU)K)K)NJ K>S>K>Uit〇K>t〇K>^ 5 8 3 0 3 public 8 0 is 9 5 0 is 7 9 0 5 9 5 0 5 04 0 is a 6 0 厶 9 1 0 52 1 0 52 1 0 5 19 0 52 1 0 602 0 65 5 0 6 9 2 0 5 100 0 is 9 2 0 is 8 3 0 OVOMVOOO^-·- 00〇\ V〇CNUlC>^.00 〇NK)〇>JU>a\〇ly»0^ I- ο ο 1-Λ OJ 〇VO U) vOOJu.OvOOWO'vJOJi.OONOlOOOOvOO^O^JOlOO^OOOOUtO^-OU » Department of Economics, Central Bureau of Standards, Staff Consumer Cooperatives, Printing 371001.8 0 0 2 厶6 0 0.2 1 0 2 7 8 2 3 M3 0 27 875. 厶公0 30 1092.7 0 0 3 0007 9.4 2 0 -230000.66 0 30836.83 0 -27 1 S7.2 00 2 7009 0.000 0 2 6 8 9 1 .009 0 25 1232.2 00 3 3 10厶1 . 6 00 3 3 1 1 6 6.6 0 0 3 1 1 1009.7 00 26 886.30 0 -2 7 8 2 1.5 2 0 .2700000.2 1 0 5 0 0.6厶么一公5 5 0 5 6 5 2 公 5 5 1 5 6 1 0.^6 1 厶5 6 0 5 *7 6 0 5 3 is 6 厶5 1 5 6 8.0 0 0 9 9 4.7厶0 16 3 2 0 0 1 5 100 0 0 182 8 0 0 13 7 8 0 0 13 0 3 0 0 13 02 00 16-4 3 00 1 6 5 9 0 0 17^7 0 0 1767 0 0 1 5厶厶〇〇, 1 6 is 2 0 0 17 5 8 0 0 1750 0 0 1 6 1 3 0 0 15 2 3 0 0 2 2 0 8 0 7 8 〇00 〇00 〇Ui ο Ο, JO v〇O 〇O VO o — -o ON o — o Lh 〇oooo, JO' JO u> 00 00 00 0〇00 00 00 00 00 oc 00 VC a\ o 00 VO ο VO Ln On 00 KJ\ 00 o 00 o 00 o 2ί 0〇n〇v〇〇v〇〇〇〇〇〇n〇C\〇0〇 0 00 Cn IO 00 OU) o

(請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7 五、發明説明U/) 2000072 1120.3 0.52 21 400.5 1.00 厶 10.92 0.19 385.5 厶 0.17 621.25 0.200 0020 100 00 10 90 9 2 0 0 0 0000003 1 . 3 2 0 · 5 7 一為厶 0.3 1.0 0 3 2 1.2 5 0.2 2 3 0 1.2 8 0.2 0 3 2 1.2 私 0.22 4 ο η000 0 3 0 9 0 3 1034.2 0·57 10017.0 1.00 3 76.5 4 0.20 328.01 0.100為 86.62 0.26 -Hse7 6 265 07 8 1 1 6 7 5.6 1 0.0 0 9.3 5 1 1 ·0 12.6 USDve/o00.厶006 2 11.厶 520 10.91-4 厶 12.55303 100.592900(Please read the notes on the back and fill out this page.) The paper size applies to the Chinese National Standard (CNS) A4 specification (210X297 mm) 1281400 A7 B7 V. Invention description U/) 2000072 1120.3 0.52 21 400.5 1.00 厶10.92 0.19 385.5厶0.17 621.25 0.200 0020 100 00 10 90 9 2 0 0 0 0000003 1 . 3 2 0 · 5 7 One is 厶0.3 1.0 0 3 2 1.2 5 0.2 2 3 0 1.2 8 0.2 0 3 2 1.2 Private 0.22 4 ο η000 0 3 0 9 0 3 1034.2 0·57 10017.0 1.00 3 76.5 4 0.20 328.01 0.100 is 86.62 0.26 -Hse7 6 265 07 8 1 1 6 7 5.6 1 0.0 0 9.3 5 1 1 ·0 12.6 USDve/o00.厶006 2 11.厶520 10.91-4 厶12.55303 100.592900

到a a» 到3 一一 到¾ 到α (請先閱讀背面之注意事項再填寫本頁) 裝· 訂 »— K> U» O U) O ON α\ οο to as i ΟΝ 1 VO K) to VO O U) o to to 到¾ 經濟部中央標準局員工消費合作社印製 si 二 7 8.2 0.5 么 0 000 683.27 0.^7 0 為 9為 0.9 6 0.5 1 3 6 12.0 1 8 . 2 9 2 6 1 1 6 923 0.7 8 0 0 8 1 0001 . 3 0.7 5 6 0 1 1 5 厶 7 .私 0 . 8 5 9 5 0 8.6公 Μ . 7 3 9 7 到3 到3〃 tt撕 到¾ 27 本紙張又度適用中國國家標準(CNS ) Α4規格(210Χ 297公釐) 1281400Go to aa» to 3 one to 3⁄4 to α (please read the notes on the back and fill out this page) Loading · Booking »—K> U» OU) O ON α\ οο to as i ΟΝ 1 VO K) to VO OU) o to to to 3⁄4 Ministry of Economic Affairs Central Bureau of Standards Staff Consumer Cooperatives printed si 2 7 8.2 0.5 0 000 683.27 0.^7 0 9 is 0.9 6 0.5 1 3 6 12.0 1 8 . 2 9 2 6 1 1 6 923 0.7 8 0 0 8 1 0001 . 3 0.7 5 6 0 1 1 5 厶 7. Private 0 . 8 5 9 5 0 8.6 mm 7 7 3 9 7 to 3 to 3 〃 tt to 3⁄4 27 paper Applicable to China National Standard (CNS) Α4 specification (210Χ 297 mm) 1281400

1 2 3 4 5 6 8 〇 1034.2 8,289 0.672 1 0 0% 76 0.572 1,… 1817.0 12343 1.000 1 00% 65 1.000 1 7 … 3 76.5 4 17 493 1.4 1 7 1 00% 7 0.208 1 R … 3 2 8.0 1 18.664 1.5 1 2 1 0 0% 1 0.181 486.62 248 8 3 2.016 1 0 0 % 6 0.267 c 525.43 275 86 2.23 5 1 0 0% 2 0.289 , 940.96 29.714 2.407 1 0 0% 3 0.516 1 547.4 2.757 1 00% 95 0850 (K 572土 0.096 1.000土 0.000 0.208土 0.040 0. 181土 0.059 0.267土 0.097 0 · 2 8 9 土 0.052 0.5 1 6 土 0.125 0.850土 0 163 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 複方丹參滴九中丹參素含量測定 (1) 色譜系統及系統適用性條件 使用十八烷基矽烷鍵合矽膠爲塡充劑,以水-乙腈-冰醋 酸(87: 12: 1)爲流動相。檢測波長281ηιη。理論塔板數按丹 參素計算不得低於25 〇〇,分離度符合要求。 (2) 儀器與試劑 色譜儀:Agilent 1100 液相色譜 檢測器:Agilent VWD 紫外檢測器 色譜柱:Alltech 公司 ODS 柱(250 x 4.6 mm,5// ) 預柱:Alltech 公司,AlltimaC18 5/z 預柱 , 柱溫:WQC , 乙腈:色譜純,天津三友生物技術有限公司 冰醋酸:分析純,天津天河試劑公司 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 1281400 A7 ______B7_____ 五、發明説明) … (3 )對照品溶液的製備 取丹參素鈉對照品.25.0mg,精密稱定,置5〇ml量瓶中, 加流動相溶解並稀釋至刻度,搖勻,作爲對照品儲備液; 精密稱定對氨基苯甲酸,流動相稀釋成0.2 mg/ml,作爲內 標物儲備液。精密吸取丹參素鈉儲備液和內標儲備液適 量,用流動相稀釋,製成每lml中含丹參素鈉50pg、對氨 基苯甲酸80 的溶液,作爲對照品溶液。加甲醇製成每 lml含1 mg的溶液,即得。 (4 )供試品溶液的製備 取本品1 0粒,內標儲備液1 m卜置2 5 m 1量瓶,流動相 溶解’定容至刻度,作爲供試品溶液。 (5 )測定 分別取對照品及供試品溶液1 01進樣,紀錄色譜圖,計 算,即得。 · n 丹參素含量應在0. 14-0. 1 8mg/粒。 - 複方丹參滴九中人參皂苷Rgl和三七皂苷Ri的含量測定 (1 )色譜系統和系統適用性條件 以十八烷基矽烷鍵合矽膠作爲固定相塡充劑;以水和乙 腈作爲流動相進行洗脫,洗脫條件爲〇4l5m^ 7 # U m 1 η,乙腈濃度 爲25%,15min後乙腈濃度爲35% ;氣體流速爲2 5L/min, 漂移管溫度93.S°C ;理論塔板數以人參皂f Rgi峰計算應 不少於5 000。 · (2 )儀器和試劑 AgilentllOO·高效液相色譜儀 本紙張尺度適用中國國家標準( CNS ) A4規格(210X2奶公釐) ' '----— (請先閱讀背面之注意事項再填寫本頁)1 2 3 4 5 6 8 〇1034.2 8,289 0.672 1 0 0% 76 0.572 1,... 1817.0 12343 1.000 1 00% 65 1.000 1 7 ... 3 76.5 4 17 493 1.4 1 7 1 00% 7 0.208 1 R ... 3 2 8.0 1 18.664 1.5 1 2 1 0 0% 1 0.181 486.62 248 8 3 2.016 1 0 0 % 6 0.267 c 525.43 275 86 2.23 5 1 0 0% 2 0.289 , 940.96 29.714 2.407 1 0 0% 3 0.516 1 547.4 2.757 1 00% 95 0850 (K 572 soil 0.096 1.000 soil 0.000 0.208 soil 0.040 0. 181 soil 0.059 0.267 soil 0.097 0 · 2 8 9 soil 0.052 0.5 1 6 soil 0.125 0.850 soil 0 163 (please read the back of the note before you fill out this page) Determination of the content of Danshensu in the compound Danshen Drops in the Central Bureau of Standards of the Ministry of Economic Affairs (1) Chromatographic system and system suitability conditions using octadecyl decane bonded tannin as a chelating agent to water-acetonitrile-glacial acetic acid (87: 12: 1) is the mobile phase. The detection wavelength is 281ηιη. The number of theoretical plates is not less than 25 按 according to Danshensu, and the resolution is in accordance with the requirements. (2) Instrument and reagent chromatograph: Agilent 1100 liquid chromatography Agilent VWD UV Detector Column: Alltech ODS Column (250 x 4.6 mm,5// ) Precolumn: Alltech, Alltima C18 5/z precolumn, column temperature: WQC, acetonitrile: chromatographic purity, Tianjin Sanyou Biotechnology Co., Ltd. glacial acetic acid: analytical grade, Tianjin Tianhe Reagent Co., Ltd. China National Standard (CNS) A4 specification (210X297 mm) Ministry of Economic Affairs Central Bureau of Standards Staff Consumer Cooperatives printed 1281400 A7 ______B7_____ V. Invention Description) (3) Preparation of reference solution Take Danshensu sodium reference substance. 25.0mg, Precisely weighed, placed in a 5 〇 ml volumetric flask, add the mobile phase to dissolve and dilute to the mark, shake well, as a reference stock solution; accurately weigh the p-aminobenzoic acid, the mobile phase is diluted to 0.2 mg / ml, as an internal standard Stock liquid. Accurately absorb the appropriate amount of Danshensu sodium stock solution and internal standard stock solution, and dilute with mobile phase to prepare a solution containing 50pg of sodium danshensu and 80% of aminobenzoic acid per lml as a reference solution. Add methanol to make a solution containing 1 mg per lml. (4) Preparation of the test solution Take 10 pieces of this product, and set the internal standard stock solution 1 m to set the 2 5 m 1 volumetric flask. Dissolve the mobile phase to constant volume to the test solution. (5) Determination Take the reference substance and the test solution 1 01 injection separately, record the chromatogram, calculate, and get. l 8 mg/粒。 n Danshensu content should be 0. 14-0. 1 8mg / grain. - Determination of ginsenoside Rgl and notoginsenoside Ri in compound Danshen Decoction (1) Chromatographic system and system suitability conditions using octadecyldecane bonded tannin as stationary phase enthalpy; water and acetonitrile as mobile phase The elution conditions were 〇4l5m^7# U m 1 η, the acetonitrile concentration was 25%, the acetonitrile concentration was 35% after 15 minutes, the gas flow rate was 25 L/min, and the drift tube temperature was 93.S °C. The number of plates should be no less than 5,000 based on the ginseng soap f Rgi peak. · (2) Instruments and reagents AgilentllOO·High Performance Liquid Chromatograph This paper scale applies to Chinese National Standard (CNS) A4 specification (210X2 milk metric) ' '----- (Please read the notes on the back and fill in the form) page)

1281400 A7 ----------B7_ 五、發明説明(夕〇 ) …1281400 A7 ----------B7_ V. Description of invention (Xi Yu) ...

Alltech公司蒸發光散射檢測器 Alltech 公司 〇ds 柱.(5u,25 0x4.6mm)Alltech Evaporative Light Scattering Detector Alltech Corporation 〇ds Column. (5u, 25 0x4.6mm)

Alltech 公司 Alltima C18 預柱(5u )Alltech Corporation Alltima C18 Precolumn (5u)

柱溫:3 0 °C (3 )對照品溶液製備 取人參巷笮Rg 1和三七皂f R i對照品,用甲醇分別 配製成每lml含〇.98mg和〇.25mg的溶液,作爲對照品溶 液。 (4 )供試品溶液的配製 取滴九50粒,放於5mi容量瓶內,加4%氨水至刻度, 過預先處理好的 Ci8小柱(STRATA C18-E column of Phenomenex Company, 5 0 0 m g and 3cc tube),用水 10ml 洗 脫’棄去洗脫液,再用2ml甲醇洗脫,將洗脫液收集至一 2ml的容量。瓶中,加甲醇稀釋至刻度,作爲供試品溶液。 (5)測定 精密吸取供試品溶液和對照品溶液各1 0 // 1,分別注入 • ,v 色譜儀,記錄色譜圖,計算,即得。 (ό )結果 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 按上述方法對20批復方丹參滴九進行了測定,結果見 表4。如表所示,三七皂杳R 1的含量在〇 . 4 0 1 % · 0.7 1 2 %之 間,平均爲0.5 5 0% ;人參皂苷Rgl含量在2· 06 9%-4.04 4% 之間,平均爲2.847%。 - 本紙張尺度適用中國國家標準( CNS ) Α4規格(210 X 2界公釐Γ 1281400 A7 B7 五、發明説明(3丨) ,, 表 4·複方丹參滴九中人參皂苷Rgl和三七皂苷R1的 • 含量 三七皂苷 R1人參皂苷 Rgl 批號_( μ g/pill)_( β g/pill ) 20000106 1 7 • 22 80 .93 20000216 1 6 .92 80 .78 20000323 1 5 .16 7 0 • 76 20000406 1 3 .65 62 • 51 20000422 1 4 .24 68 .72 20000513 1 5 .27 7 1 • 16 20000606 1 4 • 86 68.21 20000726 1 4 • 59 72 • 35 20000728 1 4 .25 57 .37 20000804 1 5 .30 70 .55 平均値 1 5 .15 70 .33 R S D % 戸 7. 53 9. 67 不得低於 1 2 .12 56 .26 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 生産的複方丹參滴九具有以下特徵: (a) 複方丹參滴九含有3,4二羥基苯基乳酸,丹參 素鈉,皂苷和冰片; / (b) 細菌檢查:低於1 000 ; (c) .真菌檢查:低於100 ; (d )重金屬檢查:低於中國政府規定的安全量。 (e)在常溫保存下,複方丹參滴九的有效期爲4年。 複方丹參滴九的臨床硏究 通常採用心絞痛的病史、血淸中的脂質水平、心電/圖、 運動心電圖、內閃法測定缺血情況、冠脈造影等方法對心 絞痛病情進行評價。使用這些方法來評價複方丹參滴九的 療效,提示複方丹參滴九對心絞痛的治療有確切的療效。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 ________B7_ 五、發明説明, 九治療心絞痛的瘠效 1 5 7名冠心病患者口服複方丹參滴九,1 0粒/次,3次/ (請先閲讀背面之注意事項再填寫本頁) 天,服用4周。觀察心絞痛的發病頻率、強度和持續時間, 以及胸悶、心悸等表現,結果顯示上述症狀消失或緩解率 爲 9 5 . 3 % 〇 痛,複方丹參滴九比複方冉焱片亩有妫 複方丹參片爲另外一種當今中國治療心絞痛的中成 藥。將複方丹參滴九與複方丹參片的療效進行比較。將ι57 名冠心病患者隨機分爲兩組,其中治療組(複方丹參滴九 組)1 0 7人,對照組(複方丹參片組)5 〇人。比較心絞痛 發病頻率,有機硝酸鹽類藥物的服用量。結果表明··在治 療心絞痛方面,複方丹參滴九比複方丹參片更有效。見表 經濟部中央標準局員工消費合作社印製 上面所述提示複方丹參滴九比複方丹參片更有效。下面 就複方丹參滴九的療效與現代美國使用的用於治療慢 性、穩定型心絞痛的藥物進行比較。 複方丹參滴九與硝酸甘油的比鮫 一 硝酸甘油是緩解心絞痛的常用藥。將複方丹參滴九緩解 心絞痛的療效與硝酸甘油比較。在心絞痛發作時,患者分 別給與複方丹參滴九或硝酸甘油進行治療,比較這兩種藥 表 5·複方丹參滴九與複方丹參片比較 患者數 總數 有效率 複方丹參滴九 107 1 02 (9 5.3 %) 複方丹參片 50 3 8 (7 6%) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 經濟部中央標準局員工消費合作社印製 A7 ____B7 五、發明説明(Η ) … 物緩解心絞痛所需要的時間。上述兩種藥物緩解心絞痛所 需時間均在15分鐘以內,複方丹參滴九的療效略低於硝 酸甘油。見表ό〇 表 6·複方丹參滴九與硝酸甘油的比較 有效患者數 1 - 5分鐘內 6- 1 0分鐘內 11-15分鐘 內 複方丹參滴 九 11 14 5 硝酸甘油 17 12 1 總數:每組3 0位患者 靈方丹參滴九不改變心率 資料表明複方丹參滴九可以有效緩解心絞痛。考察複方 丹參滴九在緩解心絞痛的同時是否增加心率。服用複/方丹 參滴九後其心率與服用前一致,表明複方丹參滴九在緩解 心絞痛的同時對心率毫無影響。(見表7 ) 、 表 7· 複方丹參滴九不影響心率 ^ $ ' 治療前 治療後 複方丹參淌九 84·3 zL 23.1 82.8 ±22.8 複方丹參滴丸與二硝酸異山梨醇的療效hh _ 已經證明複方丹參滴九緩解心絞痛的作用與硝酸/甘油 相當。,將複方丹參滴九與二硝酸異山梨醇進行比較,考 察複方丹參滴九是否具有預防心絞痛的作用。二硝酸異山 梨醇是現代美國常用的預防慢性穩定型心絞痛的藥物。患 本紙張尺度適用中國國家標準(CNS ) A4規格(210/2#公羡1 ' ' -- (請先閲讀背面之注意事項再填寫本頁)Column temperature: 30 °C (3) Preparation of reference solution Take ginseng 笮Rg 1 and notoginseng saponin R R i reference substance, and prepare a solution containing 98.98mg and 〇.25mg per lml, respectively. Reference solution. (4) Prepare the test solution by taking 90 capsules, place it in a 5mi volumetric flask, add 4% ammonia to the mark, and pre-treat the Ci8 cartridge (STRATA C18-E column of Phenomenex Company, 500) Mg and 3 cc tube), eluted with 10 ml of water. 'The eluate was discarded and eluted with 2 ml of methanol. The eluate was collected to a volume of 2 ml. In the bottle, add methanol to the mark to serve as the test solution. (5) Determination Accurately draw the test solution and the reference solution each 10 / 1, 1 into the respectively, v chromatograph, record the chromatogram, calculate, that is. (ό) Results Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page). The 20 batches of compound Danshen Drips were measured according to the above method. The results are shown in Table 4. As shown in the table, the content of Panax notoginseng saponin R 1 is between 0.41% and 0.71%, with an average of 0.550%; the content of ginsenoside Rgl is between 2.06% and 4.04%. The average is 2.847%. - This paper scale applies to Chinese National Standard (CNS) Α4 specification (210 X 2 PCT 1281400 A7 B7 V. Invention Description (3丨),, Table 4·Combined Danshen Drop ginseng saponin Rgl and notoginsenoside R1 • Content notoginsenoside R1 ginsenoside Rgl Lot number _( μ g/pill)_( β g/pill ) 20000106 1 7 • 22 80 .93 20000216 1 6 .92 80 .78 20000323 1 5 .16 7 0 • 76 20000406 1 3 .65 62 • 51 20000422 1 4 .24 68 .72 20000513 1 5 .27 7 1 • 16 20000606 1 4 • 86 68.21 20000726 1 4 • 59 72 • 35 20000728 1 4 .25 57 .37 20000804 1 5 .30 70 .55 Average 値1 5 .15 70 .33 RSD % 戸7. 53 9. 67 Not less than 1 2 .12 56 .26 (Please read the notes on the back and fill out this page) Central Standards of the Ministry of Economic Affairs The compound Danshen Drips produced by the Bureau of Staff Consumer Cooperatives has the following characteristics: (a) Compound Danshen Drip 9 contains 3,4 dihydroxyphenyl lactic acid, sodium danshensu, saponin and borneol; / (b) Bacterial examination: lower than 1 000 ; (c) . Fungal examination: less than 100; (d) Heavy metal inspection: lower than the safety amount prescribed by the Chinese government. e) Under normal temperature preservation, the effective period of compound Danshen Drip Nine is 4 years. The clinical study of compound Danshen Dianjiu usually uses the history of angina pectoris, lipid level in blood stasis, ECG/figure, exercise electrocardiogram and internal flash method. Ischemic conditions, coronary angiography and other methods to evaluate the condition of angina pectoris. These methods were used to evaluate the efficacy of compound Danshen Dianjiu, suggesting that Compound Danshen Drip Nine has a definite therapeutic effect on the treatment of angina pectoris. This paper scale applies to Chinese national standards (CNS) A4 size (210X297 mm) 1281400 A7 ________B7_ V. Invention description, nine treatment of angina pectoral effect 1 5 7 patients with coronary heart disease oral compound salvia miltiorrhiza drip nine, 10 capsules / time, 3 times / (please read the back Note: Please fill in this page again. Take 4 weeks. Observe the frequency, intensity and duration of angina pectoris, as well as chest tightness and palpitations. The results show that the above symptoms disappear or the remission rate is 95.3. Dianjiu compound scorpion scorpion 妫 妫 compound Danshen tablets is another Chinese patent medicine for treating angina in China today. Compound Danshen Drip Nine and Compound Dan Efficacy compared sheet. One hundred and seven patients with coronary heart disease were randomly divided into two groups, including 10 in the treatment group (combined Danshen Drops Group 9) and 5 in the control group (combined Danshen Tablets). Compare the frequency of angina pectoris and the amount of organic nitrates taken. The results showed that in the treatment of angina pectoris, compound Danshen drip is more effective than compound Danshen tablets. See the table printed by the Ministry of Economic Affairs' Central Standards Bureau employee consumption cooperative. The above suggests that the compound Danshen drip is more effective than the compound Danshen tablets. The following is a comparison between the efficacy of Fufang Danshen Dropping Nine and the drugs used in modern America for the treatment of chronic and stable angina. The ratio of compound Danshen Drop Nine to nitroglycerin One nitroglycerin is a commonly used drug for relieving angina pectoris. The effect of compound Danshen drip in relieving angina pectoris was compared with nitroglycerin. In the onset of angina pectoris, the patients were treated with compound Danshen Drop Nine or Nitroglycerin, and the two drugs were compared. Table 5. Compound Danshen Drip Nine and Compound Danshen Tablets compared the total number of patients. Effective Compound Danshen Drip Nine 107 1 02 (9 5.3 %) Compound Danshen Tablets 50 3 8 (7 6%) This paper scale applies to China National Standard (CNS) A4 Specification (210X297 mm) 1281400 Ministry of Economic Affairs Central Bureau of Standards Staff Consumer Cooperatives Print A7 ____B7 V. Invention Description (Η ) ... the time required to relieve angina. The time required for the above two drugs to relieve angina was within 15 minutes, and the effect of compound Danshen Drip Nine was slightly lower than that of nitroglycerin. See Table · Table 6. Comparison of Compound Danshen Drops Nine and Nitroglycerin Effective Number of Patients 1 - 5 minutes Within 6-10 minutes Within 11-15 minutes Compound Danshen Drops 9 11 14 5 Nitroglycerin 17 12 1 Total: Per The group of 30 patients with Lingfang Danshen Drop 9 did not change heart rate data, indicating that Compound Danshen Drop Nine can effectively relieve angina pectoris. Investigate whether the compound Danshen Drop 9 increases heart rate while relieving angina. After taking Fufang/Fang Dan Shen Jiu Jiu, its heart rate was consistent with that before taking it, indicating that Compound Danshen Drop Nine had no effect on heart rate while relieving angina pectoris. (See Table 7), Table 7· Compound Danshen Drop 9 does not affect heart rate ^ $ ' After treatment, compound Danshen 淌 84 84·3 zL 23.1 82.8 ± 22.8 Effect of compound Danshen dripping pills and isosorbide dinitrate hh _ It is proved that the effect of compound Danshen Drop 9 on relieving angina is equivalent to that of nitric acid/glycerin. Compare the compound Danshen drip with isosorbide dinitrate to see if the compound Danshen drip has the effect of preventing angina pectoris. Isosorbide dinitrate is a commonly used drug for preventing chronic stable angina in modern America. The paper size applies to the Chinese National Standard (CNS) A4 specification (210/2# 公羡1 ' ' -- (Please read the back note and fill out this page)

1281400 A7 _____B7 五、發明説明(舛) 者口服複方丹參滴九,3次/天,1〇粒/次,或二硝酸異山 梨醇’ 3次/天,10mg/次。考察其強心功能和心電圖。 強心功能 通過揮量每博心輸出量(c Ο ) '每博心博出量(S V )、 射血分數(EF )左室短軸縮短率分數(F S )等指標,複方 丹參滴九提高心功能的療效比二硝酸異山梨醇強。見表8 表 8.複方丹參滴九和二硝酸異山梨醇療效比較 複方丹參滴九 二硝酸異山梨醇 a 刖 後 刖 後 S V 7 5.3 8 + 8.32 83.45 ^ 9.11 74.96 ± 8.44 79.47 8.72 CO 5.61 + 1.34 6.9 4 ±_ 1.36 6.54 ^ 1.36 6.12 ±_ 1.4 1 . EF 0.5 7 ± 0.02 0.79 ±_ 0.02 0.59 t 0.03 0.70 +_ 0.03 FS 17.14 ± 3.4 16.6 9 it 3.6 17.32 ^ 3.1 18.46 九 4.2 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 複方丹參滴九改善心電圖功能 通過記錄心電圖ST段的改變,來評價複方丹參滴九對 患者心電圖的有效率。複方丹參滴九和二硝酸異山梨醇均 可以明顯地減少有ST-T改變的病人數。其中,複方丹參 滴九效果更舒。見表9。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X2的公ίΤ 1281400 A7 B7 五、發明説明) 功 表9.複方丹參滴九與二硝酸異山梨醇改善心電圖 能的比較 . 有ST改變的病人數 治療前 治療後 複方丹參滴九 13 1 3 5 二硝酸異山梨醇 129 4 2 聚了坷吁表表 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 複方丹參滴丸與阿斯匹林抑制血小板聚集功能的比 動脈粥樣硬化損傷引起的出血可以引起血小板的 集、冠脈血栓和血液瘀積,從而導致血流不暢。因此爲 改善血流,心絞痛患者必需長期服用血小板聚集抑制劑 斯匹林。通過評價Hb,Lb,P和氣流等指標,將複方 參滴九與阿斯匹林的改善血流的功效進行對比。結果 明:複方丹參滴九改善血流的功效與阿斯匹林一致。見 10 ° 表 10. 複方丹參滴九與阿斯匹林改善血流的比較 複方丹參 滴九 阿斯匹林 刖 後 、八 刖 後 Hb 6.23 + 1.67 4.35 + 1.02 6.12 上 1.56 4.28 + 1.07 LB 10.92 + 2.2 1 8.30 + 1.14 10.38 + 1.96 8.21 + 0.3 P 1.95 + 0.08 1.77 + 0.08 1.89 + 0.12 1.67 + 0.7 Air flow 1.79 ±_ 0.13 1.39 + 0.11 1.82 上 0.17 1.40 上 0.10 患者總數:複方丹參滴九組:2 5例;阿斯匹林組:2 8例 複方丹參滴丸通過抑制血小板活件來抑制血液瘀積 血栓烷§2 (TXB 2)啓動血小板的活性。被啓動的血小板 釋放大量的物質,包括/3血小板微球蛋白,它可以引起血 液鬱積,損傷血流。考察複方丹參滴九抑制血小板聚集的 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 2¾公釐) ^ 1281400 A7 ___B7_ 五、發明説明(36 ) … (請先閲讀背面之注意事項再填寫本頁) 功能。複方丹參滴九可以降低血栓烷B 2的濃度,有效地 抑制血小板的聚集。.二硝酸異山梨醇沒有血小板抑制功 能,不能降低血栓烷B2濃度或抑制血小板的活性,所以 只能用於心絞痛的控制。見表1 1。 表 U.複方丹參滴九抑制血小板聚集 治療前 治療後 β PM 複方丹參滴 九 62.44 ^ 14.37 45.65 t 12.25 硝酸鹽類藥 物 5 9.89 :L 15.42 5 4.3 6 + 13.18 TXB2 複方丹參滴 九 13 12 七 53 5 73 8 ±.3 84 硝酸鹽類藥 物 13 15 t 5 07 12 18 ±. 445 複方丹參滴九降低血漿膽固醇水平 血漿膽固醇水平的增加與動脈硬化有一定的聯繫。建議 通過飮食或服用藥物可以降低血漿膽固醇水平,預防動脈 粥樣硬化損傷。考察了複方丹參滴九是否有降低血漿膽固> 醇水平。結果:複方丹參滴九可以降低膽固醇 0.3 mmol/L,統計學具有顯著差異。見表12。 表 12.複方丹參滴九降低血漿膽固醇水平1281400 A7 _____B7 V. INSTRUCTIONS (舛) Oral compound Danshen drip nine, three times / day, 1 capsule / time, or isosorbide dinitrate ' 3 times / day, 10 mg / time. Investigate its cardiac function and electrocardiogram. The cardiac function increases the heart's output (c Ο ) by the amount of each heart (SV), the ejection fraction (EF), the left ventricular short-axis shortening rate score (FS), and other factors. The efficacy of the function is stronger than isosorbide dinitrate. See Table 8. Table 8. Comparison of the efficacy of compound Danshen drip and isosorbide dinitrate. Compound salvia miltiorrhiza octahydrate diisosorbide a 刖 After SV 7 5.3 8 + 8.32 83.45 ^ 9.11 74.96 ± 8.44 79.47 8.72 CO 5.61 + 1.34 6.9 4 ±_ 1.36 6.54 ^ 1.36 6.12 ±_ 1.4 1 . EF 0.5 7 ± 0.02 0.79 ±_ 0.02 0.59 t 0.03 0.70 +_ 0.03 FS 17.14 ± 3.4 16.6 9 it 3.6 17.32 ^ 3.1 18.46 9 4.2 Employees of the Central Bureau of Standards of the Ministry of Economic Affairs Printed by the consumer cooperative (please read the precautions on the back and fill out this page). Compound Danshen Drop 9 improves the ECG function. By recording the changes in the ST segment of the ECG, the effectiveness of the compound Danshen Drop 9 on the patient's ECG is evaluated. Compound Danshen Drop Nine and Isosorbide Dinitrate can significantly reduce the number of patients with ST-T changes. Among them, the compound Danshen drip effect is more comfortable. See Table 9. This paper scale applies to China National Standard (CNS) A4 specification (210X2 public Τ 1281400 A7 B7 V. Invention description) Table 9. Comparison of electrocardiogram energy between compound Danshen drip and isosorbide dinitrate. ST-modified disease Number of patients before treatment, compound Danshen drip nine 13 1 3 5 diisosorbide dinitrate 129 4 2 gather the 坷 表 table (please read the notes on the back and then fill out this page) Printed by the Central Bureau of Standards and Staff of the Ministry of Economic Affairs Compound Danshen Dripping Pills and Aspirin inhibit platelet aggregation than hemorrhage caused by atherosclerotic lesions can cause platelet aggregation, coronary thrombosis and blood stagnation, resulting in poor blood flow. Therefore, in order to improve blood flow, patients with angina must take long-term use of the platelet aggregation inhibitor, spironin. By evaluating Hb, Lb, P, and airflow, the efficacy of the compound ginseng and aspirin in improving blood flow was compared. Results: The effect of compound Danshen Drop 9 on improving blood flow is consistent with aspirin. See 10 ° Table 10. Comparison of compound Danshen drip and aspirin to improve blood flow Compound Danshen drip nine aspirin, after gossip Hb 6.23 + 1.67 4.35 + 1.02 6.12 on 1.56 4.28 + 1.07 LB 10.92 + 2.2 1 8.30 + 1.14 10.38 + 1.96 8.21 + 0.3 P 1.95 + 0.08 1.77 + 0.08 1.89 + 0.12 1.67 + 0.7 Air flow 1.79 ±_ 0.13 1.39 + 0.11 1.82 on 0.17 1.40 on 0.10 Total number of patients: Compound Danshen drops nine groups: 2 5 Example; Aspirin group: 28 cases of compound Danshen dripping pills inhibited blood clotting alkane § 2 (TXB 2) to initiate platelet activity by inhibiting platelet activity. The activated platelets release a large amount of substances, including /3 platelet microglobulin, which can cause blood stagnation and damage blood flow. Investigate the standard of this paper on the inhibition of platelet aggregation by Compound Danshen Dropping Nine. Apply Chinese National Standard (CNS) A4 Specification (210X 23⁄4 mm) ^ 1281400 A7 ___B7_ V. Invention Description (36 ) ... (Please read the notes on the back and fill in this section) Page) function. Compound Danshen Drop 9 can reduce the concentration of thromboxane B 2 and effectively inhibit platelet aggregation. Isosorbide dinitrate has no platelet inhibition function, can not reduce the concentration of thromboxane B2 or inhibit the activity of platelets, so it can only be used for the control of angina pectoris. See Table 1 1. Table U. Compound Danshen Drops 9 inhibits platelet aggregation treatment before treatment β PM Compound Danshen Drop 9 62.44 ^ 14.37 45.65 t 12.25 Nitrate 5 9.89 : L 15.42 5 4.3 6 + 13.18 TXB2 Compound Danshen Drop 9 13 12 7 53 5 73 8 ±.3 84 Nitrate 13 15 t 5 07 12 18 ±. 445 Compound Danshen Drop 9 Reduces Plasma Cholesterol Levels Increased plasma cholesterol levels are associated with arteriosclerosis. It is recommended to reduce plasma cholesterol levels and prevent atherosclerotic damage by foraging or taking drugs. Investigate whether the compound Danshen Drop Nine has reduced plasma cholesterol and alcohol levels. RESULTS: Compound Danshen Drop 9 could lower cholesterol by 0.3 mmol/L, with statistically significant differences. See Table 12. Table 12. Compound Danshen Drops Reduces Plasma Cholesterol Level

血漿膽固醇 (mmol/L) 治療前 治療後 複方丹參滴九 5.15 ±_0.\6 4.84 ± 0.2J 患者數:8 0 經濟部中央標準局員工消費合作社印製 複方丹參滴九對冠心病患者血淸脂質過氧化物(LPO )及 本紙張尺度適用中國國家標準(CNS ) A4規格(210X@7公釐) 1281400 A7 ______B7 _ _ 五、發明説明 超氧化物歧化酶(SOD)的影響 方法:治療組2 4例,診斷符合我國1 9 7 9年修訂的 冠心病診斷參考標準,採用複方丹參滴九10粒/次,一夭 3次。正常組2 0例,爲健康人,未進行藥物治療。 結.果:冠心病患者LPO較健康人明顯升高,而冠心 病患者S OD較健康人明顯降低(P &lt; 〇. 〇 1 =。冠心病患者 使用複方複方丹參滴九治療後,其LPO較治療前明顯降低 (P&lt; 0.01 =,而治療後SOD含量明顯升高(P&lt; 0.01 )。 見表1 3 _ 表13 兩組血淸SOD及LPO含量比較(X土 s)Plasma cholesterol (mmol/L) After treatment, compound Danshen drip nine 5.15 ±_0.\6 4.84 ± 0.2J Number of patients: 8 0 Ministry of Economic Affairs, Central Bureau of Standards, Staff Consumer Cooperatives, Printing Compound Danshen Drops, Blood Stasis for Coronary Heart Disease Patients Lipid peroxide (LPO) and the paper scale apply to China National Standard (CNS) A4 specification (210X@7 mm) 1281400 A7 ______B7 _ _ V. Invention Description of the effect of superoxide dismutase (SOD): treatment group Twenty-four cases were diagnosed in accordance with the revised reference standard for coronary heart disease revised in China in 1979. The compound Danshen drip nine 10 capsules/time, one for three times. Twenty patients in the normal group were healthy and were not treated with drugs. Conclusion: The LPO of patients with coronary heart disease is significantly higher than that of healthy people, and the S OD of patients with coronary heart disease is significantly lower than that of healthy people (P &lt; 〇. 〇1 =. The patients with coronary heart disease after treatment with compound compound Danshen drip nine, LPO Compared with the treatment before treatment (P < 0.01 =, and the SOD content increased significantly after treatment (P < 0.01). See Table 1 3 _ Table 13 Comparison of blood SOD and LPO content between the two groups (X soil s)

組別 例 SOD(ng/ml) LPO ,._ 數 (nmol/ml) 正吊糸且 2 0 348±106 4.64±1.52 治療組 24 治療前 267±76* 7. 16±1.48* ______治療後 3 0 9 ± 8 7 △_4.68±1.72δ δ 杳··與正常組比較,*Ρ &lt; 0.05 ; 與治療前比較,^ Ρ&lt; 0.05 △ △ Ρ &lt; 0·01 結論.:冠心病患者因心肌處於慢性缺血狀態,組織 缺氧,致使S OD活性,尤其是細胞外s OD下降,氧g由 基生成增多,導致LPO增高,同時又使SOD消耗增多。 本組病例應用複方丹參滴九治療後血LPO明顯降低及血、 淸SOD含量均明顯增高,證明複方丹參滴九具有較好的淸 除氧自由基’作用,這也是治療冠心病的機理之一。 經濟部中央標準局員工消費合作社印製 C请先閲讀背面之注意事項存填寫本貢) 複方丹參滴九在治療肺心病中對LPO和抗氧化酶活性的 影響 方法:物件:肺心病患者48例,隨機分爲3钽。常 規治療組li例,採用抗炎平喘吸氧改善心肺功能等為合 .治療;複方丹參‘滴九組1 4例,採用複方丹參滴九3次/天, 10粒/次;甘糖酯組18例,採用甘糖酯20 Omg於5 %葡萄 糖液25 0ml靜‘滴,1次/天,10天爲1療程。 本紙張尺度適用中國國家標準(CNS ) A4規格7 :21(^2¾公釐) 1281400 A7 B7 五、發明説明(% ) 結果:複方丹參滴九治療後GSH-Px增値,LPO的降値 以及GSH-Px/LPO增高均較常規治療組有明顯差異。見表 14 ° 表1 4 治療前後各項指標的變化 GSH-P CAT SOD LPO GSH- X (U/gHb (U/gHb) (nmol Px (U/mg Hb) ) /ml) /LPO 140.6土 3 1 2 · 7 土 5799.8土 4.2土 34.2 35.2 58.1 948 1 .2 8.7 治 -1 刖 101.3土 300.4+ 5740.5土 5 · 6土 20.4 23.6 107.7 93 9.0 1.9 8.8 治 後 120.6土 3 90土 6076.8土 4.3土 3 1.3 20.6δ 1 84·3δ 109 1 1.2 Δ Δ 土 15.1 Δ Δ 治 .1八 刖 108.8土 233.1土 5863.3土 5.9土 18.5 28.3 70.2 1072.7 2.0 7.6 158.2土 3 2 8.4 土 5 5 8 2.8土 4」土 36.4 IP 後 40.7 Δ Δ * s|i 78.5 Δ △氺 1 094.7 Δ 氺 1.6 Δ △氺氺 土 6.7 Δ 注:各組治療前後比較△ P&gt;〇.05 δδΡ&lt;0·05 治療前後比較 *Ρ&gt;〇.〇5 **Ρ&lt;〇.〇5 結論:複方丹參滴九具有抗氧化作用,減輕脂質過 * v 氧化反應,增強機體抗氧化能力。 複方丹參滴九治療原發性高血壓病 經濟部中央標準局員工消費合作社印製 健康組常規組 複方丹參滴九組 (請先閲讀背面之注意事項再填寫本頁) 方法··( 1)病例選擇:選擇原發性高血壓病I 、Π 期患者,並排除繼發性高血壓,心、肝、腎功能不全病例。 (2 )給藥方法:受試患者停用中西藥物(降壓藥 除外)2周,于第3周始測其血壓、血液流變學指標-,紀 錄臨床表現等t採用雙盲給藥法’複方丹參滴九組’口服 複方丹參滴九10粒/次,一日3次;複方丹參片組’口服 複方丹參片5 ·片/次,一日3次;對照組服用安慰劑,療程 ___________________^----—-- 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇&gt;&lt;297公楚) 1281400 A 7 B7 五、發明説明(外) … 爲6周。 結果:(1)對全血粘度的影響。治療後複方丹參滴 九組及複方丹參片組患者的全血粘度均有顯著下降,而複 方丹參滴九組患者各切變率下的全血粘度下降程度較複 方丹參片組更爲顯著。見表1 5。 (2 )對紅細胞變形及聚集性的影響。治療後複方 丹參滴九組紅細胞變形性明顯高於治療前。治療後複方丹 參滴九紅細胞聚集面積及聚集指數顯著低於治療前,且下 降程度顯著高於複方丹參片(P &lt; 0.0 1 =。見表1 6。 (3) 對血壓的影響。複方丹參滴九及複方丹參片 患者收縮壓及舒張壓治療後較治療前有明顯下降(P &lt; 0.0 1 =。兩組間比較下降程度無顯著差異。見表1 7。 (4) 對高血壓症狀的影響。複方丹參滴九組及複 方丹參片組患者治療後頭痛、頭暈、肢麻等症狀均有明顯 改善(P &lt; 0.0 1 =,失眠症狀變化不明顯。見表1 8。 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 表15複方丹參滴九對全血粘度的影響(mPas,X土s ) 組別 3.83s1 38.3s'1 192s_i 複方丹參 治 療 1 8.27±2.85 5.82±0.93 4.54±0.78 滴九組 前 (30 例) 治 療 1 1.79 土 4.78 土 3.98 土 後 3 7 5 氺*△ △ ▲ ▲ 0.65** △ △ ▲ ▲ ▲ 複方丹參 治 療 1 7.69±1 .96 5.86+0.79 4.69±0.54 片組 前 (30 例) 治 療 1 4.68 土 5 . 69 ± 0 . 8 1 * 4.42 土 後 3 4 1 * * ▲ ▲ ▲ 0.59**A A ^ .對照組 治 療 1 7.6 5 ± 2.0 7 5.69±0.79 4.75 ±0·5 8 前 (15 例) 治 療 1 8.02±2.32 5.71±2.76 4·86±0·65 本紙張尺度適财關家縣(CNS ) M祕(2lG&gt;&lt;2g公羡) 1281400 A7 五、發明説明(;. 後 Έ 粗與本比·,* ρ&lt; 0.05~~口-ρ-&lt; ο.οΠ- 與複方丹參片組治療後比較,δΡ&lt;〇·05 △△Ρ&lt;0·01 (請先閲讀背面之注意事項再填寫本頁) 與對照組治療後比較,▲ Ρ &lt; 0 · 0 5 ▲ ▲ Ρ &lt; Ο · Ο 1 $ 1 6胃力丹參滴九對紅紐胞變形及聚集性的影響(X ± s ) 紅細胞變形紅細胞聚集紅細胞聚集面 指數 指數 積(積分) 複方丹參 治 療 0.4115 土 4.06土0.39 841 ·12±67.68 滴九組 前 0.0360 (3 0 例) 治 療 0.4274 土 3.41 土 683.52 後 0.034*a 0·36**Δ ▲ ▲ 69.09**Δ ▲ ▲ 複方丹參 治 療 0.4066 土 3.98±0.34 806·90±66·30 片組 前 0.0290 (3 0 例) 治 療 0.4180 土 3.64 土 716.12 後 0.0 2 8 1 “ 〇 39**α α 8 4.2 9 * * Α 對照組 治 療 0.4091 土 4.02土0.41 812·52±65.64 '刖 0.0376 (1 5 例) 治 療 0.4001 土 4.01土0.39 804·44±68·06 後 0.0381 :與本組治療前相比,* P &lt; 〇 . 〇 5 * * P &lt; 0.0 1 ; 與複方丹參片組治療後比較,△Ρ&lt;0·05 Δ Δ Ρ &lt; 0.01 與對照組治療後比較,▲ Ρ &lt; 0.0 5 ▲ ▲ P &lt; 0 · 0 1 經濟部中央標準局員工消費合作社印製 表17複方丹參滴九對血壓的影響(mmHg,x±s ) 組別 收縮壓 舒張壓 複方丹參滴 治療前 155·00±8·08 90.70±7·93 九組 (3 0例厂 治療後 149.20 ± 86.59 8 · 8 9 * * ▲ ▲ 8 · 3 0 * * ▲ ▲ 複方丹參片 治療前 152·93±9.59 92.5 9±8.30 本紙張尺度適用中國國家標準(CNS ) A4規格(210X21^公釐Γ 1281400 A7 ______ B7__ 五、發明説明(羊Λ) … 組 (30 例) 治療後 * 1 46.02 ± 8 8.5 5 土 (請先閱讀背面之注意事項再填寫本頁) 1 0.2 0 * * A A 7.22 * * Α Α 對照組 治療前 1 5 4.0 6 ± 7.0 5 9 0.9 0 ± 9 . 1 0 (1 5 例) 治療後 1 5 2.0 8 ± 9.2 5 9 1 . 1 0 ± 8.7 0 &quot;1主:與本組治療前相比, * * p &lt; 〇 . 〇 1 ; 與對照組治療後比較,▲ ▲ P &lt; 0.0 1 表18複方丹參滴九對高血壓臨床症狀的影響(例) 組別 頭痛 頭暈 肢麻 失 眠 有 Μ 有 Μ 有 Μ 川、 有 &gt;fnT- Μ 複方丹參 治 療 2 1 1 1 1 1 8 2 滴九組 —、八 刖 0 0 6 4 2 8 2 (3 0 例) 治 療 7 2 2 2 3 2 4 2 後 3 8 7 6 * * * 氺 複方丹參 治 療 2 8 1 1 1 2 6 2 片組 、名 刖 2 7 3 0 0 4 (3 0 例). 治 療 1 1 8 2 3 2 6 2 後 5 5 2 7 4 氺 * 氺 對照組 治 療 8 7 6 9 4 1 4 1 -Λ&quot;八 刖 1 1 (1 5 例) 治 療 7 8 5 1 3 1 2 1 後 0 2 3 注:與本興治療前比較,* P &lt; 0.0 1 經濟部中央標準局員工消費合作社印製 結論:原發性高血壓病患者紅細胞流變特性存在明 顯異常,其紅細胞變形性明顯降低,紅細胞聚集性明顯升 高。本實驗證明複方丹參滴九具有明顯降低全血粘度、降 _4J___ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7 五、發明説明(β) .… 低紅細胞聚集指數及面積,明顯提高紅細胞變形能力的作 用’並能降低血壓,故善患者的臨床症狀,故複方丹參滴 九對防治或延緩原發性高血壓病及其心腦合倂症的發生 大有裨益。 毒性 複方丹參滴九安全無毒。在中國,已經有超過500萬患 者接受過複方丹參滴九的治療,並沒有出現嚴重的副作 用,只是有及少數出現了頭痛或頭暈等輕微副作用。 臨床硏究總結 複方丹參滴九爲新一代治療冠心病的中藥。臨床試驗表 明,複方丹參滴九從改善心功能,減少心肌缺血,抑制血 小板聚集減少血液鬱積,降低血漿膽固醇水平等方面,來 緩解及預防心絞痛的發生。複方丹參滴九的治療作用優於 其他丹參製劑,如複方丹參片。複方丹參滴九具有和興代 美國使用的藥物相同的療效。複方丹參滴九緩解心絞痛的 功能與硝酸甘油相當,預防冠心病的作甩與長效二硝酸山 梨醇相當,抑制血小板聚集功能與阿斯匹林相當。複方丹&gt; 參滴九無任何毒性:已經有超過5 〇 〇萬人接受過複方丹參 滴九的治療,絕大多數沒有出現嚴重的副作用。 經濟部中央標準局員工消費合作社印製 (請洗閲讀背面之注意事項再填寫本頁) 臨床前硏究 臨床前的硏究揭示了複方丹參滴九緩解和預防心絞痛 的機理。+ ’ 複方丹參滴九通過增加血流量來緩解心絞—Group case SOD (ng/ml) LPO, ._ number (nmol/ml) is concealed and 2 0 348±106 4.64±1.52 treatment group 24 before treatment 267±76* 7. 16±1.48* ______ after treatment 3 0 9 ± 8 7 △_4.68±1.72δ δ 杳·· Compared with the normal group, *Ρ &lt;0.05; compared with before treatment, ^ Ρ &lt; 0.05 △ △ Ρ &lt; 0·01 Conclusion.: Coronary heart disease Due to the chronic ischemic state of the myocardium, the tissue is hypoxic, resulting in the decrease of S OD activity, especially extracellular s OD, and the increase of oxygen g from the base, resulting in an increase in LPO and an increase in SOD consumption. In this group of patients, the application of compound Danshen Dianjiu treatment decreased blood LPO significantly and blood and sputum SOD levels increased significantly, which proved that compound Danshen Dianjiu has a good role in the elimination of oxygen free radicals, which is one of the mechanisms for the treatment of coronary heart disease. . Ministry of Economic Affairs, Central Bureau of Standards, Staff Consumer Cooperatives, Print C, please read the notes on the back and fill in the tribute. Effect of Compound Danshen Dropping Nine on LPO and Antioxidant Activity in the Treatment of Pulmonary Heart Disease: Method: 48 Cases of Pulmonary Heart Disease , randomly divided into 3钽. In the conventional treatment group, the patients were treated with anti-inflammatory and anti-inflammatory oxygen to improve cardiopulmonary function, etc.; Compound Danshen's drip nine groups of 14 cases, compound Danshen drip nine times / day, 10 capsules / time; Group 18 cases, using glycoside 20 Omg in 5% glucose solution 25 0ml static 'drop, 1 time / day, 10 days for a course of treatment. This paper scale applies to Chinese National Standard (CNS) A4 Specification 7:21 (^23⁄4 mm) 1281400 A7 B7 V. Description of Invention (%) Result: GSH-Px increase after treatment of Compound Danshen Drip Nine, LPO drop and The increase in GSH-Px/LPO was significantly different from that in the conventional treatment group. See Table 14 ° Table 1 4 Changes in indicators before and after treatment GSH-P CAT SOD LPO GSH- X (U/gHb (U/gHb) (nmol Px (U/mg Hb) ) /ml) /LPO 140.6 soil 3 1 2 · 7 soil 5799.8 soil 4.2 soil 34.2 35.2 58.1 948 1 .2 8.7 treatment-1 刖101.3 soil 300.4+ 5740.5 soil 5 · 6 soil 20.4 23.6 107.7 93 9.0 1.9 8.8 post-treatment 120.6 soil 3 90 soil 6076.8 soil 4.3 soil 3 1.3 20.6δ 1 84·3δ 109 1 1.2 Δ Δ soil 15.1 Δ Δ treatment. 1 gossip 108.8 soil 233.1 soil 5863.3 soil 5.9 soil 18.5 28.3 70.2 1072.7 2.0 7.6 158.2 soil 3 2 8.4 soil 5 5 8 2.8 soil 4 soil 36.4 After IP 40.7 Δ Δ * s|i 78.5 Δ △ 氺 1 094.7 Δ 氺 1.6 Δ △ 氺氺 6.7 Δ Note: Comparison before and after treatment in each group △ P> 〇.05 δδΡ&lt;0·05 before and after treatment *Ρ&gt;〇 .〇5 **Ρ&lt;〇.〇5 Conclusion: Compound Danshen Drop Nine has anti-oxidation effect, relieves lipid over-v oxidation reaction and enhances the body's antioxidant capacity. Compound Danshen Dropping Nine Treatment of Essential Hypertension The Central Bureau of Standards of the Ministry of Economic Affairs, the Consumer Consortium, the Printing Health Group, the Regular Group, the Compound Danshen Dropping Group (please read the notes on the back and fill out this page) Method··(1) Case Choice: Select patients with primary hypertension I and sputum, and exclude secondary hypertension, heart, liver and kidney dysfunction. (2) Administration method: The patients in the test were stopped with Chinese and Western medicines (except antihypertensive drugs) for 2 weeks, and their blood pressure and blood rheology indexes were measured at the 3rd week. The clinical manifestations were recorded. 'Combined Danshen Drop Nine Group' Oral Compound Danshen Drop 9 10 capsules/time, 3 times a day; Compound Danshen Tablets' Oral Compound Danshen Tablets 5 · tablets/time, 3 times a day; control group taking placebo, course of treatment _ __________________^------- This paper scale applies to China National Standard (CNS) A4 specification (21〇&gt;&lt;297 public Chu) 1281400 A 7 B7 V. Description of invention (external) ... for 6 weeks. Results: (1) The effect on the viscosity of whole blood. After treatment, the whole blood viscosity of the compound Danshen Decoction Group 9 and Fufang Danshen Tablets group decreased significantly, while the whole blood viscosity of the compound Danshen Drop 9 group was more significant than that of the compound Danshen Tablets. See Table 1 5. (2) Effects on red blood cell deformation and aggregation. After treatment, the deformability of red blood cells in the compound Danshen drip group was significantly higher than that before treatment. After treatment, the area of aggregation and aggregation index of compound Danshen sap was significantly lower than that before treatment, and the degree of decline was significantly higher than that of compound Danshen tablets (P &lt; 0.0 1 =. See Table 16. 6. (3) Effect on blood pressure. Compound Danshen The systolic blood pressure and diastolic blood pressure of patients with Dianjiu and Fufang Danshen tablets were significantly lower than those before treatment (P &lt; 0.0 1 =. There was no significant difference in the degree of decline between the two groups. See Table 17. 7. (4) Symptoms of hypertension The effects of headache, dizziness and limb numbness were significantly improved after treatment in patients with compound Danshen Dianjiu and Fufang Danshen tablets (P &lt; 0.0 1 =, the symptoms of insomnia were not obvious. See Table 18. Read the notes on the back and fill out this page.) Department of Economics, Central Bureau of Standards, Staff Consumer Cooperatives, Printed Table 15 Effect of Compound Danshen Drops on Whole Blood Viscosity (mPas, X Soils) Group 3.83s1 38.3s'1 192s_i Compound Salvia Treatment 1 8.27±2.85 5.82±0.93 4.54±0.78 Before the drop of the nine groups (30 cases) Treatment 1 1.79 Soil 4.78 Soil 3.98 Soil 3 7 5 氺*△ △ ▲ ▲ 0.65** △ △ ▲ ▲ ▲ Compound Danshen treatment 1 7.69±1 .96 5.86+0.79 4.69±0.54 Before the group (30 cases) Treatment 1 4.68 Soil 5. 69 ± 0 . 8 1 * 4.42 After the soil 3 4 1 * * ▲ ▲ ▲ 0.59**AA ^ . Treatment 1 7.6 5 ± 2.0 7 5.69 ± 0.79 4.75 ± 0 · 5 8 before (15 cases) Treatment 1 8.02 ± 2.32 5.71 ± 2.76 4 · 86 ± 0 · 65 This paper scale is suitable for Guanjia County (CNS) M secret ( 2lG&gt;&lt;2g public 羡) 1281400 A7 V. Description of invention (;. Έ Έ 粗 粗 、, * ρ&lt; 0.05~~ 口-ρ-&lt; ο.οΠ- Compared with compound Danshen tablets, ΡΡ&lt;〇·05 △△Ρ&lt;0·01 (Please read the note on the back and fill out this page) Compared with the control group, ▲ Ρ &lt; 0 · 0 5 ▲ ▲ Ρ &lt; Ο · Ο 1 $ 1 6 gastric force Danshen drip nine effects on red cell deformation and aggregation (X ± s) red blood cell deformation red blood cell aggregation red blood cell aggregation surface index index product (integration) compound salvia treatment 0.4115 soil 4.06 soil 0.39 841 ·12±67.68 Before the group 0.0360 (30 cases) Treatment 0.4274 soil 3.41 soil 683.52 after 0.034*a 0·36**Δ ▲ ▲ 69.09**Δ ▲ ▲ Compound Danshen treatment 0.4066 soil 3.98±0.34 806·90±66·30 before the tablet group 0.0290 (30 cases) Treatment 0.4180 soil 3.64 soil 716.12 after 0.0 2 8 1 “ 〇39**α α 8 4.2 9 * * Α Group treatment 0.4091 soil 4.02 soil 0.41 812·52±65.64 '刖0.0376 (1 5 cases) Treatment 0.4001 soil 4.01 soil 0.39 804·44±68·06 after 0.0381: compared with before treatment, * P &lt; 〇. 〇5 * * P &lt; 0.0 1 ; Compared with the compound Danshen tablet group, △Ρ&lt;0·05 Δ Δ Ρ &lt; 0.01 compared with the control group, ▲ Ρ &lt; 0.0 5 ▲ ▲ P &lt; 0 · 0 1 Ministry of Economic Affairs, Central Bureau of Standards, Staff Consumer Cooperatives, Printed Table 17, Effect of Compound Danshen Dropping Nine on Blood Pressure (mmHg, x±s) Group systolic and diastolic blood pressure, compound Danshen drip before treatment 155·00±8·08 90.70± 7·93 Nine groups (190 cases after treatment of 190.20 ± 86.59 8 · 8 9 * * ▲ ▲ 8 · 3 0 * * ▲ ▲ Compound Danshen tablets before treatment 152·93±9.59 92.5 9±8.30 This paper scale applies to China National Standard (CNS) A4 Specification (210X21^Metric Γ1281400 A7 ______ B7__ V DESCRIPTION OF THE INVENTION (羊羊) ... group (30 cases) After treatment * 1 46.02 ± 8 8.5 5 soil (please read the notes on the back and fill out this page) 1 0.2 0 * * AA 7.22 * * Α Α Before treatment 1 5 4.0 6 ± 7.0 5 9 0.9 0 ± 9 . 1 0 (1 5 cases) After treatment 1 5 2.0 8 ± 9.2 5 9 1 . 1 0 ± 8.7 0 &quot;1 Master: Compared with before treatment in this group, * * p &lt; 〇. 〇1 ; Compared with the control group after treatment, ▲ ▲ P &lt; 0.0 1 Table 18 The effect of compound Danshen drip on clinical symptoms of hypertension (example) Group headache, dizziness, limb insomnia, Μ Μ 有Μ川,有&gt;fnT- Μ Compound Danshen treatment 2 1 1 1 1 1 8 2 Drop nine groups —, gossip 0 0 6 4 2 8 2 (3 0 cases) Treatment 7 2 2 2 3 2 4 2 After 3 8 7 6 * * * 氺 compound Danshen treatment 2 8 1 1 1 2 6 2 tablets, name 7 2 7 3 0 0 4 (3 0 cases). Treatment 1 1 8 2 3 2 6 2 after 5 5 2 7 4 氺* 氺 control group treatment 8 7 6 9 4 1 4 1 -Λ&quot; gossip 1 1 (1 5 cases) treatment 7 8 5 1 3 1 2 1 after 0 2 3 Note: Compared with before treatment, * P &lt; 0.0 1 Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economics Conclusion: There is a clear abnormality in the rheological properties of red blood cells in patients with essential hypertension, and the red blood cell deformability is significantly reduced and the red blood cell aggregation is significantly increased. This experiment proves that compound Danshen Drip Nine has a significant reduction in whole blood viscosity and drop _4J___ This paper scale applies Chinese National Standard (CNS) A4 specification (210X297 mm) 1281400 A7 B7 V. Invention description (β) .... Low red blood cell aggregation index And the area, significantly improve the role of red blood cell deformability 'and can lower blood pressure, so the clinical symptoms of patients, so the compound Danshen drip nine is beneficial to prevent or delay the occurrence of essential hypertension and heart and brain syndrome . Toxicity Compound Danshen Drop 9 is safe and non-toxic. In China, more than 5 million patients have been treated with Compound Danshen Dianjiu, and there have been no serious side effects, but only a few have mild side effects such as headache or dizziness. Clinical research summary Compound Danshen Drop Nine is a new generation of traditional Chinese medicine for treating coronary heart disease. Clinical trials have shown that Compound Danshen Drop 9 relieves and prevents angina from improving heart function, reducing myocardial ischemia, inhibiting platelet aggregation, reducing blood stasis and lowering plasma cholesterol levels. The therapeutic effect of compound Danshen Dianjiu is better than other Danshen preparations, such as compound Danshen tablets. Compound Danshen Drip Nine has the same effect as the drug used in the United States. Compound Danshen Drops 9 relieves angina and functions similarly to nitroglycerin. Prevention of coronary heart disease is equivalent to long-acting sorbitan dinitrate, and inhibition of platelet aggregation is comparable to that of aspirin. Compound Dan> Ginseng Nine has no toxicity: more than 5 million people have received the treatment of compound Danshen Dianjiu, and most of them have no serious side effects. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) Preclinical Studies The preclinical study reveals the mechanism by which Compound Danshen Drop 9 relieves and prevents angina pectoris. + ' Compound Danshen Drop 9 relieves the heart by increasing blood flow -

Wistar大鼠,重量約爲260g,烏拉坦麻醉,開胸,取出 心臟,置於37°C的Langendorff液中,在65cm水柱的壓 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 --- -__B7______——- 五、發明説明(衫) … 力下進行冠脈灌注。 待心率穩定後,通遍主動脈外側枝插管給予不同劑量的 複方丹參滴九和複方丹參片,接下來測量冠脈流量和心 率。結果表明複方丹參滴九起效的劑量範圍較寬’而複方 丹參片的範圍則較窄。見表2 0。 ^ 20.複方丹參滴九增加冠脈血流 冠脈流量 劑 量 (mg/ml) 治療前 治療後 None 7.0 ±_ 1 · 1 7.1 ±_〇.97 複方丹參滴 九 5 . 8 7.2 ± IA 7.0 ±_ 1.4 290 6.7 ±1.6 8.7 i 1.4 5 80 6.7 ±1.5 9.3 +2.9 複方丹參片 5 . 8 6.7 ±1.4 7.1 ±.1.5 290 7.3 ±1.7 9.1 t 2. 1 580 6.8 ±1.4 7.1+1.5 考察了複方丹參滴九和複方丹參片對心率的影響。結果&gt; 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 複方丹參滴·九和複方丹參片對心率沒有任何影響。見表 2卜 表2 1 複方丹參滴九不增加心率 心率 劑 量 (mg/ml) 治療前 治療後 None 1 94 ±_ 1 7 193 ±_ 12 複方丹參滴 九 5.8 18 0 ±_ 1 1 1 89 ±_ 9 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 Α7 ______Β7 五、發明説明(外) 290 18 8 ±7 1 84 ±_ 8 580 T73 ^ 14 167+13 複方丹參片 5.8 180 ^ 1 1 1 89 ±_ 9 290 T89 +16 1 83 亡 14 5 80 1 8 6 九 2 3 17 1 ±_ 8 (請先閱讀背面之注意事項再填寫本頁) 複九通過舒張血管平滑肌燴加冠脈流鲁戸雜 到擴張血管的作田 複方丹參滴九對鉀離子誘導的兔主動脈條收縮的影 響。複方丹參滴九有明顯舒張平滑肌、擴張血管的作用。 在豬冠狀動脈環上也能觀察到同樣效果。 複方丹參滴九抑制血小板聚集的作用 考察了複方丹參滴九抑制血小板聚集的作用,觀察複方 丹參滴九對兔血小板聚集的治療作用。複方丹參滴九可以 明顯地抑制血小板的聚集。見表22。 表 2 2 ·複方丹參滴九抑制血小板聚集的作用 - 複方丹參滴 九(mg/ml) 動物數 聚集率(%) 抑制率 (%) 0 6 6.7 土 4.4 0 1.8 6 42.7±2.5 8 · 3 ± 4.5 3.5 6 33.4土3.4 2 3.6 士 6 · 7 * 7 6 匕5.3 士 2.1 ^7.6土5.9* 14 6 15.8土3.0 6 9 . 〇士 6.9 * 經濟部中央標準局員工消費合作社印製 由表2 3可知’服甩複方丹參滴九後不同時間小鼠微核率 (8400 mg/kg) 表23 時間(h) 紅細胞 微核細胞 微核率 本紙張尺度適用中國國家標準(CNS ) A4規格(210χ297公釐) 1281400 A7 _ B7 五、發明説明(私) (〇/〇(x 土 S D) 1 2 6,000 9 1 · 5士〇· 8 2 4 6,000 11 1 .8士0.7 3 6 6,000 11 1.8士 1.2 48 6,000 11 1.8土 1 ·5 72 6,000 13 2.2 土 0.7 溶劑 2 4 6,000 9 1 .5士 1.4 表2 4表明服用複方丹參滴九24小時後’小鼠的微核 表24 時間(h) 紅細胞 微核細胞 微核率 (%)(x土 SD) 8,400 6,000 12 2.0 士 0.6 840 , 6,000 9 1.5士 1.0 84 6,000 11 1 .8±1.0 Solvent 6,000 9 1.5士 1.4 CP (80mg/kg) 6,000 13 8 23.0土4.0* 與溶劑對、照組比較 P&lt;0.01. 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 表25表明對於受試藥品療效不同級別的評估標準 表25 參數\療效 療效非 - 常尚 療效高 有效 無效 紅細胞聚集 不 有點 顯著 劇烈 起效時間 &lt;90 90-180 180-300 &gt;3 00 ---45_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7 五、發明説明) 微循環血流 狀態 比平時 好· 轉正常 改善 惡化 持續時間 (min) &gt;15 15-10 10-5 &lt;5 複方丹參滴九改善徼循環 觀察複方丹參滴九對倉鼠微循環的影響。所有動物ill 分鐘的面頰給藥中,複方丹參滴九面頰給藥後,所有動物 均在1 1 1分鐘內起效,且改善微循環的作用可達到2 3分 鐘。見表2 ό 〇 表2 6 .複方丹參滴九改善微循環 起效時間 (min) 持續時間 (min) 有效率 (%) 複方丹參轉 九 111 23 100 表27說明了對垂體後葉素誘導的心肌損傷的保護作用 (第二階段) 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 表 27 (n = 8) 組別 劑量 給藥 給藥後 (g/kg 刖 給垂體 給予垂體後葉素後40 ) 後葉素 秒至15分鐘之後,出現/ 之前 異常心電圖的大白鼠 數量 對照 正常 正常 7 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 1281400 A7 ___ _B7 五、發明説明(47 ) 組 複方 丹參 滴九 組 0.4 正常 正常 3 * 0.8 正常 正常 1 * * ,1.2 正常 正常 1 * * 複方 丹參 片組 铤對眧 0.4 正常 正常 4 0.8 正常 正常 Λ Γ\ Γ . 3k sic ^ 1 * * (請先閲讀背面之注意事項再填寫本頁) 血 經濟部中央標準局員工消費合作社印製 ^ 28表複方丹參滴九對垂體後葉素誘導的心肌 的保護作用。 表28 組別 劑量(g/kg) 抑制率(%) 複方丹參滴九組 0.4 7 1.4* 0.8 85.7* 1.2 7 1.4* 複方丹參片組 0.4 42.8* 0.8 85.7* 與對照組比較,*p&lt;0.05。 表 29表明複方丹參滴九對大鼠垂體後葉素引起的心肌 缺血的保護作用 ____42_---— 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 1281400 A7 _______ B7 五、發明説明(冬f ) 表 2 9 組別 劑量 (g/kg 第一 階段Π心電圖T-ST的變化 給藥後 給藥前 在給垂 在給垂體後葉素 〇至 ) 體後葉 40秒之後,出現異常 素之前 心電圖的大白鼠數量 T段升 T段翻 總 高 轉 數 對照 • 正常 正常 4 3 7 組 複方 丹參 0.4 正常 正常 3 0 3 * )J 乡 滴九 0.8 正常 正常 1 1 2* 組 1.2 正常 正常 2 1 3 * 複方 0.4 正常 正常 3 2 5 7T爹 片組 0.8 正常 正常 1 1 2* 與對照組比較 複方丹參滴九的氧自由基淸除作用 用黃嘌呤——黃嘌呤氧化酶體系産生超氧陰離子,用 H202— Fe2 + P系産生羥自由基,利用電子順磁共振和洎旋 捕集技術,硏究複方丹參滴九的氧自由基淸除作用。 方法:(1)經自由基的生成。根據Fenton反應原理建 實驗ί旲型。將 H2O2、硫酸亞鐵按和 DMPO ( 5, ______4S_____ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)Wistar rats, weighing about 260g, urethane anesthesia, open the chest, remove the heart, placed in Langendorff solution at 37 ° C, on the 65cm water column of the standard paper size applicable to China National Standard (CNS) A4 specifications (210X297 mm) 1281400 A7 --- -__B7______ --- V. Description of the invention (shirt) ... under the force of coronary perfusion. After the heart rate was stabilized, different doses of compound Danshen Dianjiu and Fufang Danshen tablets were administered through the lateral branches of the aorta, and then the coronary flow and heart rate were measured. The results showed that the dose range of the compound Danshen Drop 9 was wider, while the range of the Compound Danshen Tablet was narrower. See Table 2 0. ^ 20. Compound Danshen Dropping Nine Increases Coronary Flow Coronary Flow Dosage (mg/ml) Before Treatment, None 7.0 ± _ 1 · 1 7.1 ± _ 〇. 97 Compound Danshen Drop 9.5. 8 7.2 ± IA 7.0 ± _ 1.4 290 6.7 ±1.6 8.7 i 1.4 5 80 6.7 ±1.5 9.3 +2.9 Compound Danshen Tablets 5. 8 6.7 ±1.4 7.1 ±.1.5 290 7.3 ±1.7 9.1 t 2. 1 580 6.8 ±1.4 7.1+1.5 The compound salvia miltiorrhiza was examined. The effect of Dijiu and Compound Danshen Tablets on heart rate. Results&gt; Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) Compound Danshen Drip Jiuhe and Compound Danshen Tablets have no effect on heart rate. See Table 2 Table 2 1 Compound Danshen Drop 9 does not increase heart rate heart rate dose (mg/ml) Before treatment Before treatment 1 None 1 94 ± _ 1 7 193 ± _ 12 Compound Danshen drops 9 5.8 18 0 ± _ 1 1 1 89 ± _ 9 This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1281400 Α7 ______Β7 V. Invention description (external) 290 18 8 ±7 1 84 ±_ 8 580 T73 ^ 14 167+13 Compound Danshen Tablet 5.8 180 ^ 1 1 1 89 ±_ 9 290 T89 +16 1 83 Death 14 5 80 1 8 6 九 2 3 17 1 ±_ 8 (Please read the notes on the back and fill out this page) Repeat 9 to relax the vascular smooth muscle The effect of Guantian compound Danshen drip on the contraction of rabbit aortic strip induced by potassium in the venous flow. Compound Danshen Drop Nine has the effect of relaxing the smooth muscle and dilating blood vessels. The same effect was observed on the porcine coronary artery ring. The effect of compound Danshen Drop 9 on inhibiting platelet aggregation The effect of Compound Danshen Drop 9 on platelet aggregation was investigated, and the therapeutic effect of Compound Danshen Drop N on rabbit platelet aggregation was observed. Compound Danshen Drop Nine can significantly inhibit platelet aggregation. See Table 22. Table 2 2 · The effect of compound Danshen Drop 9 on inhibiting platelet aggregation - Compound Danshen Drop Nine (mg/ml) Animal number aggregation rate (%) Inhibition rate (%) 0 6 6.7 Soil 4.4 0 1.8 6 42.7±2.5 8 · 3 ± 4.5 3.5 6 33.4 Soil 3.4 2 3.6 ± 6 · 7 * 7 6 匕 5.3 ± 2.1 ^ 7.6 5.9 * 14 6 15.8 Soil 3.0 6 9 . Gentleman 6.9 * Printed by the Central Bureau of Standards and Staff of the Ministry of Economic Affairs by Table 2 3 It can be seen that the micronucleus rate of mice at different times after the treatment of compound Danshen Drops (8400 mg/kg) Table 23 Time (h) Micronucleus rate of erythrocyte micronuclei cells This paper scale applies Chinese National Standard (CNS) A4 specification (210χ297 public) PCT) 1281400 A7 _ B7 V. Description of invention (private) (〇/〇 (x soil SD) 1 2 6,000 9 1 · 5 士 · 8 2 4 6,000 11 1 .8 士 0.7 3 6 6,000 11 1.8 士 1.2 48 6,000 11 1.8 soil 1 · 5 72 6,000 13 2.2 soil 0.7 solvent 2 4 6,000 9 1 .5 士 1.4 Table 2 4 shows that taking compound Danshen drops nine hours after 24 hours of mouse micronucleus table 24 time (h) erythrocyte micronucleus Cell micronucleus rate (%) (x soil SD) 8,400 6,000 12 2.0 ± 0.6 840 , 6,000 9 1.5 ± 1.0 84 6,000 11 1 .8 ± 1.0 Solvent 6,000 9 1.5士 1.4 CP (80mg/kg) 6,000 13 8 23.0 soil 4.0* Compared with the solvent pair and the photo group P&lt;0.01. Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) Table 25 shows the evaluation criteria for different levels of efficacy of the test drug. Table 25 Parameters\Efficacy efficacy Non-Normal effect Highly effective Ineffective red blood cell aggregation does not have a significant significant onset time &lt;90 90-180 180-300 &gt;3 00 ---45_ This paper scale is applicable to China National Standard (CNS) A4 specification (210X297 mm) 1281400 A7 B7 V. Invention description) Microcirculation blood flow state is better than usual · Turn normal improvement Deterioration duration (min) &gt;15 15-10 10-5 &lt;5 Compound Danshen Dropping Nine Improves the Circulation Observation The effect of Compound Danshen Dropping Nine on the microcirculation of hamsters. In the ill-dose administration of all animals for ill minutes, after the administration of the compound Danshen drops on the cheeks, all the animals took effect within 11 minutes, and the effect of improving the microcirculation was 23 minutes. See Table 2 ό 〇 Table 2 6. Compound Danshen Dropping Nine Improves Microcirculation Initiation Time (min) Duration (min) Efficacy (%) Compound Danshen Turns Nine 111 23 100 Table 27 shows the levofin-induced myocardium Protection of Injury (Phase 2) Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) Table 27 (n = 8) After dose administration (g/ Kg 刖 after pituitary administration of pituitrin 40) After vasopressin seconds to 15 minutes, the number of rats with abnormal electrocardiogram appeared/normal before normal 7 paper size applicable to Chinese National Standard (CNS) Α4 specification (210Χ297 mm) 1281400 A7 ___ _B7 V. Description of invention (47) Group compound Danshen drip nine groups 0.4 Normal normal 3 * 0.8 Normal normal 1 * * , 1.2 Normal normal 1 * * Compound Danshen tablets group 铤 0.4 Normal normal 4 0.8 Normal normal Λ \ Γ . 3k sic ^ 1 * * (Please read the notes on the back and fill out this page) Printed by the Central Bureau of Standards, Department of Blood Economics, Consumer Cooperatives ^ 28 Forms Protective effect of ginseng drop nine pairs of vasopressin-induced heart muscle. Table 28 Group dose (g/kg) Inhibition rate (%) Compound Danshen Drop Nine Group 0.4 7 1.4* 0.8 85.7* 1.2 7 1.4* Compound Danshen Tablets 0.4 42.8* 0.8 85.7* Compared with the control group, *p&lt;0.05 . Table 29 shows the protective effect of compound Danshen Decoction on myocardial ischemia induced by vasopressin in rats____42_---- This paper scale applies Chinese National Standard (CNS) A4 specification (210X297 mm) Consumer Cooperatives Printed 1281400 A7 _______ B7 V. Description of the Invention (Winter f) Table 2 9 Group Dose (g/kg Changes in the first stage of electrocardiogram T-ST) After administration, administration of vasopressin in the pituitary 40 ) 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 0.8 Normal normal 1 1 2* Group 1.2 Normal normal 2 1 3 * Compound 0.4 Normal normal 3 2 5 7T Septal group 0.8 Normal normal 1 1 2* Compared with the control group, the oxygen free radical elimination effect of compound Danshen drip嘌呤——The xanthine oxidase system produces superoxide anion, H202-Fe2 + P system produces hydroxyl radicals, and uses electron paramagnetic resonance and cyclotron capture technology to study compound The oxygen free radical elimination of Salvia miltiorrhiza. Method: (1) Formation of free radicals. According to the Fenton reaction principle, an experimental type is built. H2O2, ferrous sulfate and DMPO ( 5, ______4S_____ This paper scale applies to Chinese National Standard (CNS) A4 specification (210X297 mm) (please read the back note before filling out this page)

1281400 A7 _____B7__ 五、發明説明) ,. S-dimethyl-l-pyrroiine-boxide)混合後進行 EPR 檢測, 所得信號作爲對照/處理組加入複方丹參滴九。 、 (請先閲讀背面之注意事項再填寫本頁) (2)超氧陰離子的生成。根據黃嘌呤——黃嘌呤氧化 酶反應建立實驗模型。將黃嘌呤,Dietrylene triamine Pent acetic ace d,DMPO和黃嘌呤氧化酶混合後進行epr 檢測作爲對照。處理組加入複方丹參滴九。 上述4組各檢測1 〇個樣品,所得結果用均數表示,用 t檢驗進行統計分析。 結果:(1 )複方丹參滴九對H2〇2— Fe2 +體系産生的羥自 由基淸除作用。羥自由基被DMPO捕捉後形成DMPO-OH 加合物,對照組中加合物的的峰高爲1 1 . 8 ± 0.6相對單位, 加複方丹參滴九組爲4.1 ± 0.5相對單位,兩者差別有高度 顯著性(P &lt; 〇. 0 1 ),複方丹參滴九對羥自由基的淸除率達 65% 〇 (2)複方丹參滴九對黃嘌呤---黃嘌呤氧化酶體系産 生的超氧陰離子的淸除作用。超氧陰離子被DMPO捕捉後 形成DMPO-OOH加合物,對照組中加合物的的峰高爲10.6 ± 0 . 67相對單位,加複方丹參滴九組的加合物波譜信號完 全消失,與對照組相比,其差別有高度顯著性(P&lt; 0.01) + 複方丹參滴.九對超氧陰離子的淸除率達100%。 經濟部中央標準局員工消費合作社印製 由以上實驗可知,複方丹參滴九對黃嘌呤——黃嘌呤氧 化酶體系産生超氧陰離子和H2〇2 — Fe2 +體系産生羥自由 基由很好的淸除作用。 複方丹參滴九對實驗性大鼠腦缺血再灌注韻傷 組織自由基的影響 方法:SD大鼠3 0只,隨機分3組,分別爲假手術 組(手術,但不結紮血管和神經),腦缺血再灌注模型組’ 複方丹參滴九組(4g/kg )。Ip給藥,連續3天。於第三天 __45-------- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7五、發明説明(沁) 藥後2小時’在2〇%烏拉坦麻醉下分離並結紮大鼠兩側頸 總動脈及迷走神經,·再灌注30min,然後斷頭取腦。取左 側大腦皮層組織約5 OOmg及兩側海馬組織,放入液氮中勻 漿,·與冰凍的生理鹽水製成勻漿液,離心,取上淸液測過 氧化氫酶(C AT )活性、S Ο D活性、MD A含量及G S Η含 量。 結果:見表3 0。( 1 )複方丹參滴九對腦組織CAT活 性及GSH含量的影響。缺血再灌大鼠模型組大腦皮層及海 馬組織的CAT活性及皮層的GSH含量均顯著低於假手術 組。複方丹參滴九組海馬組織的CAT活性及皮層的GSH 含量均較模型組顯著增高。 (2)複方丹參滴九對腦組織S〇D活性及MDA的影響。 模型組大鼠腦組織SOD活性較假手術組明顯降低,而MD A 含量則顯著增多。複方丹參滴九組大腦皮層及海馬部位的 SOD活性顯著增高,而MDA含量則明顯下降。· 表30 各組大鼠腦組織CAT活性、SOD活性、MDA含量 及 ___GSH 含量的變化(mPas,x土s) (n=l〇)_ CAT 活性 G~SH SOD 活 g MDA~~_ 組別 (u/mg 蛋 (// (u/mg 蛋 (nmol/mg 白.) mol)mg蛋 白) 蛋白) _______ 白) —___ (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 手組 型β 方參九且 假術 模—複丹滴— 大腦 皮層 2.94 土 0.17 2.17 土 0.24 氺 2.55 土 0.35 海 馬 2.78 土 0.14 1.97 土 0.23 * 2.79 土 0.2 1 大腦 皮層 18.4 9土 0.70 14.7 6土 1.12 * 17.1 4土 0.76 海 馬 16.8 7 土 0.92 13.8 0 土 0.74 15.7 6 土 1.18 大腦 皮層 14.2 4土 0.90 10.4 4土 0.79 氺 13.3 1土 0.77 海 馬 2 0.3 4 土 0.74 18.1 8 土 0.62 * 20.5 9 土 0.59 大腦 皮層 0.50 2土 0.05 4 0.71 8土 0.07 海 馬 1.08 4 土 0.11 7 1.44 3 土 0.14 0 * 0.48 1.06 3土 9 土 0.06 0.13 5δ 1δ 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 50 1281400 A7 B7 五、發明説明(訶) … 注:與假手術組比較 * P &lt; 0.0 5 ;與模型組比較 △ P &lt; 0 · 0 5 結論:大鼠腦組織缺血再灌注後,腦組織中MD A含 量升高,GSH水平下降,組織中淸除氧自由基的兩種重要 的酶CAT和SOD活性明顯降低,表明在大腦的缺血再灌 注過程中,自由基淸除系統功能障礙,導致大量的氧自由 基産生,引起脂質過氧化反應,造成腦組織的損害。複方 丹參滴九可使缺血再灌注大鼠大腦皮層及海馬組織的 MDA含量下降,GSH水平升高,CAT及SOD活性明顯升 高’說明其具有顯著的抑制氧自由基反應,減少脂質過氧 化的作用,對缺血再灌注引起的腦細胞損傷具有保護作 甩。 複方丹參滴九在慢性肝損傷中的抗氧化作用 方法:採用CC14高脂低蛋白複合方法致Wister大鼠 輕度慢性肝損傷模型。複方丹參滴九組以4g/kg鼠重灌 胃’正常Μ和造模組按體重以等量生理鹽水灌胃。SOD活 力測定用黃嘌呤氧化酶法,MDA含量測定用改良硫代巴比 妥酸法。 結果:見表31。造模組與正常組比·較,SOD活力下降,而 MDA升高;複方丹參滴九組則升高SOD,降低MDA,使 之趨於正常。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 表31 肝損傷SOD、MDA變化(x±s ) 組別 鼠 (只) SOD (NU/mg.pr ) MD A(nM/mg . pr ) 正常組 12 1·717±0.521 15·21±4.35,- 造模組 12 1.3 26±0.321* 19.3 9±4.62* 複方丹參滴 11 1.710±0.415δ 1 5 . 1 6±4.29δ 九組 注:與正常組比較, *Ρ &lt; 0.05 .與造摸組比較 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7 五、發明説明(0) Δ P &lt; 0.05 結論:MDA是脂質過氧化的主要降解産物,可嚴重 損傷細胞膜結構,導致肝細胞損害。S OD是超氧陰離子自 由基的淸除劑,可抑制自由基啓動的脂質過氧化反應。複 方丹參滴九可使SOD活力顯著上升,MDA顯著下降,降 低了脂質過氧化水平,起到減輕肝損傷的作用。 複方丹參滴九沒有致突變的作用 通過艾姆斯氏實驗,考察複方丹參滴九是否真有致突變 作用。結果表明複方丹參滴九沒有致突變的作用。見表32。 表32. 複方丹參滴九的致突變作用(艾姆斯氏實驗) (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 每碟菌落數 S9 TA97 Ta98 TA1 00 TA1 02 複方 丹 參 滴九 0.0 - 141±13 3 6士 3 1 6 1土2 1 3 03 士44 0.5 - 140土 17 3 5 土2 148土2 1 2 8 8土 15 5 1 3 6 土 1 4 34 士 4 1 54土26 280士 1 6 50 _ 13 3土20 3 3 土5 142士25 292土3 7 500 109土 1 5 34 士 3 154土 1 6 3 1 1士32 5 000 67 土 8* 3 0士4 1 49士27 298土32 0.0 + 1 4 1 ± 1 3 44 士 6 176土 1 9 296士3 9 0.5 + 148土 13 42 士 9 161土27 296土3 7 _______52_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 at B7 五、發明説明(G ) 5.0 + 152土 1 1 44 士 7 161土 16 292土3 8 50.0 + 140土 1 8 3 7土 6 16 6土 9 3 07土5 5 5 00.0 + 1 3 5士2 1 42±7 152土22 287土 16 5 000.0 + 1 19 土 17 3 8±7 162土 17 363土57 D ex ο η 50 - 2155土81 952土 1 8 831土 1 1 15 10土2 1 2-AF 40 - 125土 18 3 8±3 * 161土 16 + 1404土64 4 * 1 5 9 8土 1 24 1222土3 09 DAN 100 - 364土50 + * 943土 102 氺 (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消費合作社印製 藥材的生産 1 · 丹參· (1 )質量控制 從中國各地生産的丹參藥材中收集樣本,並對這^ 的主要化學成分進行分析,結果顯示一個名叫商洛白 生産的丹參質量最好,丹參中的活性成分如丹參酮 酸A的含量..最高,證明商洛的氣候最適宜丹參的生 (2 )地形 商洛位於東經1 0 8 ° 3 4 ’ 2 0 ”〜1 1 1 ° 1 ’ 2 5 ”,北緯3 3。 ——_____q__ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 本區酚 樣地丹 勺 、 長 1281400 at B7 五、發明説明(舛) … 〜34° 24’40”,平均海拔900米。該地區中低山巒環抱, 沒有污染,沒有污藥的環境成爲丹參藥材生長的理想之 處。 (3 )氣候 該地區氣候溫和,濕度適中,爲典型的亞熱帶向溫帶過 渡的山巒地區。在東南季風的影響下,有明顯的四季,雨 量充沛,每年的降雨量約爲73 3.9〜899mm,一年的光照 約1 874.1〜2185小時,相當於119.57〜1 24.36千卡/cm2, 溫度爲18°C〜40.8°C,每年非霜凍期達198〜218天。 (4) 土壤 商洛地區80%的土壤爲沙質,大部分爲PH値6.5〜 8的中性和弱鹼性的可耕種土壤,有營養的耕作層達0〜 20cm,其營養成分包括:1.36%有機物,0.0 8 5 %氮,18ppm 活性磷,Γ3 6 p p m活性紳,6 0 p p m城水解的氮,土壤中/的重 金屬和其他有害物質不超過國家規定的農業標準。當地農 作物使用的是有機肥。 * - &gt; (5 )重金屬 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 八種重金屬包括鉛、鎘、汞、砷等,及農藥殘留、空氣 質量、水質等均符合國家環保標準。 (6)標準化生産 丹參地栽培和耕種按GAP規範進行。有關丹參生産 的技術要點·和步驟被編撰成冊,種植基地丹參生産者人手 一冊。在丹參種植季節,技術員會到田間進行現場指導, 給予技術支援,使丹參大規模的種植規範化和標準化。 -_- _____ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 Α7 Β7 五、發明説明(π) … (7 )在商洛丹參基地,培育和栽種了 20個不同品種的丹 參,對他們的生長狀&gt;J、産量、外觀、化學成分進行了 3 年的觀察和比較,最後選擇了質量最好的丹參品種進行大 規模種植。 (8 )在丹參的培育中應用組織培育和克隆技術,以加速 生産,縮短生長周期。 (9)在30天的試管培養之後,在長根前有一個40天的 迅速繁殖過程,接下來1 0天是根的生長和壯大,出根率 達到9 0 %或以上,然後轉移到由電腦控制的有先進噴淋灌 溉裝置和設施的培育室裏,培育一個月後再移植到室外。 (1 〇 )如專家所說,商洛丹參基地培育的丹參高質高産, 具有豐富的根莖(比其他地區出產的丹參重5 0 %以上)和 高含量的化學成分(比其他地區的丹參樣品的活性藥用成 分含量高70%以上)。 2 · 天然冰片 (1 )生長條件 / 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 天然冰片的生長基地位於中國湖南省新晃縣,該地 區屬中等高度的丘陵地帶,海拔300〜600米,森林覆蓋 率6 0 %,爲p Η値5〜6的黃色和紅色沙質的土壤,沒有空 氣和水的污染。 (2 )樹的生物特性 ^ 爲有極磕的生長能力的低灌木叢,每畝3 00〜400 株,採集枝葉以上部分,每畝可淨得1 000公斤。 - -5S-:—— 本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐) 1281400 Δ7 A 7 B7 五、發明説明(α) (3) 繁殖和移植 (請先閲讀背面之注意事項再填寫本頁) 用嫁接和插木殖技術進行繁殖,頭一年在培育室 裏進行生長,第二年春天移植到田間,田間需要定期施肥 和修整等。 (4) 植株可生長到80〜100(:111高,最大直徑可達3〇mm。 樹的不同部分如葉、枝、莖、根等含天然樟腦是不同的, 其中葉中的含量最高。 (5 )新晃地區的冰片型樟腦樹是 Cirnamonium glandullferm (wall) Noes的一個變種,各品種樟腦樹在樟 腦和冰片上的含量有所不同,一些冰片含量低,樟腦含量 高’而另一些則反之。經過大樣本的檢測和很多次的高效 液相色譜法分析,我們最終選擇了一個冰片含量達8 〇%以 上而少有雜質的品種。 3 · 三七 A ·植物的種子 (1 )三七的鑒定 經濟部中央標準局員工消費合作社印製 應用分子質量標記的聚合酶鏈反應,觀察三七的染 色情況,三七具有自己獨特的DNA指紋圖譜。 (2 )形狀和特性 三七種子爲圓形、環狀,根據不同的生長期,可分 爲兩年期和二年期的種子。兩年期種子直徑 0.45 〇.55cm,幹重Φ5〜103 g;三年期種子0.54〜0.65cm,幹重 9 8 〜1 0 9 g 〇 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7 五、發明説明U7) … (3 )種子萌芽的合適溫度 種子萌芽的適k溫度爲10〜3〇°C,理想溫度爲15 〜20〇c。 (4 )水分 水分含量應該爲6 0〜7 0 %。如果長期低於2 0 %的話, 種子將失活。 (5 )冬眠 種子在採集後經歷一個4 5〜6 0天的冬眠期。 (6 )壽命 種子採摘後在自然狀態下的壽命爲1 5天。 (7 )進行貯藏種子的要求 進行·貯藏的種子應該從生長兩年以上、無蟲害、枝 葉繁茂的植物的地上部分採集,推薦從三年期的植物上採1281400 A7 _____B7__ V. Inventive Note), S-dimethyl-l-pyrroiine-boxide) After mixing, EPR was detected, and the obtained signal was added as a control/treatment group to the compound Danshen Drop 9. (Please read the precautions on the back and fill out this page) (2) Formation of superoxide anion. An experimental model was established based on the jaundice-xanthine oxidase reaction. The scutellaria, Dietrylene triamine Pent acetic ace d, DMPO and xanthine oxidase were mixed and subjected to epr detection as a control. The treatment group was added to the compound Danshen Drop 9. One of the above four groups was tested for one sample, and the results were expressed as mean, and statistical analysis was performed by t test. Results: (1) Compound Danshen Drop 9 eliminated the hydroxyl radical generated by H2〇2-Fe2 + system. The hydroxyl radical was captured by DMPO to form DMPO-OH adduct. The peak height of the adduct in the control group was 11. 8 ± 0.6 relative units, and the compound Danshen drip group was 4.1 ± 0.5 relative units. The difference is highly significant (P &lt; 〇. 0 1 ), the elimination rate of compound salvia miltiorrhiza drops is 65% 〇 (2) compound Danshen drip nine pairs of jaundice---xanthine oxidase system The removal of superoxide anion. The superoxide anion was captured by DMPO to form DMPO-OOH adduct. The peak height of the adduct in the control group was 10.6 ± 0.67 relative units, and the signal of the adduct of the compound Danshen drip group completely disappeared. Compared with the control group, the difference was highly significant (P < 0.01) + compound Danshen drip. The elimination rate of nine pairs of superoxide anion reached 100%. Printed by the Consumers' Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs From the above experiments, it is known that the compound Danshen Drip Nine produces a superoxide anion and a H2〇2 —Fe2 + system to produce hydroxyl radicals from the Astragalus membranaceus oxidase system. In addition to the effect. Effect of Compound Danshen Decoction on Free Radical of Experimental Rats with Cerebral Ischemia Reperfusion Injury: 300 SD rats, randomly divided into 3 groups, respectively, sham operation group (surgery, but no ligation of blood vessels and nerves) , cerebral ischemia-reperfusion model group 'complex Danshen drip nine groups (4g / kg). Ip was administered for 3 consecutive days. On the third day __45-------- This paper scale applies Chinese National Standard (CNS) A4 specification (210X297 mm) 1281400 A7 B7 V. Invention description (沁) 2 hours after drug 'at 2〇% Under the anesthesia of urethane, the common carotid arteries and vagus nerves were isolated from both sides of the rat, reperfused for 30 min, and then the brain was decapitated. Take about 500 mg of the left cerebral cortex and the hippocampus on both sides, and mix them in liquid nitrogen. Make a homogenate with frozen saline, centrifuge, and take the sputum to measure the activity of catalase (C AT ). S Ο D activity, MD A content and GS Η content. Results: See Table 30. (1) The effect of compound Danshen Decoction on CAT activity and GSH content in brain tissue. The CAT activity and GSH content in the cerebral cortex and hippocampus of the ischemic reperfusion model group were significantly lower than those in the sham operation group. The CAT activity and the GSH content of the hippocampus in the compound Danshen drip group were significantly higher than those in the model group. (2) The effect of compound Danshen Decoction on the activity of S〇D and MDA in brain tissue. The SOD activity in the brain tissue of the model group was significantly lower than that in the sham operation group, while the MD A content was significantly increased. The SOD activity in the cerebral cortex and hippocampus of the compound Danshen drip group was significantly increased, while the MDA content was significantly decreased. · Table 30 Changes in CAT activity, SOD activity, MDA content and ___GSH content in brain tissue of each group (mPas, x soil s) (n=l〇)_ CAT activity G~SH SOD live g MDA~~_ group Do not (u/mg eggs (// (u/mg eggs (nmol/mg white.) mol) mg protein) _______ white) —___ (please read the notes on the back and fill out this page) Central Standards of the Ministry of Economic Affairs Bureau staff consumption cooperative printed hand-type β ginseng nine and fake model - Fudan drip - cerebral cortex 2.94 soil 0.17 2.17 soil 0.24 氺 2.55 soil 0.35 hippocampus 2.78 soil 0.14 1.97 soil 0.23 * 2.79 soil 0.2 1 cerebral cortex 18.4 9 Soil 0.70 14.7 6 soil 1.12 * 17.1 4 soil 0.76 hippocampus 16.8 7 soil 0.92 13.8 0 soil 0.74 15.7 6 soil 1.18 cerebral cortex 14.2 4 soil 0.90 10.4 4 soil 0.79 氺 13.3 1 soil 0.77 hippocampus 2 0.3 4 soil 0.74 18.1 8 soil 0.62 * 20.5 9 soil 0.59 cerebral cortex 0.50 2 soil 0.05 4 0.71 8 soil 0.07 hippocampus 1.08 4 soil 0.11 7 1.44 3 soil 0.14 0 * 0.48 1.06 3 soil 9 soil 0.06 0.13 5δ 1δ This paper scale applies to China National Standard (CNS) A4 specification ( 210 X 297 mm) 50 1281400 A7 B7 V. Invention (诃) ... Note: Compared with the sham operation group * P &lt; 0.0 5 ; compared with the model group △ P &lt; 0 · 0 5 Conclusion: Rat brain tissue ischemia and reperfusion, increased MDA content in brain tissue The level of GSH decreased, and the activities of CAT and SOD, two important enzymes for deoxygen free radicals in tissues, decreased significantly, indicating that during the process of ischemia and reperfusion in the brain, free radicals eliminated systemic dysfunction, resulting in a large number of oxygen free radicals. Produced, causing lipid peroxidation, causing damage to brain tissue. Compound Danshen Dianjiu can decrease the MDA content in cerebral cortex and hippocampus of rats with ischemia-reperfusion, increase the level of GSH, and increase the activity of CAT and SOD, indicating that it has significant inhibition of oxygen free radical reaction and reduced lipid peroxidation. The role of protection against brain cell damage caused by ischemia-reperfusion. Antioxidant effect of compound Danshen Dianjiu in chronic liver injury Method: A mild chronic liver injury model of Wister rats was induced by CC14 high fat and low protein complex method. The compound Danshen drip group was re-irrigated with 4g/kg rats. The normal sputum and the model were administered by the same amount of normal saline. The SOD activity was measured by the xanthine oxidase method and the MDA content was determined by the modified thiobarbituric acid method. Results: See Table 31. Compared with the normal group, the SOD activity decreased and the MDA increased. The compound Danshen drip group increased SOD and decreased MDA, which made it normal. Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) Table 31 Changes in SOD and MDA in Liver Injury (x±s) Groups in Rats (only) SOD (NU/mg.pr) MD A (nM/mg . pr ) Normal group 12 1·717±0.521 15·21±4.35,- Module 12 1.3 26±0.321* 19.3 9±4.62* Compound Danshen Drop 11 1.710±0.415δ 1 5 . 6±4.29δ Nine groups Note: Compared with the normal group, *Ρ &lt; 0.05. Compared with the test group, the paper scale is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) 1281400 A7 B7 V. Invention Description (0 Δ P &lt; 0.05 Conclusion: MDA is the main degradation product of lipid peroxidation, which can seriously damage the cell membrane structure and lead to liver cell damage. S OD is a scavenger for superoxide anion radicals and inhibits free radical initiated lipid peroxidation. Compound salvia miltiorrhiza can significantly increase SOD activity, significantly reduce MDA, reduce lipid peroxidation level, and reduce liver damage. Compound Danshen Drop No. 9 has no mutagenic effect. Through the Ames test, it is investigated whether the compound Danshen Drop Nine is really mutagenic. The results showed that the compound Danshen Drop No. 9 had no mutagenic effect. See Table 32. Table 32. Mutagenic effects of compound Danshen Drips (Ames test) (Please read the notes on the back and fill out this page) Department of Economics Central Bureau of Standards Staff Cooperatives Prints the number of colonies per dish S9 TA97 Ta98 TA1 00 TA1 02 Compound Danshen Drop Nine 0.0 - 141±13 3 6士3 1 6 1土2 1 3 03 士44 0.5 - 140土17 3 5 土2 148土2 1 2 8 8土15 5 1 3 6 土1 4 34士4 1 54土26 280士1 6 50 _ 13 3土20 3 3 土5 142士25 292土3 7 500 109土1 5 34士士3 154土1 6 3 1 1士32 5 000 67 土8 * 3 0士4 1 49士27 298土32 0.0 + 1 4 1 ± 1 3 44 士6 176土1 9 296士3 9 0.5 + 148 soil 13 42 士9 161土27 296土3 7 _______52_ The paper scale Applicable to China National Standard (CNS) A4 specification (210X297 mm) 1281400 at B7 V. Invention description (G) 5.0 + 152 soil 1 1 44 士 7 161 soil 16 292 soil 3 8 50.0 + 140 soil 1 8 3 7 soil 6 16 6土 9 3 07 soil 5 5 5 00.0 + 1 3 5 ± 2 1 42 ± 7 152 soil 22 287 soil 16 5 000.0 + 1 19 soil 17 3 8 ± 7 162 soil 17 363 soil 57 D ex ο η 50 - 2155 soil 81 952 soil 1 8 831 soil 1 1 15 10 soil 2 1 2-AF 40 - 125 soil 18 3 8±3 * 161 soil 16 + 1404 soil 64 4 * 1 5 9 8 soil 1 24 1222 soil 3 09 DAN 100 - 364 soil 50 + * 943 soil 102 氺 (please Read the notes on the back and fill out this page. The Ministry of Economic Affairs, the Central Bureau of Standards, the staff of the Consumer Cooperatives, the production of printed pharmaceutical materials. 1 · Danshen · (1) Quality Control Collect samples from the Salvia miltiorrhiza medicinal herbs produced in various parts of China, and The analysis of chemical composition showed that the quality of Salvia miltiorrhiza produced by Shangluobai was the best, and the content of active ingredients such as tanshinone A in Salvia miltiorrhiza B. was the highest, which proved that the climate of Shangluo is most suitable for the birth of Salvia miltiorrhiza. 1 0 8 ° 3 4 ' 2 0 ”~1 1 1 ° 1 ' 2 5 ”, north latitude 3 3 . ——_____q__ This paper scale is applicable to China National Standard (CNS) A4 specification (210X297 mm). The phenolic sample in this area is 1281400 at B7. 5. Description of invention (舛) ... ~34° 24'40”, average elevation 900 meters. The region is surrounded by low-lying mountains, no pollution, and no pollution environment is an ideal place for the growth of Salvia miltiorrhiza. (3) Climate The climate is mild and moderate in humidity. It is a typical subtropical to temperate transitional foothill. Under the influence of the southeast monsoon, there are obvious four seasons with abundant rainfall. The annual rainfall is about 73 3.9~899mm, and the annual light is about 1 874.1~2185 hours, which is equivalent to 119.57~1 24.36 kcal/cm2. The temperature is 18 ° C ~ 40.8 ° C, the annual non-frost period of 198 ~ 218 days. (4) 80% of the soil in the Shangluo area of the soil is sandy, most of which are neutral and weakly alkaline cultivables of pH 値 6.5 ~ 8. The soil, nutritious tillage layer reaches 0~20cm, and its nutrient composition includes: 1.36% organic matter, 0.085% nitrogen, 18ppm active phosphorus, Γ3 6 ppm active 绅, 60 ppm hydrolyzed nitrogen, soil/heavy metal And other harmful substances It has passed the national agricultural standards. The local crops use organic fertilizer. * - &gt; (5) Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Heavy Metals (please read the notes on the back and fill out this page). Lead, cadmium, mercury, arsenic, etc., as well as pesticide residues, air quality, water quality, etc. are in line with national environmental protection standards. (6) Standardized production of Danshen cultivation and cultivation according to GAP specifications. Technical points and steps for the production of Danshen are compiled. In the book, the planting base Danshen producers have a handbook. During the Danshen planting season, the technicians will go to the field for on-site guidance and technical support to standardize and standardize the large-scale planting of Danshen. -_- _____ This paper scale applies to Chinese national standards. (CNS) A4 specification (210X297 mm) 1281400 Α7 Β7 V. Invention description (π) ... (7) At the Shangluo Danshen base, 20 different varieties of Salvia miltiorrhiza were cultivated and planted, their growth status>J, yield The appearance, chemical composition and observation were compared for 3 years. Finally, the best quality Salvia miltiorrhiza varieties were selected for large-scale cultivation. (8) Apply tissue cultivation and cloning techniques in the cultivation of Salvia miltiorrhiza to accelerate production and shorten the growth cycle. (9) After 30 days of test tube culture, there is a 40-day rapid propagation process before the long roots, followed by 1 0 days is the growth and growth of the roots, the rooting rate reaches 90% or more, and then transferred to a computer-controlled breeding room with advanced sprinkler irrigation facilities and facilities, and then transplanted to the outside after one month of cultivation. (1 〇) As the experts said, Salvia miltiorrhiza cultivated at Shangluo Danshen Base is high in quality and high in yield, rich in rhizomes (more than 50% more than other parts of Salvia miltiorrhiza) and high in chemical content (more than other parts of Salvia miltiorrhiza) The active pharmaceutical ingredient content is higher than 70%). 2 · Natural borneol (1) Growth conditions / Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) The natural borneol growth base is located in Xinhuang County, Hunan Province, China. The height of the hilly area, 300 to 600 meters above sea level, forest coverage of 60%, is yellow and red sandy soil of p Η値 5~6, no air and water pollution. (2) The biological characteristics of the tree ^ For the low shrubs with extremely strong growth ability, 300 to 400 plants per mu, collecting the above branches and leaves, the net can be 1 000 kg per mu. - -5S-:—— This paper size applies to Chinese National Standard (CNS) Α4 size (210 X 297 mm) 1281400 Δ7 A 7 B7 V. Invention Description (α) (3) Reproduction and transplantation (please read the back) Precautions: Please fill in this page. Use the grafting and planting techniques to breed. In the first year, grow in the breeding room, and in the second year, transplant to the field. The field needs regular fertilization and dressing. (4) Plants can grow to 80~100 (: 111 high, the maximum diameter can reach 3〇mm. Different parts of the tree such as leaves, branches, stems, roots, etc. contain different natural camphor, and the content of leaves is the highest. (5) The borneol-type camphor tree in Xinhuang area is a variant of Cirnamonium glandullferm (wall) Noes. The content of camphor trees on camphor and borneol is different, some borneol content is low, camphor content is high, and others On the contrary, after a large sample test and many times of high performance liquid chromatography analysis, we finally chose a variety with a borneol content of more than 8 〇% and less impurities. 3 · Sanqi A · Plant seeds (1) three Seven Identification of the Ministry of Economic Affairs Central Bureau of Standards Staff Employees Cooperatives printed the application of molecular mass labeling polymerase chain reaction to observe the staining of Panax notoginseng, Sanqi has its own unique DNA fingerprinting. (2) Shape and characteristics of the seeds of Sanqi Round, ring, according to different growth period, can be divided into two-year and two-year seeds. The two-year seed diameter is 0.45 〇.55cm, dry weight Φ5~103 g; three-year seed 0.54~0.65cm ,dry 9 8 ~1 0 9 g 〇本纸标准Applicable to China National Standard (CNS) A4 Specification (210X297 mm) 1281400 A7 B7 V. Invention Description U7) ... (3) Suitable temperature for seed germination The optimum temperature for seed germination is 10~3〇°C, ideal temperature is 15~20〇c. (4) Moisture The moisture content should be 60 to 70%. If it is less than 20% for a long time, the seed will be inactivated. (5) Hibernation Seeds undergo a hibernation period of 4 5 to 60 days after collection. (6) Lifespan The life in the natural state after seed picking is 15 days. (7) Requirements for storage of seeds The seeds to be stored and stored should be collected from the aerial parts of plants that have been grown for more than two years and are free from pests and foliage. It is recommended to harvest from three-year plants.

(8 )種子保留田的管理 V 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 種子保留田的管理比一般的生産田要嚴格,不管什 麽時候被污染的種子都要祛除,在發芽時期決不能有蟲 害。在出芽和長葉的時候,應用3 0 00ppm的YunDa-120和 稀釋400倍的YangKang生物肥料噴灑2次;在開花和結 果時期,則噴以細胞分裂素。 .(9)種子的收‘割期 三七種子的收割期從十月底到十二月初。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 1281400 A7 __B7_____ 五、發明説明(W) … (1 0 )種子的採集方法 根據種子的成熟水平決定是否採集,從生長強壯的 植株上採集種子並分開貯藏,嚴禁從不成熟的植株上採 集。 (· 1 1 )初步處理 種子採集後立即淸洗,剔出果肉和枯萎的種子,將 淸洗後的種子在太陽下進行乾燥。 (1 2 )貯藏 用 58% metalaxyl manganous zinc稀釋 300 倍後的溶 液對三七種子進行3 0分鐘的處理,使種子表面變得乾燥, 在含水量爲20%的濕沙中貯藏,這是至關重要的一步。 (13 )包裝 最終·産品裝載無污染的容器中,容器上標明採集的 日期、加工的過程和産品批號。 (14)運輸 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 應使用潔淨、防水和通風良好的運輸工具和設備/ 防止産品被有毒物質污染。如果運輸時間超過8小時,種 子應放置在濕沙裏。 (1 5 )種子的活力檢驗 用 TTC法進行檢驗:精密稱取lg四唑粉末,用 1 00 0ml蒸鍵·水溶解,使成爲0.1 %的TTC溶液。將樣品浸 入溶液中並保持24小時,取出,對半切開,將其中一半 放置在培養皿中。用預先準備好的〇. 1 %的TTC溶液對樣 品染色3 0分鐘。根據種子的顔色可確定種子的活力程度。 _|___SR _____ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 at B7 五、發明説明(θ ) ,, (1 6 )蟲害的檢查’ I. 在白色紙上或玻璃上放5 00〜1〇〇〇個樣品,用肉眼觀 察,如果有不尋常的斑點或害蟲出現在樣品表面,可確 認爲有污染。有污染的樣品應該被分離出來,並鑒定它 的污染程度。 II. 切開檢查:用手術刀切開2套樣品(每套有100粒種 子),計算有污染種子的數量來確定污染程度。 III. 氣味檢查:將樣品放在手上,用鼻嗅之,看是否有發 .黴的氣味,或者將樣品放入盛有60〜70°C熱水的杯中, 蓋上蓋浸泡2〜3分鐘,然後將水倒出,聞種子的氣味, 種子應散發出輕淡的香氣。如果沒有,則可能被污染。 (1 7 )顔色檢查 未被污染的種子應呈淡黃白色。 (1 8 )顯微檢查 隨機挑選5組樣品(每組不得少於5 0粒種子),在 培養皿中放置24小時,然後在顯.微鏡下觀察’看是否氧 致病菌,如果有,計算其污染的程度。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) B ·植物的秧苗 (1 )發芽的溫度 三七發芽的溫度爲1〜2 0 °C,理想的溫度爲1 5 °C。 (2 )水分量 適宜狹亩生長的土壤水分含量爲20〜2 5% ° (3 )貯藏 _____^--~~-— - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7_ 五、發明説明) … 三七發芽前有90天的冬眠期,lOOppm的赤黴素可 幫助縮短三七的冬眠’期。 (請先閱讀背面之注意事項再填寫本頁) (4.)精選 三七的精選期從十二月底到一月初。精選時,應該 仔細對根部進行處理,精選後立即栽種。 (5 )運輸 三七不宜長途運輸,否則會受到損害。如果不能避 免長時間運輸,應該把三七放置在通風良好、有土壤的容 器中,不能直接受陽光的曝曬。 (6 )質量檢驗 I·單位重量:選300〜500幼苗作爲樣品,每1〇〇個幼苗 爲一組,在天平上稱定重量,計算其單位重量。 II·殺蟲劑檢查:選4組樣品,每組100個幼苗,將樣品放 置在一個玻璃盤上,肉眼觀察或用5〜10倍的放大鏡觀 察,看是否有殺蟲劑。 III·顯微檢查:選4組樣品,每組100個幼苗,把樣品切 - ' v 片,放置在顯微鏡下進行觀察。 經濟部中央標準局員工消費合作社印製 c ·狹苗的培育 (1) 田壟條件 三七幼苗需要在條件良好的地方培育。三七基地應. 用了中心培育和大規模培養的方法。 1281400 A7 B7_ 五、發明説明(έί) 厂· (3 )水源 ’ (請先閱讀背面之注意事項再填寫本頁) 該地區水源由雨水、地下水和自然的流水組成,用 GB. 5 0 84-92進行水質的監測。 (4 ) 土壤 軟土不適宜三七的栽種,栽種三七的土壤中重金屬 的含量不得超過國家有關的標準。 (5 )理想的土壤 爲得到所期望的最佳效果,我們選擇了傾斜度不超 過15度的坡地,其土質偏酸性,pH爲5.5〜7.0,海拔1600 米以下有8〜12%的光照,16〇0米以上有10〜20%的光照。 (ό )溫度 在發·芽時期,大氣溫度應該爲20〜25t,土壤溫度 爲1 0〜1 5 °C。在結籽時期,最佳的大氣溫度爲2 0〜2 5 °C, 最佳的土壤溫度爲15〜20°C。 (7 )含水量 ; 土壤水分含量應爲25〜30%。 經濟部中央標準局員工消費合作社印製 (8 ) 土壤的翻耕 在栽種之前,應翻耕土壤3次,使土壤充分暴露在 陽光下,這樣有助於殺滅土壤中的細菌。 (9 ) 土壤的處'理 爲防止三七根部損害,在移植之前每平方米土壤應 加75〜100g的石灰。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1281400 A7 B7 _ 五、發明説明(“) … (10 )遮光建築及其’管理 遮光物離地面1 .8米,地下有2米深的壕溝,海拔 16〇.〇米以下地方的陽光透過率最好爲8〜10%,1 600以上 爲10〜15%。地面要平整,深層土壤較松,而表層土壤較 硬。栽種季節最好在十二月底至一月底。栽種前,種子應 該在58% metalaxylic zinc 的稀釋500〜800倍後的溶液 或1.5%的抗黴素稀釋液(稀釋後濃度爲200ppm)中浸泡 3〇〜50分鐘,取出,晾乾,這樣可保護植物免受疾病的危 害(已塗漬的種子不必再進行上述程式)。種植密度爲4 X 5cm或5x5cm,每畝10〜20萬顆種子。用特殊工具耕出 淺溝,再用機器或人工播種和種植,種子需用精製的土壤 完全覆蓋。 以上完成後,進行施肥、灌溉、除草。除草應時刻 進行。如果遮光物有破損,應及時修理,以保證適宜的透 光率。天然肥料包括畜禽肥料、爐灰、骨灰,但不宜使用 人屎肥料。 D ·三七的栽培 (1 )佈局 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 地面最好呈小於1 5度的坡狀,有良好的光照。 1281400 A7 B7____ 五 '發明説明(0 ) 、 可在新田裏預先種植穀物、小麥、豆類以避免土質 的破壞。 · (請先閲讀背面之注意事項再填寫本頁) (5.)海拔高度 海拔高度1 400〜1 800米以上、北緯23.5度的地區 最適宜三七的生長。 (6 )光照 三七是一種僅需要8〜20%光照的植物,光照的多少 應隨生長時期的不同而逐步增加,但過多的光照會導致生 長停滯不前。 (7 )含水量 土壤水分含量應爲2 5〜3 0 °/。。 。 (8 )肥料- 有機肥料同複合肥料、微量營養物肥料、微量元素 肥料一起被應用。 (9 )溫度 ^ 經濟部中央標準局員工消費合作社印製 三七種植基地一年的平均溫度爲15〜18。(:。在出芽 期間,大氣溫度最佳爲20〜25 °C,土壤溫度最佳爲15t ; 在迅速生長和開花期,溫度最好爲25 °C,如果溫度低於 1 5 °C,開花將受影響。 (1 〇 )田土』勺翻耕 ,一 在種植之前,田土應翻耕松土 3次,使土壤呈粉末 狀。 —_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公慶) 1281400 A7 B7_ 五、發明説明(6f) … (11 ) 土壤處理 (請先閱讀背面之注意事項再填寫本頁) 在播種和移植乏前,在每平米土壤中加入75〜100g 石灰以起到殺菌作用。 (1 2 )田床的規格 平整地面,使土床高20〜25cm,傾斜 15〜20cm, 寬120〜140 cm,呈瓦片狀。土床下部土壤較松而上部土 壤較硬,這樣會有更好的滲透率。 _( 13 )種子的浸泡 在移植前,應將種子放在58% metalaxyl稀釋500 〜6 0 0倍後的溶液中浸泡3 〇〜5 〇分鐘,取出,晾乾,這樣 可防治疾病和祛除害蟲。 (1 4 )種植密度 種植‘密度爲10x12.5cm〜10x15cm,每畝2.6〜3.2 禹株。 (1 5 )移植方法 經濟部中央標準局員工消費合作社印製 爲便於管理,狹苗應朝著同一個方向種植。如果是 坡地,秧苗就從低的一邊向高的一邊進行栽種,第一排向 上而第二排向下,芽朝上而底朝下。 (1〇 土壤覆蓋物 用粉末狀、鬆軟潮濕的土壤完全覆蓋秧苗,不要暴 露根部或芽-苞。 ' (1 7 )施肥 使用畜禽肥、爐灰、骨灰、鈣鎂磷等專用肥料。 11_________^4___ - 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 1281400 A7 A7 ____B7 五、發明説明(Μ ) 參考文獻 1. US Pat. N〇. 5 2 8 84 8 5 “vasodilating agent” 2. US Pat. No. 5 4 3 3 9 5 7 “vasodilating agent” 3. US Pat. No. 5 7 7 6 4 6 3 “Method of reducing stress and circulatory heart disease with freeze-dried borage petalextracts” 4. 楊桂元等.寬葉纈草治療冠心病的臨床硏究.中國中西 醫結合雜誌,1994,14(9): 540-542 5 ·吳曄良.心痛康膠囊治療冠心病心絞痛療效觀.察.中西 醫結合灘誌,1 9 9 0,( 7 ) : 3 9 5 - 3 9 8 6.劉康永等.天保寧治療冠心病心絞痛45例臨床觀察.中 國中西醫結合雜誌, 1 995,1 5 ( 1 1 ): 649-65 1 • ' &gt; 7 .胡錦心/參芍通冠片治療冠心病心絞痛的臨床及實驗 硏究.中西醫結合雜誌, 1990,(10): 596-599 8.李應東·擴冠沖劑對心絞痛患者血漿鋅與銅和紅細胞 谷胱甘 過氧化物酶活性的影響·中西醫結合雜 誌,1 9 90,(6): 3 4 8 -3 5 0 … 9·王博文.蒺藜皂f治療冠心病心絞痛4〇6例臨床觀察.中 西醫結合雜誌,1 990,(2): 85-87 _ ._____^ ____ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)(8) Management of seed reserve field V Printed by the Central Bureau of Standards and Staff Consumer Cooperative of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) The management of the seed reserve field is stricter than the general production field, no matter when it is polluted The seeds must be removed, and there must be no pests during the germination period. In budding and long leaves, 3 000 00 YunDa-120 and 400-fold diluted YangKang bio-fertilizer were sprayed twice; during flowering and fruiting, cytokinin was sprayed. (9) Harvesting of seeds The harvesting period of the seeds of Panax notoginseng is from the end of October to the beginning of December. This paper scale applies to China National Standard (CNS) A4 specification (210X 297 mm) 1281400 A7 __B7_____ V. Description of invention (W) ... (1 0 ) Seed collection method determines whether to collect according to the maturity level of the seed, from strong growth Seeds are collected on the plants and stored separately. It is strictly forbidden to collect from immature plants. (· 1 1 ) Preliminary treatment Immediately after seed collection, the seeds are washed, the flesh and the withered seeds are removed, and the washed seeds are dried in the sun. (1 2) The solution was diluted 300 times with 58% metalaxyl manganous zinc, and the seeds of Panax notoginseng were treated for 30 minutes to make the surface of the seeds dry and stored in wet sand with a water content of 20%. An important step. (13) Packaging Final • The product is loaded in a non-contaminating container with the date of collection, the process of processing, and the lot number of the product. (14) Transportation Printed by the Consumer Standards Bureau of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page). Use clean, waterproof and well-ventilated transportation tools and equipment / prevent products from being contaminated with toxic substances. If the transport time exceeds 8 hours, the seeds should be placed in wet sand. (1 5) Seed vigor test The test was carried out by the TTC method: lg tetrazolium powder was accurately weighed and dissolved in 100 ml of steamed water to make a 0.1% TTC solution. The sample was immersed in the solution for 24 hours, taken out, cut in half, and half of it was placed in a Petri dish. The sample was stained for 30 minutes with a pre-prepared 1. 1% TTC solution. The degree of vigor of the seed can be determined based on the color of the seed. _|___SR _____ This paper scale applies to Chinese National Standard (CNS) A4 specification (210X297 mm) 1281400 at B7 V. Invention description (θ) ,, (1 6 ) Pest inspection ' I. Put on white paper or glass 5 00 to 1 样品 sample, observed with the naked eye, if there are unusual spots or pests appear on the surface of the sample, it can be confirmed as contamination. Contaminated samples should be separated and their contamination level identified. II. Incision examination: Two sets of samples (100 seeds per set) were cut with a scalpel, and the number of contaminated seeds was counted to determine the degree of contamination. III. Odor check: Place the sample on the hand, sniff it with the nose, see if there is a mildew smell, or put the sample into a cup containing 60~70 °C hot water, cover the lid and soak 2~3 Minutes, then pour out the water, smell the smell of the seeds, and the seeds should emit a light aroma. If not, it may be contaminated. (1 7) Color check Uncontaminated seeds should be yellowish white. (1 8) Microscopic examination Randomly select 5 groups of samples (no less than 50 seeds in each group), place them in a Petri dish for 24 hours, and then observe under the microscopic microscope to see if there is oxygen pathogen, if any , calculate the extent of its pollution. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) B · Plant seedlings (1) Germination temperature The temperature of the germination of germination is 1~2 0 °C, ideal temperature It is 1 5 °C. (2) The moisture content is suitable for the growth of soil with a moisture content of 20~2 5% ° (3) Storage _____^--~~-- - This paper scale applies Chinese National Standard (CNS) A4 specification (210X297 mm) 1281400 A7 B7_ V. Inventive Note) ... There are 90 days of hibernation before the germination of Panax notoginseng, and 100 ppm of gibberellin can help shorten the hibernation period of Panax notoginseng. (Please read the notes on the back and fill out this page) (4.) Featured The selection period of Sanqi is from the end of December to the beginning of January. When selecting, the roots should be carefully treated and planted immediately after selection. (5) Transportation Sanqi is not suitable for long-distance transportation, otherwise it will be damaged. If long-term transportation cannot be avoided, the Sanqi should be placed in a well-ventilated, soil-containing container that cannot be directly exposed to sunlight. (6) Quality inspection I·Unit weight: 300~500 seedlings are selected as samples, one for each seedling, and the weight is weighed on the balance to calculate the unit weight. II. Insecticide inspection: Select 4 groups of samples, 100 seedlings per group, place the sample on a glass plate, or observe with a magnifying glass 5 to 10 times to see if there is any pesticide. III. Microscopic examination: 4 groups of samples were selected, 100 seedlings per group, and the samples were cut - 'v pieces and placed under a microscope for observation. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs c · Cultivation of narrow seedlings (1) Tentative conditions The seedlings of Panax notoginseng need to be cultivated in well-conditioned areas. The Sanqi Base should use the methods of center cultivation and large-scale cultivation. 1281400 A7 B7_ V. INSTRUCTIONS (έί) 厂· (3) Water source' (Please read the notes on the back and fill out this page) The water source in this area is composed of rainwater, groundwater and natural flowing water. GB. 5 0 84- 92 Conduct water quality monitoring. (4) The soil soft soil is not suitable for the planting of Panax notoginseng. The content of heavy metals in the soil of the planting of Panax notoginseng should not exceed the relevant national standards. (5) The ideal soil is to obtain the best effect expected. We choose the slope with the slope not exceeding 15 degrees. The soil is acidic, the pH is 5.5~7.0, and the light is 8~12% below 1600 meters. 10~20% of the light above 16〇0 meters. (ό) Temperature During the hair bud period, the atmospheric temperature should be 20~25t, and the soil temperature should be 1 0~1 5 °C. During the seeding period, the optimum atmospheric temperature is 20 to 2 5 ° C, and the optimum soil temperature is 15 to 20 ° C. (7) Water content; soil moisture content should be 25~30%. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (8) Soil tillage Before planting, the soil should be ploughed three times to expose the soil to the sun, which helps to kill the bacteria in the soil. (9) The location of the soil To prevent damage to the roots of the Panax notoginseng, 75 to 100 g of lime should be added per square meter of soil before transplantation. This paper scale applies to China National Standard (CNS) A4 specification (210X297 mm) 1281400 A7 B7 _ V. Invention description (") ... (10) Shading building and its 'management shades are 1. 8 meters from the ground, 2 underground The depth of the ditch in the depth of the rice is 16 海拔. The transmittance of sunlight below the glutinous rice is preferably 8 to 10%, and the temperature above 1 600 is 10 to 15%. The ground should be flat, the deep soil is loose, and the surface soil is hard. The season is best from the end of December to the end of January. Before planting, the seeds should be soaked in a solution of 58% metalaxylic zinc diluted 500-800 times or 1.5% anti-mycin dilution (diluted concentration 200ppm). ~50 minutes, remove, dry, so as to protect plants from disease (the coated seeds do not have to do the above procedure). Planting density is 4 X 5cm or 5x5cm, 10~200,000 seeds per acre. Special tools for ploughing shallow ditch, and then planting or planting with machinery or artificially, the seeds should be completely covered with refined soil. After the above, fertilization, irrigation, weeding should be carried out. Weeding should be carried out at all times. If the sunshade is damaged, it should be repaired in time. To Ensure the appropriate light transmittance. Natural fertilizers include livestock and poultry fertilizer, ash, and ashes, but it is not suitable to use human cockroach fertilizer. D · Cultivation of Sanqi (1) Printed by the Central Bureau of Standards and Staff of the Ministry of Economic Affairs (please read first) Precautions on the back side. Fill in the page. The ground is preferably sloped at less than 15 degrees and has good illumination. 1281400 A7 B7____ Five 'Inventions (0), can be pre-planted with grain, wheat, beans in Xintian Avoid soil damage. (Please read the note on the back and fill out this page.) (5.) The altitude above 1 400~1 800 meters above sea level and 23.5 degrees north latitude is most suitable for the growth of Panax notoginseng. (6) Illumination Panax notoginseng is a plant that requires only 8 to 20% of light. The amount of light should increase gradually with the growth period, but excessive light will cause growth to stagnate. (7) Water content The soil moisture content should be 2 5~3 0 °/... (8) Fertilizer - Organic fertilizer is applied together with compound fertilizer, micronutrient fertilizer, and trace element fertilizer. (9) Temperature ^ Ministry of Economic Affairs, Central Bureau of Standards, Staff Consumer Cooperative, Printed Sanqi The average temperature of the planting base is 15~18. (: During the budding, the atmospheric temperature is optimally 20~25 °C, the soil temperature is best 15t; in the rapid growth and flowering period, the temperature is preferably 25 °. C. If the temperature is lower than 15 °C, the flowering will be affected. (1 〇) Field soil spoon ploughing, one field should be ploughed and soiled 3 times before planting, so that the soil is powdery. —_ This paper The scale applies to China National Standard (CNS) A4 specification (210X297 public celebration) 1281400 A7 B7_ V. Invention description (6f) ... (11) Soil treatment (please read the notes on the back and fill in this page) Before sowing and transplanting Add 75~100g of lime per square meter of soil for bactericidal action. (1 2) Specifications of the field bed Level the ground so that the soil bed is 20 to 25 cm high, inclined 15 to 20 cm, and 120 to 140 cm wide, in a tile shape. The soil in the lower part of the soil bed is looser and the upper soil is harder, which will result in better permeability. _( 13 ) Seed soaking Before transplanting, the seeds should be immersed in a solution of 58% metalaxyl diluted 500 ~ 6,000 times for 3 〇 ~ 5 〇 minutes, taken out, dried, so as to prevent diseases and eliminate pests . (1 4) Planting Density Planting 'density is 10x12.5cm~10x15cm, 2.6~3.2 每 per mu. (1 5) Transplantation method Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs In order to facilitate management, the narrow seedlings should be planted in the same direction. If it is a sloping field, the seedlings are planted from the low side to the high side, with the first row facing up and the second row going down, with the buds facing up and bottom facing down. (1) Soil cover completely covered with seedlings in powdery, soft and moist soil, do not expose roots or buds - 苞. ' (1 7 ) Fertilizer uses special fertilizers such as livestock and poultry, ash, ashes, calcium, magnesium and phosphorus. 11_________ ^4___ - This paper scale applies to China National Standard (CNS) Α4 specification (210X297 mm) Printed by the Central Bureau of Standards and Staff of the Ministry of Economic Affairs 1281400 A7 A7 ____B7 V. Invention Description (Μ) References 1. US Pat. N〇 5 2 8 84 8 5 “vasodilating agent” 2. US Pat. No. 5 4 3 3 9 5 7 “vasodilating agent” 3. US Pat. No. 5 7 7 6 4 6 3 “Method of reducing stress and circulatory Heart disease with freeze-dried borage petalextracts” 4. Yang Guiyuan et al. Clinical study on the treatment of coronary heart disease with broadleaf valerian. Chinese Journal of Integrated Traditional Chinese and Western Medicine, 1994, 14(9): 540-542 5 · Wu Yuliang. Xintongkang Capsule Treatment Coronary heart disease angina pectoris effect observation. Inspection. Integrated Chinese and Western medicine Beach, 1 9 9 0, (7): 3 9 5 - 3 9 8 6. Liu Kangyong et al. Clinical observation of 45 cases of coronary heart disease with angina pectoris. Chinese Journal of Traditional Chinese Medicine Combined with the magazine, 1 995, 1 5 ( 1 1 ): 649-65 1 • ' &gt; 7 . Hu Jinxin / Shenqi Tongguan Tablets for the treatment of coronary heart disease with angina pectoris clinical and experimental research. Chinese Journal of Integrated Traditional and Western Medicine, 1990, (10): 596-599 8. Li Yingdong · crown-expanding agent for plasma of patients with angina pectoris Effects of Zinc and Copper and Erythrocyte Glutathione Enzyme Activity · Chinese Journal of Integrated Traditional and Western Medicine, 1 9 90, (6): 3 4 8 -3 5 0 ... 9·Wang Bowen. 蒺藜 soap f treatment of coronary heart disease angina 4〇 6 cases of clinical observation. Chinese Journal of Integrated Traditional and Western Medicine, 1 990, (2): 85-87 _ ._____^ ____ This paper scale applies Chinese National Standard (CNS) A4 specification (210X297 mm) (please read the notes on the back first) Fill in this page again)

1281400 A7 B7 五、發明説明(以) 1 0.金椿.黃芪對冠心病患者紅細胞內鈉含量和鈉轉運的 影響.中西醫結合雜誌,1 9 9 1,( 1 1 ) : 6 5 1 - 6 5 3 (請先閲讀背面之注意事項再填寫本頁) 1 1 .錢振淮.氣血沖劑治療氣虛血瘀型冠心病心絞痛的臨 床硏究.中國中西醫結合雜誌,1 992,( 1 1 ): 663 -665 12.汪曉芳.溫心湯治療冠心病自發性心絞痛82例臨床觀 察.中國中西醫結合雜誌,1 996,1 6(4): 20 1 -203 1 1 2 3 ·雷正一等.黃芪對心絞痛患者心功能的影響.中國中 西醫結合雜誌,1 994,1 4(4): 1 99-202 1 4 .何維.冠心病心絞痛本虛標實證患者免疫功能狀態的 硏究.中醫雜誌, 1 9 8 9,( 2 ) : 2 3 - 2 6 1 4 ·陳楷·舒血寧片治療冠心病的臨床硏究.中國中西醫 結合雜誌, 1 996,1 6( 1 ): 24-26 1 5 ·張華.補陽還五湯治療冠心病的臨床硏究及其作用機-制探討·.中國中西醫結合雜誌, 1 994, 14(4): 213-215 經濟部中央標準局員工消費合作社印製 1 7 .張秀蘭·玫瑰舒心口服液治療氣滯血瘀型冠心病心絞 痛的硏究.中國中西醫結合雜誌,1 9 9 2,( 7 ) : 4 1 4 - 4 1 6 1 8 · Zhu W et al.,“Protective effect of danshen 2 during myocardial ischemia and reperfusion: an 3 isolated rat heart study” American Journal of Clinical 4 _____66 ____ 5 本紙張尺度適用中國國家標準(CNS ) A6^洛(210X297公釐) 61281400 A7 B7 V. Description of the invention (I) 1 0. Jin Qi. Effect of Astragalus membranaceus on sodium content and sodium transport in erythrocytes of patients with coronary heart disease. Chinese Journal of Integrated Traditional and Western Medicine, 1 9 9 1, (1 1 ) : 6 5 1 - 6 5 3 (Please read the precautions on the back and then fill out this page) 1 1 . Qian Zhenhuai. Clinical observation of qi and blood granules in the treatment of angina pectoris with qi deficiency and blood stasis type. Chinese Journal of Integrated Traditional and Western Medicine, 1 992, (1 1): 663 -665 12. Wang Xiaofang. Clinical observation of 82 cases of spontaneous angina pectoris treated by Wenxin Decoction. Chinese Journal of Integrated Traditional and Western Medicine, 1 996,1 6(4): 20 1 -203 1 1 2 3 · Lei Zheng First-class. Effect of Astragalus on cardiac function in patients with angina pectoris. Chinese Journal of Integrated Traditional and Western Medicine, 1 994,1 4(4): 1 99-202 1 4. He Wei. Coronary heart disease angina pectoris Research. Journal of Traditional Chinese Medicine, 1 9 8 9,( 2 ) : 2 3 - 2 6 1 4 ·Chen Yi·Shu Xuening Tablets for the treatment of coronary heart disease. Chinese Journal of Integrated Traditional and Western Medicine, 1 996,1 6 ( 1 ): 24-26 1 5 · Zhang Hua. Clinical study of Buyang Huanwu Decoction in the treatment of coronary heart disease and its mechanism--Discussion. Chinese Journal of Integrated Traditional and Western Medicine, 1 994, 14(4): 213-2 15 Department of Economics, Central Bureau of Standards, Staff Consumer Cooperatives, Printing 1 7 . Zhang Xiulan·Rose Shuxin Oral Liquid for the treatment of angina pectoris with qi stagnation and blood stasis type. Chinese Journal of Integrated Traditional and Western Medicine, 1 9 9 2, ( 7 ) : 4 1 4 - 4 1 6 1 8 · Zhu W et al., "Protective effect of danshen 2 during myocardial ischemia and reperfusion: an 3 isolated rat heart study" American Journal of Clinical 4 _____66 ____ 5 This paper scale applies to Chinese national standards (CNS ) A6^洛 (210X297 mm) 6

Medicine, 1 8( 1 -2): 1 9-24, 1 990. 1281400 at Β7 五、發明説明(0) , 1 9.李以義.血脈通治療冠心病的臨床觀察與實驗硏究. 中西醫結合雜誌,1 989, (2): 79_81 2 0 ·蔡沛源等.合歡湯治療冠心病臨床硏究.中國中西醫 結合雜誌,1 996,1 6(4): 204_206 2 1.林求誠·冠脈樂治療冠心病的臨床硏究.中西醫結合 雜誌,1 98 9; (5): 280-282 2 2 .李樹青等·黃蔑治療缺血性心臟病的臨床觀察中國 中西醫結合雜誌,1 995.02.20; 15(2): 77-80 23 ·呂寶經等.生脈散對急性心肌梗塞患者的抗脂質過氧 化作用.中國中西醫結合雜誌,1 9 9 4,1 4 ( 1 2 ) : 7 1 2 - 7 1 4 24·王碩仁·黨參對血栓素A1 2和前列環素合成的影響'中 西醫結合雜誌,1 9 9 0 ;( 7 ) : 3 9 1 - 3 9 4 2 5 ·關曼聲♦擴冠祛瘀靈治療冠心病的硏究.中醫雜誌; 1989, (6): 27-29 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 26·複方複方丹參片.中華人民共和國藥典一部(英文版), 第280頁 1 7.祝厚剛等·心可寧治療冠心病無症狀心肌缺血療效觀 2 察·中ίψ西醫結合雜誌,1994,14(4): 213-215 n 經濟部中央標準局員工消費合作社印製 281400 A7 A7 B7 五、發明説明(從) 1982; (1): 31-20 2 9 ·孫錫銘.丹參素的新藥理作用.中草藥,1 9 9 1,( 1 ) ·· 20-23 3〇.程彰華.丹參素對微循環障礙和血漿乳酸含量影響的 實驗硏究.上海醫科大學學報,1 9 8 7,(1): 25 _2 9 3 1.黃聰.三七總皂笮對淸醒兔心肌缺血再灌注損傷的保 護作用.中國藥理學通報,1991; (3): 190-193 3 2 .石琳.三七總皂f升高頸動脈前列腺素12及降低血小 板血栓素A2的作用.中國藥理學報,1990,(1): 29-32 3 3 ·徐偉等·薄荷醇及冰片對磺胺嘧啶和伊文思藍在腦中 分佈的影響·中藥藥理與臨床,1 99 5,1 1(6)彳3 1-33 3 4 ·陳鐵鐸.冰片促進四甲基吡嗪的吸收.中國藥理學報, 1990, (1): 42-44 3 5 .李杏·三七皂f對大鼠實驗性心肌缺血再灌注損傷的 保護作用.中國藥理學報,1990,(1):26-29 3 6 ·潘炯光·艾葉揮發油的化學硏究·中國中藥雜誌, 1992, (12): 741-744 3 7 ·吳堯忠·等·丹參活血化瘀作用及機理探討南京中醫 藥大學學報,1995,11(6): 35-36 3 8 ·王寧生等.冰片“佐使則有功,,之實驗硏究中醫雜 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) 1281400 A7 _ B7五、發明説明(θ ) … 誌,1994, 35(1): 46-47 3 9·李承珠.丹參素抗凝血作用的硏究.中西醫結合雜誌, 1983, (5): 297-299 4〇 ·李承珠.丹參抑制體外血栓形成機理的實驗硏究.上 海第一醫學院學報,1979,(3):146-149 41·莫啓忠· 3H-冰片動力學的硏究:中藥冰片芳香開竅機 理的初步探討.中成藥硏究,1 9 8 2,( 8 ) : 5 - 7 42·鄭若玄.丹參對大白鼠冠狀動脈結紮引起心肌缺血的 預防作用·中國中西醫結合雜誌,1992,(7): 424-426 經濟部中央標準局員工消費合作社印製 準 標 家 一國 i國 中 用 適 度 尺 |張 紙 本 ¥ 1公 7 ^ 9 (請先閲讀背面之注意事項再填寫本頁)Medicine, 1 8( 1 -2): 1 9-24, 1 990. 1281400 at Β7 5, invention description (0), 1 9. Li Yiyi. Clinical observation and experimental study of Xuemaitong in the treatment of coronary heart disease. Integrative Chinese and Western medicine Journal, 1 989, (2): 79_81 2 0 · Cai Peiyuan et al. Clinical study of Hehuan Decoction in the treatment of coronary heart disease. Chinese Journal of Integrated Traditional Chinese and Western Medicine, 1 996,1 6(4): 204_206 2 1. Lin Qiucheng·Cronical Treatment Clinical study of coronary heart disease. Chinese Journal of Integrated Traditional and Western Medicine, 1 98 9; (5): 280-282 2 2. Clinical observation of Li Shuqing et al. in the treatment of ischemic heart disease. Chinese Journal of Integrated Traditional and Western Medicine, 195.02.20 15(2): 77-80 23 · Lu Baojing et al. Anti-lipid peroxidation of Shengmaisan in patients with acute myocardial infarction. Chinese Journal of Integrated Traditional and Western Medicine, 1 9 9 4, 1 4 ( 1 2 ) : 7 1 2 - 7 1 4 24·Wang Shuoren·Dangshen's effect on the synthesis of thromboxane A1 2 and prostacyclin' Journal of Integrated Traditional Chinese and Western Medicine, 1 9 9 ; ( 7 ) : 3 9 1 - 3 9 4 2 5 · Guan Mansheng ♦ Expanding the crown Qi Ling's treatment of coronary heart disease. Journal of Traditional Chinese Medicine; 1989, (6): 27-29 Printed by the Consumer Standards Agency of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back and fill out this page) 26· Compound Fufang Danshen Tablets. Pharmacopoeia of the People's Republic of China (English version), p. 280 1 7. Zhu Hougang et al. Treatment of asymptomatic myocardial ischemia in coronary heart disease 2 察·中ίψ西医联合杂志,1994,14 (4): 213-215 n Ministry of Economic Affairs Central Bureau of Standards Staff Consumer Cooperatives Printed 281400 A7 A7 B7 V. Description of the Invention (from) 1982; (1): 31-20 2 9 · Sun Ximing. The new pharmacological effects of Danshensu. Chinese herbal medicine, 1 9 9 1,( 1 ) ·· 20-23 3〇. Cheng Zhanghua. Experimental study on the effects of Danshensu on microcirculatory disorders and plasma lactic acid content. Journal of Shanghai Medical University, 1 9 8 7,(1): 25 _2 9 3 1. Huang Cong. Protective effect of Panax notoginseng saponins on myocardial ischemia-reperfusion injury in rabbits. Chinese Journal of Pharmacology, 1991; (3): 190-193 3 2 . Shi Lin. Total soap f increased carotid prostaglandin 12 and decreased platelet thromboxane A2. Chinese Journal of Pharmacology, 1990, (1): 29-32 3 3 · Xu Wei et al. Menthol and borneol on sulfadiazine and Evans blue The influence of distribution in the brain · Chinese medicine pharmacology and clinical, 1 99 5,1 1 (6) 彳 3 1-33 3 4 · Chen Tiezhen. Borneol promotes tetramethylpyrazine Chinese Journal of Pharmacology, 1990, (1): 42-44 3 5. Protective effect of Lixing·Sanqi Soap F on experimental myocardial ischemia-reperfusion injury in rats. Chinese Journal of Pharmacology, 1990, (1): 26-29 3 6 ·Pan Shuguang·Ai Ye volatile oil chemical research ·Chinese Journal of Traditional Chinese Medicine, 1992, (12): 741-744 3 7 ·Wu Yuzhong·etc. Danshen's effect on promoting blood circulation and phlegm. Journal of Nanjing University of Traditional Chinese Medicine, 1995 ,11(6): 35-36 3 8 ·Wang Ningsheng et al. The borneol "the ambassador is active, the experimental study of Chinese medicine miscellaneous paper scale applies to the Chinese National Standard (CNS) A4 specification (210X297 mm) (please read first Note on the back side of this page) 1281400 A7 _ B7 V. Inventive Note (θ ) ... 志,1994, 35(1): 46-47 3 9·Li Chengzhu. Study on the anticoagulant effect of Danshensu. Chinese and Western Medicine Journal of Integrative Medicine, 1983, (5): 297-299 4〇·Li Chengzhu. Experimental study on the inhibition of thrombosis in vitro by Salvia miltiorrhiza. Journal of Shanghai First Medical College, 1979, (3): 146-149 41·Mo Qizhong· Study on the dynamics of 3H-ice flakes: a preliminary discussion on the mechanism of aromatic opening of traditional Chinese medicine borneol. Chinese patent medicine research, 1 9 8 2, (8) : 5 - 7 42·Zheng Ruoxuan. Preventive effect of salvia miltiorrhiza on myocardial ischemia caused by coronary artery ligation in rats·Chinese Journal of Integrated Traditional Chinese and Western Medicine, 1992, (7): 424-426 Ministry of Economic Affairs, Central Bureau of Standards, Staff Consumer Cooperatives, Printing Standards I use moderate scale in i country|sheet paper ¥1 public 7 ^ 9 (please read the notes on the back and fill out this page)

Claims (1)

1281400 拾、申請專利範圍: 1 · 一種治療慢性穩定性心絞痛的中藥組合物滴九,其 牛寸徵在於’匕是由包括如下步驟的方法製備而成: (1 )丹參提取物的製備: (a) 提取:將丹參放於多功能提取罐內,加水至超過 藥材15〜20cm (大約爲藥材量的5〜7倍);蒸汽加 熱’罐內氣壓保持在〇.〇4〜〇 〇6mPa之間,使之沸騰; 分兩次提取,第一次2小時,第二次1.5小時;收集 提取液,過10 0目濾過;棄去殘渣; (b) 濃縮:將提取液轉移置真空罐,控制蒸汽壓低於 0.05mPa,同時調整真空度爲0.076〜0.088mPa,保持 灌內沸騰;濃縮至藥液體積與藥材重量比爲1升:1 千克; (c) 醇沈:濃縮完畢,將濃縮液轉移至醇沈罐,緩緩 地攪動並加入9 5 %乙醇,用酒精計測量直到乙醇濃度 降爲7 0 %,放置2 4小時; (d) 回收乙醇:將醇沈完畢的上淸液轉移至真空罐 中,調節輸入空氣壓力爲〇·〇4〜0.〇6mPa、真空度爲 0.076〜0.088mPa,保持沸騰;濃縮至藥液體積與藥材 重量比爲1升:1千克; (e) 聚酰胺層析精製:將步驟(d)所得溶液置於預先處 理好的聚酰胺柱,上樣體積爲每1克聚酰胺加5ml 樣品;3倍量的水沖洗後,用5〜1 0倍量9 5 %乙醇洗 脫,使用步驟(d)的方法回收乙醇’濃縮洗脫液至相 對密度爲1. 3 3〜1 . 3 5 ; 70 1281400 (2)三七提取物的製備: U)提取:將三七放於多功能提取罐內,加水至超過 藥材15〜20cm (大約爲藥材量的5〜7倍);加熱産 生蒸汽’罐內氣壓保持在〇.〇4〜0.06mPa之間,保持 此種狀態7分兩次提取,第一次2小時,第二次1 · 5 小時;收集提取液,過1 〇〇目濾過,棄去殘渣,濾液 適當濃縮; (b) 大孔吸附樹脂精製:將步驟(a)所得濃縮液上柱, 加樣量與樹脂比例爲 1 ·· 1 ,流速爲 0.5〜 5cm/cm2/min,加樣完畢,以水洗脫,直至其淸亮爲 止;用70%的乙醇洗脫,流速爲〇.5〜5(:111/(:]112/111丨11, 收集洗脫液; (c) 三七洗脫液的濃縮··打開真空泵,用100目過濾 洗脫液後加入真空罐中;調整進口空氣壓力爲0.04 〜0.06mPa,真空度爲0.076〜0.08 8mPa,保持其沸騰 勿暴沸;回收乙醇濃縮至其相對密度爲1. 3 3〜1 . 3 5, 得三七的提取物; (3)中藥組合物滴九的製備: (a) 取重量百分比爲5%〜40 %的上述丹參提取物,重 量百分比爲1%〜10 %的上述三七提取物,重量百分比 爲1%〜5%冰片,其餘量爲輔料聚乙二醇6000,放入 化料罐中,混合均勻,用水蒸氣加熱至80〜85 °C, 持續30〜40分鐘,直到混合均勻無任何結塊爲止; (b) 將混合均勻的物料加入滴九機的滴罐內,並保持 溫度爲89〜93 °C,並進行滴制;冷凝劑爲液狀石蠟, 1281400 其溫度低於8C,滴頭內徑爲i.7mm、外徑爲2.4mm; 藥液與滴頭的距離爲5〜6cm ;滴頭與冷凝液面的距 離爲26〜3 1cm ;冷凝液深度爲im ;滴速爲 60〜80 粒/min ; (c)將九從冷凝液中取出,離心除油,即得該中藥組 合物滴九。 2 ·如申請專利範圍第1項所述的中藥組合物滴九,其 特徵在於,所述(3 )組合物的製備爲:取重量百分比 爲10%〜30%的上述丹參提取物,重量百分比爲2%〜6% 的上述三七提取物,重量百分比爲1%〜5%冰片,其餘 爲輔料,混合均勻,製成組合物。 3 ·如申請專利範圍第1或2項所述的中藥組合物滴九, 其特徵在於,所述(2 )三七提取物製備中大孔樹脂吸 附樹脂可用多孔聚合物、矽膠、氧化鋁、聚酰胺、活性 碳、纖維素或交聯葡聚糖代替。 4 ·如申請專利範圍第1或2項所述的中藥組合物滴九, 其特徵在於,所述(2 )三七提取物製備中洗脫液在60 °C減壓濃縮至相對密度爲1, 3 3〜1. 3 5。 5 ·如申請專利範圍第1或2項所述的中藥組合物滴九, 其特徵在於,所述(2 )三七提取物製備中大孔吸附樹 脂的預處理爲:95 %乙醇浸泡24小時,將非極性的大孔 72 I 1281400 樹脂ZTC -1添入樹脂柱內,粒徑爲ο · 3〜1 . 2 m m、空隙 爲130〜300A ;用等量的水和乙醇進行洗脫,直至洗脫 液淸亮爲止,或者用0.1〜lmol/L的Na〇H和HCL淸洗, 直至沒有乙醇的味道或洗脫液近中性爲止;大孔樹脂的 再生爲:用95 %的乙醇洗脫樹脂,直至洗脫液淸亮無顔 色,再用水淸洗直至無乙醇的味道。 6 ·如申請專利範圍第1項所述的中藥組合物滴九,其 特徵在於,所述滴九呈紅棕色或棕黑色圓球,大小均 勻,氣香,微苦,重量差異大約爲±15%,範圍在21.25 〜2 8.75mg之間,密度爲1.13〜l.40mg/mm3 ,平均直 徑爲0.33〜0.34cm;每九含丹參素0.14〜0.18mg,三七 皂苷R1大於12.12//g ,人參皂甙Rgl大於56.26//g。 7 .如申請專利範圍第1或2項所述之中藥組合物滴九, 其特徵在於 ,其指紋圖譜如下表所示: 峰號 保留時間 相對保留時間 出現槪率 峰面積 峰面積比 峰面積比範圍 1 8.289 0. 672 100% 1034.276 0. 572 0. 572±0. 096 2 12. 343 1.000 100% 1817.065 1.000 1.000±0. 000 3 17. 493 1.417 100% 376. 547 0.208 0. 208±0. 040 4 18. 664 1.512 100% 328.011 0. 181 0.181±0. 059 5 24. 883 2.016 100% 486. 626 0. 267 0. 267±0. 097 6 27. 586 2. 235 100% 525. 432 0. 289 0. 289±0. 052 7 29.714 2.407 100% 940. 963 0.516 0· 516±0· 125 73 1281400 Q 34.030 2.757 100% 1547.495 0.850 0.850±0. 163 •如申請專利範圍第7項所述中藥組合物滴九,其特徵 在於,所述指紋圖譜由如下方法獲得: a) 前處理: 1 ·將適量所述組合物溶於以對氨基苯甲酸爲內標 物的溶液中; ii. 加甲醇超聲15分鐘溶解; iii. 放冷,加甲醇稀釋,離心; iv. 收集上淸液,作爲樣品溶液; b) 將適量丹參素鈉對照品溶於以對氨基苯甲酸爲內 標物的溶液中,加甲醇溶解,作爲參照溶液; c) 高效液相色譜條件如下: i ·流動相:甲醇··水:冰醋酸=8 ·· 91 : 1 ; ii.柱溫:30°C ; i i i.進樣量:1 0 // 1 ; i v .檢測波長:2 8 1 n m ; ν·理論塔板數按丹參素鈉峰計算不得低於2000 ; d) 將樣品溶液和參照溶液分別注入高效液相液,照 高效液相色譜法測定,以對照品的色譜峰的相對 保留時間和峰面積爲1計算相對保留時間和相對 峰面積,即得到指紋圖譜。 741281400 Pickup, patent application scope: 1 · A traditional Chinese medicine composition for treating chronic stable angina pectoris, the cow's inch sign is that '匕 is prepared by the following steps: (1) Preparation of Salvia miltiorrhiza extract: a) Extraction: Place the salvia in a multi-purpose extraction tank, add water to 15~20cm beyond the medicinal material (about 5~7 times the amount of the medicinal material); steam heating 'the inner pressure of the tank is kept at 〇.〇4~〇〇6mPa In between, extract twice, the first 2 hours, the second 1.5 hours; collect the extract, filter through 10 mesh; discard the residue; (b) Concentrate: transfer the extract to the vacuum tank, Control the vapor pressure below 0.05mPa, and adjust the vacuum to be 0.076~0.088mPa, keep the boiling in the pot; concentrate to the weight ratio of the liquid to the drug is 1 liter: 1 kg; (c) Alcohol: After concentration, concentrate Transfer to an alcohol-tank, slowly agitate and add 95% ethanol, measure with alcohol until the ethanol concentration drops to 70%, and place for 24 hours; (d) Recover ethanol: transfer the alcoholic supernatant Adjust the input air pressure to the vacuum tank 〇·〇4~0.〇6mPa, vacuum degree 0.076~0.088mPa, keep boiling; concentrated to the ratio of the volume of the liquid to the weight of the medicine is 1 liter: 1 kg; (e) Polyamide chromatography purification: the step ( d) The obtained solution is placed on a pre-treated polyamide column, the loading volume is 5 ml sample per 1 g of polyamide; after 3 times the amount of water is rinsed, it is eluted with 5 to 10 times the amount of 9 5 % ethanol, and used The method of the step (d) recovers the ethanol 'concentrated eluate to a relative density of 1. 3 3~1 . 3 5 ; 70 1281400 (2) Preparation of the extract of Panax notoginseng: U) Extraction: placing the three-seven in the multifunctional In the extraction tank, add water to 15~20cm over the medicinal material (about 5~7 times the amount of medicinal material); heat to generate steam'. The gas pressure in the tank is kept between 〇.〇4~0.06mPa, and this state is maintained 7 points twice. Extraction, the first 2 hours, the second time 1 · 5 hours; collect the extract, filter through 1 mesh, discard the residue, and concentrate the filtrate properly; (b) Refining the macroporous resin: the step (a) The concentrate is applied to the column, the ratio of the sample to the resin is 1 ··1, the flow rate is 0.5~5cm/cm2/min, and the sample is finished, washed with water. Until it is bright; elute with 70% ethanol at a flow rate of 5.5~5 (:111/(:]112/111丨11, collect the eluent; (c) Concentrate the Sanqi eluate · Open the vacuum pump, filter the eluent with 100 mesh and add it to the vacuum tank; adjust the inlet air pressure to 0.04 ~ 0.06mPa, the vacuum degree is 0.076~0.08 8mPa, keep it boiling and not bump; the recovered ethanol is concentrated to its relative density. 1. 3 3~1 . 3 5, extract of notoginseng; (3) preparation of traditional Chinese medicine composition drip: (a) taking 5% to 40% by weight of the above-mentioned salvia miltiorrhiza extract, the weight percentage is 1%~10% of the above extract of Panax notoginseng, the weight percentage is 1%~5% borneol, the remaining amount is the auxiliary material polyethylene glycol 6000, put into the chemical tank, mix well, and heated to 80~85 ° with steam C, last for 30~40 minutes, until the mixture is uniform without any agglomeration; (b) Add the evenly mixed material into the drip tank of the drip machine, keep the temperature at 89~93 °C, and carry out the dropping; condensation The agent is liquid paraffin, 1281400, the temperature is lower than 8C, the inner diameter of the dripper is i.7mm, the outer diameter is 2.4mm; the liquid medicine and the dripper The distance is 5~6cm; the distance between the dripper and the condensate surface is 26~3 1cm; the depth of the condensate is im; the dropping speed is 60~80 particles/min; (c) the nine is taken out from the condensate, and the oil is removed by centrifugation. That is, the Chinese medicine composition is dripped nine. 2. The traditional Chinese medicine composition according to claim 1, wherein the (3) composition is prepared by taking 10% to 30% by weight of the above-mentioned salvia miltiorrhiza extract, weight percentage The above-mentioned Panax notoginseng extract is from 2% to 6%, and the weight percentage is from 1% to 5% of borneol, and the rest is an auxiliary material, which is uniformly mixed to prepare a composition. The Chinese medicine composition according to claim 1 or 2, wherein the macroporous resin adsorption resin in the preparation of the (2) Panax notoginseng extract is made of porous polymer, tannin, alumina, Polyamide, activated carbon, cellulose or cross-linked dextran is substituted. 4. The Chinese medicine composition according to claim 1 or 2, wherein the eluate is concentrated under reduced pressure at 60 ° C to a relative density of 1 in the preparation of the (2) Panax notoginseng extract. , 3 3~1. 3 5. 5. The Chinese medicine composition according to claim 1 or 2, wherein the pretreatment of the macroporous resin in the preparation of the (2) notoginseng extract is: soaking in 95% ethanol for 24 hours. Add non-polar macroporous 72 I 1281400 resin ZTC -1 to the resin column, the particle size is ο · 3~1 . 2 mm, the gap is 130~300A; elute with equal amount of water and ethanol until Eluent is bright, or washed with 0.1~lmol/L Na〇H and HCL until there is no taste of ethanol or near neutrality of the eluent; regeneration of macroporous resin is: wash with 95% ethanol Remove the resin until the eluent is bright and colorless, then rinse with water until there is no taste of ethanol. 6. The traditional Chinese medicine composition according to claim 1, wherein the drip is a reddish brown or brownish black sphere, uniform in size, fragrant, slightly bitter, and the weight difference is about ±15. %, the range is between 21.25 and 2 8.75mg, the density is 1.13~l.40mg/mm3, the average diameter is 0.33~0.34cm; every nine contains Danshensu 0.14~0.18mg, and the notoginsenoside R1 is greater than 12.12//g, Ginsenoside Rgl is greater than 56.26 / / g. 7. The Chinese medicine composition according to claim 1 or 2, wherein the fingerprint is as shown in the following table: peak number retention time relative retention time occurrence ratio peak area peak area ratio peak area ratio Range 1 8.289 0. 672 100% 1034.276 0. 572 0. 572±0. 096 2 12. 343 1.000 100% 1817.065 1.000 1.000±0. 000 3 17. 493 1.417 100% 376. 547 0.208 0. 208±0. 040 4 18. 664 1.512 100% 328.011 0. 181 0.181±0. 059 5 24. 883 2.016 100% 486. 626 0. 267 0. 267±0. 097 6 27. 586 2. 235 100% 525. 432 0 289 0. 289 ± 0. 052 7 29.714 2.407 100% 940. 963 0.516 0· 516±0· 125 73 1281400 Q 34.030 2.757 100% 1547.495 0.850 0.850±0. 163 • Chinese medicine as claimed in item 7 of the patent application Composition Drop No. 9, characterized in that the fingerprint is obtained by the following method: a) pretreatment: 1) dissolving an appropriate amount of the composition in a solution using p-aminobenzoic acid as an internal standard; ii. adding methanol Ultrasound for 15 minutes; iii. Let cool, add methanol to dilute, centrifuge; iv. Collect the upper sputum as a sample solution; b) The appropriate amount of sodium danshensu reference substance is dissolved in a solution containing p-aminobenzoic acid as an internal standard, and dissolved in methanol as a reference solution; c) High performance liquid chromatography conditions are as follows: i · Mobile phase: methanol··water : glacial acetic acid = 8 ·· 91 : 1 ; ii. column temperature: 30 ° C; ii i. injection amount: 1 0 // 1 ; iv . detection wavelength: 2 8 1 nm; ν · theoretical plate number The calculation of Danshensu sodium peak should not be lower than 2000; d) Inject the sample solution and the reference solution into the high-performance liquid solution separately, and determine by HPLC, the relative retention time and peak area of the reference product are calculated as 1 Retention time and relative peak area, that is, a fingerprint is obtained. 74
TW90132075A 2000-12-22 2001-12-21 Herbal composition for angina pectoris, method to prepare same and uses thereof TWI281400B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TW90132075A TWI281400B (en) 2001-12-21 2001-12-21 Herbal composition for angina pectoris, method to prepare same and uses thereof
US10/210,548 US8486464B2 (en) 2000-12-22 2002-07-31 Herbal composition for angina pectoris, method to prepare same and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW90132075A TWI281400B (en) 2001-12-21 2001-12-21 Herbal composition for angina pectoris, method to prepare same and uses thereof

Publications (1)

Publication Number Publication Date
TWI281400B true TWI281400B (en) 2007-05-21

Family

ID=38779584

Family Applications (1)

Application Number Title Priority Date Filing Date
TW90132075A TWI281400B (en) 2000-12-22 2001-12-21 Herbal composition for angina pectoris, method to prepare same and uses thereof

Country Status (1)

Country Link
TW (1) TWI281400B (en)

Similar Documents

Publication Publication Date Title
EP1351698B1 (en) Herbal composition for angina pectoris, method to prepare same and uses thereof
AU2002246730A1 (en) Herbal composition for angina pectoris, method to prepare same and uses thereof
US8486464B2 (en) Herbal composition for angina pectoris, method to prepare same and uses thereof
Kavitha et al. Coleus forskohlii: a comprehensive review on morphology, phytochemistry and pharmacological aspects
EP1741439B1 (en) Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method
Baliga Review of the phytochemical, pharmacological and toxicological properties of Alstonia scholaris Linn. R. Br (Saptaparna)
Pleskanovskaya et al. Glycyrrhiza glabra (licorice) in Turkmenistan: medicinal and biological aspects
WO2008145064A1 (en) The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof
TWI281400B (en) Herbal composition for angina pectoris, method to prepare same and uses thereof
JP3390443B2 (en) Salvia officinalis flower extract, preparation method and use thereof
Ahmed et al. Curative Effects of Ethanol Extract of Prosopis Farcta (Syrian Mesquite) Against Ethylene Glycol Induced Urolithiasis in Male Albino Rats
NZ551135A (en) A composition capable of treating chronic stable angina pectoris comprising Danshensu, sanchinoside and ginsenoside Rg1
JP4979053B2 (en) Anticancer agent containing gentian extract, health supplement and medicinal cosmetic, and method for producing gentian extract
Adjileye et al. Antihypertensive effect of Dialium guineense Wild. and Trema orientalis L. in L-NAME-induced hypertensive rats
WO2004069263A1 (en) Analgesic composition
Sharmin et al. Screening of biological activities of Acacia farnesiana (Guyababla), a medicinal plant of Bangladesh
Mohebbati et al. Hypotensive Effect of Hydroalcoholic Ziziphus jujuba Extract on Normotensive Rats
Wong et al. Kudzu/Puerarin: medical applications
CN112274557A (en) Rabdosia rubescens leaf water extract powder, preparation method thereof, anti-arterial thrombosis effect and application thereof
Sharma et al. Role of Karela in Diabetes: A Review
KR100509414B1 (en) Compositions produced with components extracted from ivy
CN118830466A (en) Planting method of tribute chrysanthemum
CN115252660A (en) N-butyl alcohol part extract of oleaster leaves, preparation method and application thereof
Joshi Plectranthus Barbatus Syn. Coleus Forskohlii: The Plant with Dynamic Medicinal Potential
Dohroo et al. Bacopa rejuvenator cultivation and Importance to human beings

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees